



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification:</b> <b>C07K 14/00</b>	<b>A2</b>	<b>(11) International Publication Number:</b> <b>WO 00/20447</b> <b>(43) International Publication Date:</b> 13 April 2000 (13.04.2000)
<b>(21) International Application Number:</b> PCT/US99/23294 <b>(22) International Filing Date:</b> 06 October 1999 (06.10.1999) <b>(30) Priority Data:</b> 60/103,195 06 October 1998 (06.10.1998) US <b>(60) Parent Application or Grant</b> CURAGEN CORPORATION [/]; (). SHIMKETS, Richard, A. [/]; (). SHIMKETS, Richard, A. [/]; (). ELRIFI, Ivor, R. ; ().	<b>Published</b>	
<b>(54) Title: NOVEL SECRETED PROTEINS AND POLYNUCLEOTIDES ENCODING THEM</b> <b>(54) Titre: NOUVELLES PROTEINES SECRETEES, ET POLYNUCLEOTIDES LES CODANT</b>		
<b>(57) Abstract</b> <p>The present invention provides novel isolated polypeptides chosen from among a) a syncollin-like protein having a syncollin-like activity; b) a novel polypeptide whose amino acid sequence is given by or is similar to SEQ ID NO:6; c) a claudin-like protein having a claudin-like activity; d) a cytokine-like protein whose amino acid sequence has at least 80 % identity to human GRO-beta and having a GRO-beta-like activity, and e) a fragment of any of them; as well as polynucleotides encoding them and antibodies that immunospecifically bind to them. The invention additionally provides several methods in which these proteins, polynucleotides and antibodies are used in methods of detection and methods of treatment are also disclosed. These methods additionally include methods employing proteins, polynucleotides and antibodies related to the additional substances a cysteine-rich soluble protein, and a mammaglobin homologue/endometrial specific steroid-binding factor III. These methods of detection and treatment are directed to a broad range of pathological states.</p> <b>(57) Abrégé</b> <p>La présente invention concerne de nouveaux polypeptides isolés choisis parmi a) une protéine de type syncolline ayant une activité de type syncolline; b) un nouveau polypeptide dont la séquence d'acides aminés est donnée par SEQ ID NO:6 ou est similaire à cette séquence; c) une protéine de type claudine ayant une activité de type claudine; d) une protéine de type cytokine dont la séquence d'acides aminés présente au moins une similitude à 80 % avec la protéine GRO-bêta humaine ainsi qu'une activité de type GRO-bêta, et e) un fragment de l'une quelconque des ces protéines ; ainsi que les polynucléotides codant ces protéines et les anticorps qui lient immunospécifiquement ces protéines. L'invention concerne également plusieurs techniques utilisant ces protéines, polynucléotides et anticorps dans le cadre de méthodes de détection et de traitement. Ces techniques comprennent, en outre, des méthodes utilisant des protéines, des polynucléotides et des anticorps associés aux substances supplémentaires d'une protéine soluble riche en cystéine et d'un homologue de mammaglobine/ facteur III de liaison des stéroïdes spécifique à l'endomètre. Ces techniques sont destinées à la détection et au traitement d'une large gamme d'états pathologiques.</p>		

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>7</sup> : <b>C07K 14/00</b>		<b>A2</b>	(11) International Publication Number: <b>WO 00/20447</b>
			(43) International Publication Date: 13 April 2000 (13.04.00)
(21) International Application Number: <b>PCT/US99/23294</b>		(74) Agent: ELRIFI, Ivor, R.; Mintz, Levin, Cohn, Ferris, Glovsky, and Popeo, P.C., One Financial Center, Boston, MA 02111 (US).	
(22) International Filing Date: 6 October 1999 (06.10.99)			
(30) Priority Data: 60/103,195 6 October 1998 (06.10.98) US Not furnished 5 October 1999 (05.10.99) US		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Applications US 60/103,195 (CIP) Filed on 6 October 1998 (06.10.98) US Not furnished (CIP) Filed on 5 October 1999 (05.10.99)		Published <i>Without international search report and to be republished upon receipt of that report.</i>	
(71) Applicant (for all designated States except US): CURAGEN CORPORATION [US/US]; 11th floor, 555 Long Wharf Drive, New Haven, CT 06511 (US).			
(72) Inventor; and (75) Inventor/Applicant (for US only): SHIMKETS, Richard, A. [US/US]; 191 Lecete Street, West Haven, CT 06516 (US).			
(54) Title: NOVEL SECRETED PROTEINS AND POLYNUCLEOTIDES ENCODING THEM			
(57) Abstract			
<p>The present invention provides novel isolated polypeptides chosen from among a) a syncollin-like protein having a syncollin-like activity; b) a novel polypeptide whose amino acid sequence is given by or is similar to SEQ ID NO:6; c) a claudin-like protein having a claudin-like activity; d) a cytokine-like protein whose amino acid sequence has at least 80 % identity to human GRO-beta and having a GRO-beta-like activity, and e) a fragment of any of them; as well as polynucleotides encoding them and antibodies that immunospecifically bind to them. The invention additionally provides several methods in which these proteins, polynucleotides and antibodies are used in methods of detection and methods of treatment are also disclosed. These methods additionally include methods employing proteins, polynucleotides and antibodies related to the additional substances a cysteine-rich soluble protein, and a mammaglobin homologue/endometrial specific steroid-binding factor III. These methods of detection and treatment are directed to a broad range of pathological states.</p>			
A. Clone 2353875f			
Translated Protein: Nucleotides 25 to 426			
1 ACGCGTGCAGGTGGCACTGCCACCATGTCCCGCTGCGCCCGCTG MetSerProLeuArgProLeu			
46 CTGCTGGCCCTGGCCCTTGCCTCCCTGCGCCCGAGGCGCC LeuLeuAlaLeuAlaLeuAlaSerValProCysAlaGlnGlyAla			
91 TGCCCGGCTCCGCGACCTCAAGCACTCGGACGGGACGCGCACT CysProAlaSerAlaAspLeuLysHisSerAspGlyThrArgThr			
136 TGGCCCAAGCTCTATGACAAGAGCGACCCCTACTATGAGAACTGC CysAlaLysLeuTyrAspLysSerAspProTyrTyrGluAsnCys			
181 TGCGGGGCGCGGAGCTGTGCTGGAGTCGGGCGCAGACCTGCC CysGlyGlyAlaGluLeuSerLeuGluSerGlyAlaAspLeuPro			
226 TACCTGCCCTCCAACTGGGCAACACCGCTCCTCACTTGTGTG TyrLeuProSerAsnTrpAlaAsnThrAlaSerSerLeuValVal			
271 GCCCCGCGCTGCGAGCTCACCGTGTGTCCCGGCAAGGCAAGGCG AlaProArgCysGluLeuThrValTrpSerArgGlnGlyLysAla			
316 GGCAAGACGACAAAGTCTCTGCGCGCACCTACCCGCGCTGGAG GlyLysThrHisLysPheSerAlaGlyThrTyrProArgLeuGlu			
361 GAGTACGCGCGGGCATCTTAGAGAGCTGTTCAACGCTATCTCC GluTyrArgArgGlyIleLeuGlyAspTrpSerAsnAlaIleSer			
406 GCGCTCTACTGCAGGTGCAGCTGATGCATTGCTGCTCTCATCT AlaLeuTyrCysArgCysSer			
451 GCAGCTTCCACAGAGTGCCAAAGCCCTCACTACCCATCCCTGGG			
496 CTCTGCTCCGGGCCCCAAGACCCAGGAGGAGGAGCGTTCTGCGCTG			
541 CCCCCTCCCACTCCCTGCAATACAGCCTTTGTGAGTTGTATAA			
586 AAAAAAAAAA			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	BS	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

**Description**

5

10

15

20

25

30

35

40

45

50

55



# NOVEL SECRETED PROTEINS AND POLYNUCLEOTIDES ENCODING THEM

## RELATED APPLICATIONS

This application claims priority to the United States Provisional Application Serial Number 60/103,195, filed October 6, 1998, and the United States Nonprovisional Application filed October 5, 1999, entitled "Novel Secreted Proteins and Polynucleotides Encoding Them," which are incorporated by reference herein in their entirety.

## FIELD OF THE INVENTION

The invention relates to polynucleotides and polypeptides encoded by such polynucleotides, as well as vectors, host cells, antibodies and recombinant methods for producing the polypeptides and polynucleotides.

## BACKGROUND OF THE INVENTION

Eukaryotic cells are subdivided by membranes into multiple functionally distinct compartments that are referred to as organelles. Each organelle includes proteins essential for its proper function. These proteins can include sequence motifs often referred to as sorting signals. The sorting signals can aid in targeting the proteins to their appropriate cellular organelle. In addition, sorting signals can direct some proteins to be exported, or secreted, from the cell.

One type of sorting signal is a signal sequence, which is also referred to as a signal peptide or leader sequence. The signal sequence is present as an amino-terminal extension on a newly synthesized polypeptide chain. A signal sequence can target proteins to an intracellular organelle called the endoplasmic reticulum (ER).

The signal sequence takes part in an array of protein-protein and protein-lipid interactions that result in translocation of a polypeptide containing the signal sequence through a channel in the ER. After translocation, a membrane-bound enzyme, named a signal peptidase, liberates the mature protein from the signal sequence.

The ER functions to separate membrane-bound proteins and secreted proteins from proteins that remain in the cytoplasm. Once targeted to the ER, both secreted and

5 membrane-bound proteins can be further distributed to another cellular organelle called the Golgi apparatus. The Golgi directs the proteins to other cellular organelles such as vesicles, lysosomes, the plasma membrane, mitochondria and microbodies.

10 Only a limited number of genes encoding human membrane-bound and secreted proteins  
5 have been identified. Examples of known secreted proteins include human insulin, interferon, interleukins, transforming growth factor-beta, human growth hormone, erythropoietin, and  
15 lymphokines.

### SUMMARY OF THE INVENTION

20 The present invention is based, in part, upon the discovery of novel polynucleotides  
10 identified as containing presumptive signal sequences. These clones nucleotide sequences have been designated clone 2355875 (SEQ ID NOs:3 and 27), which encodes a protein having  
25 sequence similarity to syncollin; clone 3223867 (SEQ ID NO:5); clone 3224646 (SEQ ID NO:7), which encodes a protein having similarity to claudin; and clone 3482699 (SEQ ID NO:9), which encodes a cytokine-like protein. Also provided in the invention are proteins  
15 encoded by these sequences. These polypeptides correspond to the amino acid sequences of SEQ ID NOs: 4, 6, 8, and 10, respectively.  
30

35 The invention includes an isolated nucleic acid molecule which includes a nucleotide sequence at least 85% similar to the nucleotide sequence of SEQ ID NOs : 3, 5, 7, 9, or 27, or a complement thereof.

20 The invention also includes an isolated polypeptide having an amino acid sequence at least 80% homologous to SEQ ID NOs: 4, 6, 8, or 10, or a fragment having at least 15 amino  
40 acids of these amino acid sequences. Also included is a naturally occurring polypeptide variant consisting of the amino acid sequence of SEQ ID NOs. 4, 6, 8, or 10, wherein the polypeptide is encoded by a nucleic acid molecule which hybridizes under stringent conditions to a nucleic acid  
25 molecule consisting of SEQ ID NOs: 3, 5, 7, 9, or 27.  
45

Also included in the invention is an antibody which selectively binds to the polypeptide of SEQ ID NOs:2, 4, 6, 8, 10, or 12.

50

55

5 The invention further includes a method for producing the aforementioned polypeptides by culturing a host cell expressing one of the herein described nucleic acids under conditions in which the nucleic acid molecule is expressed.

10 The invention also includes methods for detecting the presence of these polypeptides in a sample from a mammal, *e.g.*, a human, by contacting a sample from the mammal with an antibody which selectively binds to one of the herein described polypeptides, and detecting the formation of reaction complexes including the antibody and the polypeptide in the sample. 15 Detecting the formation of complexes in the sample indicates the presence of the polypeptide in the sample.

20 10 The invention further includes a method for detecting or diagnosing the presence of a disease associated with altered levels of a polypeptide having an amino acid sequence at least 80% identical to a polypeptide with an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 4, 6, 8, 10, and 12 in a sample. The method includes measuring the level of 25 the polypeptide in a biological sample from the mammalian subject, *e.g.*, a human, and 15 comparing the level detected to a level of the polypeptide present in normal subjects, or in the same subject at a different time, *e.g.*, prior to onset of a condition. An increase or decrease in the level of the polypeptide as compared to normal levels indicates a disease condition. 30

Also included in the invention is a method of detecting the presence of a nucleic acid molecule having a sequence at least 80% identical to a nucleic acid comprising a sequence 35 20 selected from the group consisting of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 25 or 27 in a sample from a mammal, *e.g.*, a human. The method includes contacting the sample with a nucleic acid probe or primer which selectively hybridizes to the nucleic acid molecule and determining whether the nucleic acid probe or primer binds to a nucleic acid molecule in the sample. Binding of the 40 nucleic acid probe or primer indicates the nucleic acid molecule is present in the sample.

25 The invention further includes a method for detecting or diagnosing the presence of a disease associated with altered levels of a nucleic acid at least 80% identical to a nucleic acid comprising a sequence selected from the group consisting of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 25 or 27 in a sample from a mammal, *e.g.*, a human. The method includes measuring the level of the nucleic acid in a biological sample from the mammalian subject and comparing the level 45 30 detected to a level of the nucleic acid present in normal subjects, or in the same subject at a 50

different time. An increase or decrease in the level of the nucleic acid as compared to normal levels indicates a disease condition.

The invention also includes a method of treating a pathological state in a mammal, e.g., a human, by administering to the subject a polypeptide to the subject in an amount sufficient to alleviate the pathological condition. The polypeptide has an amino acid sequence at least 80% identical to a polypeptide with an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 4, 6, 8, 10, and 12, or a biologically active fragment thereof.

Alternatively, the mammal may be treated by administering an antibody as herein described in an amount sufficient to alleviate the pathological condition.

Pathological states for which the methods of treatment of the invention are envisioned include a cancer, a tumor, an immune disorder, an immune deficiency, an autoimmune disease, acquired immune deficiency syndrome, transplant rejection, allergy, an infection by a pathological organism or agent, an inflammatory disorder, arthritis, a hematopoietic disorder, a skin disorder, atherosclerosis, restenosis, a neurological disease, Alzheimer's disease, peripheral neuropathy, trauma, a surgical or traumatic wound, a spinal cord injury, and a skeletal disorder.

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In the case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.

Other features and advantages of the invention will be apparent from the following detailed description and claims.

#### BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is an illustration depicting (Panel A) the nucleotide (SEQ ID NO:3) and amino acid (SEQ ID NO:4) sequence of clone 2355875 and (Panel B) an updated nucleotide sequence (SEQ ID NO:27) of clone 2355875.

FIG. 2 is an illustration depicting the nucleotide (SEQ ID NO:5) and amino acid (SEQ ID NO:6) sequence of clone 3223867.

FIG. 3 is an illustration depicting (**Panel A**) the coding strand nucleotide sequence (SEQ ID NO:7) and amino acid sequence (SEQ ID NO:8) of clone 3224646 and (**Panel B**) the noncoding strand nucleotide sequence (SEQ ID NO:26) of clone 3224646.

FIG. 4 is an illustration depicting the nucleotide (SEQ ID NO:9) and amino acid (SEQ ID NO:10) sequence of clone 3482699.

FIG. 5 is an illustration depicting (**Panel A**) the nucleotide (SEQ ID NO:1) and amino acid (SEQ ID NO:2) sequence of clone 2156647 and (**Panel B**) an updated nucleotide sequence (SEQ ID NO:25) of clone 2156647.

FIG. 6 is an illustration depicting the nucleotide (SEQ ID NO:11) and amino acid (SEQ ID NO:12) sequence of clone MAMMX.

#### DETAILED DESCRIPTION OF THE INVENTION

An examination of nucleic acid sequences identified based on their differential expression in cells revealed six clones with candidate secreted sequences. Of these sequences, four are not previously described. These include clones 2355875, 3223867, 3224646, and 3482699. Two clones, clone 21556471 and MAMM-X (MAMMAGLOBIN) corresponded to previously described sequences.

##### Clone 2355875 (SYN COLLIN-HOMOLOG)

2353875 is 769 nucleotides in length and includes an open reading frame encoding a secreted protein (also referred to herein as "2355875 protein") from nucleotides 209 to 610. The nucleotide sequence of 2353875 is shown in Fig. 1 as SEQ ID NOs:3 and 27. The predicted amino acid sequence is also shown (SEQ ID NO:4).

The nucleotide sequence 2353875 was searched against the GenBank database using BLASTP search protocols. 83% homology (111 of 133 amino acids) was found to rat syncollin (GenBank-Accession Number O35775). Syncollin is a 18-kDa secretory granule membrane protein involved in regulating exocytosis in exocrine tissues. Syncollin is reported to bind to syntaxin at low calcium concentrations, and dissociates from syntaxin at concentrations known to stimulate exocytosis (Edwardson *et al.*, 1997, Cell 90:325-333). Syncollin is likely a

cytoplasmic protein. Other members of the protein family to which syncollin belong includes syntaxin. Syntaxin contains an N-terminal domain that is required for the binding of Munc-18 and a second domain, close to its membrane anchor, to which most other proteins bind, including -SNAP, SNAP-25, synaptobrevin, synaptotagmin, and the N-type Ca<sup>2+</sup> channel. Syncollin has also been demonstrated in the art to bind to the cytoplasmic domain of syntaxin and also to the C-terminal region, although with less affinity. Syncollin has not been reported to interact with the N-terminal region.

The 2355875 protein, like rat syncollin, has a single hydrophobic domain at its amino terminus. Based upon homology, 2355875 protein proteins and each homologous protein or peptide may share at least some activity.

The 2355875 protein was examined for presumptive signal peptide cleavage sequences using SignalPep and PSort search protocols. The 2355875 protein has a cleavable amino terminal signal peptide with a cleavage site between positions 21 and 22, *i.e.*, in the region having the amino acid sequence AQG-AC. The protein is most likely located outside of the cell.

#### **Clone 3223867**

Clone 3223867 is 876 nucleotides in length and includes an open reading frame encoding a secreted protein (also referred to herein as "3223867 protein") from nucleotides 129 to 533. The nucleotide sequence of 3223867 is shown in Fig. 2 (SEQ ID NO:5), along with an encoded polypeptide of 135 amino acids (SEQ ID NO:6). No significant homology was found when the 3223867 nucleotide sequence was searched against other sequences in the GenBank database using BLASTP search protocols. Clone 3223867 was isolated from human testis.

The nucleotide sequence and amino acid sequence for 3223867 was searched against other databases using SignalPep and PSort search protocols. 3223867 apparently has no amino terminal signal peptide and is likely located in the mitochondrial matrix space or in the microbody (peroxisome).

#### **Clone 3224646 (CLAUDIN HOMOLOG)**

3224646 is 1530 nucleotides in length and includes an open reading frame from nucleotides 301 to 1083(also referred to herein as "3224646 protein"). The nucleotide sequence of 3224646 (SEQ ID NO:7) is shown in FIG. 3, along with an encoded polypeptide of 261 amino acids (SEQ ID NO:8) and the noncoding strand (SEQ ID NO:26). Clone 3224646 was

isolated from human testis.

The 3224646 nucleic acid sequence was searched against the GenBank database using BLASTP search protocols. A similarity of 56% (110 of 196 amino acids) was found to human claudin-1 (GenBank Accession Number TREMBLNEW:AAD22062), which is a protein of 211 amino acids. Proteins of the claudin family are integral membrane proteins with four transmembrane domains and are found in tight junctions (Furuse *et al.*, 1998, J. Cell Biol. 141:1539-50). 3224646 proteins and claudin proteins may thus share at least some activities. Claudins are a newly discovered family of integral membrane proteins implicated in maintenance of the intercellular tight junctions (Morita *et al.*, PNAS 96: 511-16 (1999). They occur at the most apical portion of polarized epithelial and endothelial cells, and serve to prevent intercellular transport of solutes. They occur in many tissues, including liver and kidney. Accordingly, the claudin-like protein of the present invention or its gene will be useful in therapeutic intervention in human subjects in whom this gene or the product protein is a defective allele.

The nucleotide sequence and amino acid sequences of the 2355875 protein were searched against other databases using SignalPep and PSort search protocols. 2355875 protein has a presumptive cleavable amino terminal signal peptide with a cleavage site between positions 23 and 24 (CIA:AT). The protein is most likely located in the plasma membrane.

Northern analysis showed expression of 3224646 in a variety of human fetal and adult tissues. The human 3224646 maps onto human chromosome 3q21, 1.6 centiRay below D3S2576 and 4.6 cR above WI-3522.

#### Clone 3482699

Clone 3482699 is 603 nucleotides in length and includes an open reading frame from nucleotides 341 to 538 (also referred to herein as "3482699 protein"). The nucleotide sequence of 3482699 is shown in FIG. 4 as SEQ ID NO:9, along with its encoded polypeptide of 66 amino acids (SEQ ID NO:10).

The 3482699 nucleotide sequence was searched against the GenBank database using BLASTP search protocols. No significant homologies were found. A search against the GenBank database using BLASTN search proteins showed two regions with 100% identities to human MGSA/GRO pseudogene sequence (GenBank Accession Number U88432). One region

with identity was found between nucleotides 1-179 of 3482699 and nucleotides 1148 and 1326 of MGSA-GRO pseudogene. The second region of identity was found between nucleotides 180-603 of 3482699 and nucleotides 1425 and 1848 of MGSA-GRO pseudogene (MGSA/GRO pseudogene sequence has an intron between nucleotides 1327 and 1424). The 3482699 sequence showed 82% identities (251 of 303 nucleotides) to human cytokine (GRO-beta) mRNA sequence (GenBank Accession Number M36820).

The nucleotide sequence and amino acid sequence disclosed herein for 3482699 was searched against other databases using SignalPep and PSort search protocols. 3482699 most likely has a signal peptide with a cleavage site between position 17 and 18 (IQK-NN). It is most likely located in the membrane of the endoplasmic reticulum.

#### **Clone 21556471**

Clone 2155647 is 508 nucleotides (SEQ ID NO:25, see also SEQ ID NO:1) in length and includes an open reading frame from nucleotides 148 to 402 (also referred to herein as "2155647 protein").

The nucleotide sequence for 2155647 was searched against the GenBank databases using BLASTN search protocols. The BLASTN search showed 58% homology (223 of 396 nucleotides) to the cDNA encoding a human thromboxane receptors (GenBank-Accession Number E03829).

The amino acid sequence of 108 amino acids is 100% identical to the sequence of a cysteine rich soluble protein designated C23 (Accession Number W87710, Patent application WO98/58061, Schering Corp.) and to a human secreted polypeptide (Accession Number Y12933, Patent application WO99/11293, Human Genome Sciences, Inc). Further searches using the GenBank database BLASTP showed some homology to rat MEGF6 protein (SPTREMBL-ACC:O88281).

The 2155647 sequence was also examined for signal peptidase cleavages using SignalPep and PSort search protocols. 2155647 has an apparent amino terminal signal peptide with a cleavage site between TLC and SM. The protein is most likely located outside of the cell. The predicted molecular weight is 11419.2 daltons.



5 The cDNA of clone 2155647 was inserted into expression vectors for mammalian embryonic kidney 293 and insect (baculo) cell expression. The protein expressed in mammalian cells was secreted as 20 kDa protein. The protein secreted by Sf9 insect cells is about 45 kDa.

#### 10 MAMM-X (MAMMAGLOBIN)

5 Clone Mamm-X is 517 nucleotides in length and includes an open reading frame from nucleotides 65 to 349 encoding a polypeptide of 95 amino acids (also referred to herein as  
15 "Mamm-X protein"). The nucleotide sequence of Mamm-X and its encoded protein are reported in FIG. 6 as SEQ ID NOs: 11 and 12, respectively. The nucleotide sequence is 100% identical (517 of 517 nucleotides) to the mRNA sequence of human Mammaglobin B precursor (GenBank  
20 Accession Number AF071219; Becker *et al.*, 1998, Genomics 54:70-78). The amino acid sequence is 100% identical to the sequence of a human mammaglobin homologue (Accession Number Y02590, Patent application WO99/19487, Incyte Pharmaceuticals) and to human  
25 endometrial specific steroid-binding factor III (Accession Number W35804, Patent application WO97/34997, Human Genome Sciences, Inc.). Mammaglobin is a potential marker of breast  
15 cancer nodal metastasis and is expressed in primary, metastatic and occult breast cancer cells. Based upon homology, Mamm-X proteins and each homologous protein or peptide may share at  
30 least some activity.

The cDNA of clone Mamm-X was inserted into expression vectors for mammalian embryonic kidney 293 cells and expressed as a 10 kDa protein in the cell pellet. No secreted  
35 20 form of Mamm-X was detected.

Herein is described are nucleic acids, polypeptides, antibodies, therapeutics, and methods of using the afore-mentioned nucleic acids and their encoded polypeptides.

#### 40 Nucleic Acids

One aspect of the invention pertains to isolated nucleic acid molecules that encode  
25 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X proteins or biologically active portions thereof, as well as nucleic acid fragments sufficient for use as hybridization probes to  
45 identify 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X-encoding nucleic acids (*e.g.*, 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X mRNA) and fragments for  
50 use as PCR primers for the amplification or mutation of 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X nucleic acid molecules. The invention also pertains to polynucleotides  
30

5 and encoded proteins that have amino acid and corresponding codon substitutions within certain defined limits, as disclosed herein.

10 As used herein, the term "nucleic acid molecule" and/or "polynucleotide" is intended to include DNA molecules (*e.g.*, cDNA or genomic DNA), RNA molecules (*e.g.*, mRNA), analogs  
5 of the DNA or RNA generated using nucleotide analogs, and derivatives, fragments and homologs thereof. The nucleic acid molecule can be single-stranded or double-stranded, but preferably is double-stranded DNA.  
15

An "isolated" nucleic acid molecule is one that is separated from other nucleic acid molecules which are present in the natural source of the nucleic acid. Preferably, an "isolated"  
20 nucleic acid is free of sequences which naturally flank the nucleic acid (*i.e.*, sequences located at the 5' and 3' ends of the nucleic acid) in the genomic DNA of the organism from which the nucleic acid is derived. For example, in various embodiments, the isolated 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X nucleic acid molecule can contain less than about 5  
25 kb, 4 kb, 3 kb, 2 kb, 1 kb, 0.5 kb or 0.1 kb of nucleotide sequences which naturally flank the nucleic acid molecule in genomic DNA of the cell from which the nucleic acid is derived. Moreover, an "isolated" nucleic acid molecule, such as a cDNA molecule, can be substantially  
30 free of other cellular material or culture medium when produced by recombinant techniques, or of chemical precursors or other chemicals when chemically synthesized.

A nucleic acid molecule of the present invention, *e.g.*, a nucleic acid molecule having the  
35 nucleotide sequence of SEQ ID NO:1, 3, 5, 7, 9, 11, 25 or 27, or a complement of any of these nucleotide sequences, can be isolated using standard molecular biology techniques and the sequence information provided herein. Using all or a portion of the nucleic acid sequences of SEQ ID NO:1, 3, 5, 7, 9, 11, 25 or 27 as a hybridization probe, 2155647, 2355875, 3223867,  
40 3224646, 3482699, or Mamm-X molecules can be isolated using standard hybridization and cloning techniques (*e.g.*, as described in Sambrook *et al.*, eds., MOLECULAR CLONING: A LABORATORY MANUAL 2<sup>nd</sup> Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989; and Ausubel, *et al.*, eds., CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley &  
45 Sons, New York, NY, 1993.)

A nucleic acid of the invention can be amplified using cDNA, mRNA or alternatively,  
50 genomic DNA, as a template and appropriate oligonucleotide primers according to standard PCR amplification techniques. The nucleic acid so amplified can be cloned into an appropriate vector

5 and characterized by DNA sequence analysis. Furthermore, oligonucleotides corresponding to 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X nucleotide sequences can be prepared by standard synthetic techniques, *e.g.*, using an automated DNA synthesizer.

10 In another embodiment, an isolated nucleic acid molecule of the invention comprises a nucleic acid molecule that is a complement of the nucleotide sequence shown in SEQ ID NO:1, 3, 5, 7, 9, 11, 25 or 27. In another embodiment, an isolated nucleic acid molecule of the invention comprises a nucleic acid molecule that is a complement of the nucleotide sequence shown in SEQ ID NO:1, 3, 5, 7, 9, 11, 25 or 27, or a portion of this nucleotide sequence. A nucleic acid molecule that is complementary to the nucleotide sequence shown in SEQ ID NO:1, 10 3, 5, 7, 9, 11, 25 or 27 is one that is sufficiently complementary to the nucleotide sequence shown in SEQ ID NO:1, 3, 5, 7, 9, 11, 25 or 27 that it can hydrogen bond with little or no mismatches to the nucleotide sequence shown in SEQ ID NO:1, 3, 5, 7, 9, 11, 25 or 27, thereby forming a stable duplex..

25 Moreover, the nucleic acid molecule of the invention can comprise only a portion of the nucleic acid sequence of SEQ ID NO:1, 3, 5, 7, 9, 11, 25 or 27, *e.g.*, a fragment that can be used as a probe or primer or a fragment encoding a biologically active portion of 2155647, 2355875, 30 3223867, 3224646, 3482699, or Mamm-X. Fragments provided herein are defined as sequences of at least 6 (contiguous) nucleic acids or at least 4 (contiguous) amino acids, a length sufficient to allow for specific hybridization in the case of nucleic acids or for specific recognition of an epitope in the case of amino acids, respectively, and are at most some portion less than a full length sequence. In various embodiments, fragments may be at least about 6, 15, 30, 100, 250, 35 500, or 1000 amino acids in length. Fragments may be derived from any contiguous portion of a nucleic acid or amino acid sequence of choice. Derivatives are nucleic acid sequences or amino acid sequences formed from the native compounds either directly or by modification or partial substitution. Analogs are nucleic acid sequences or amino acid sequences that have a structure 40 similar to, but not identical to, the native compound but differs from it in respect to certain components or side chains. Analogs may be synthetic or from a different evolutionary origin and may have a similar or opposite metabolic activity compared to wild type. Homologs are nucleic acid sequences or amino acid sequences of a particular gene that are derived from different 45 species.

5 Derivatives and analogs may be full length or other than full length, if the derivative or  
analog contains a modified nucleic acid or amino acid, as described below. Derivatives or  
analogues of the nucleic acids or proteins of the invention include, but are not limited to, molecules  
10 comprising regions that are substantially homologous to the nucleic acids or proteins of the  
invention, in various embodiments, by at least about 30%, 50%, 70%, 80%, or 95% identity  
(with a preferred identity of 80-95%) over a nucleic acid or amino acid sequence of identical size  
or when compared to an aligned sequence in which the alignment is done by a computer  
15 homology program known in the art, or whose encoding nucleic acid is capable of hybridizing to  
the complement of a sequence encoding the aforementioned proteins under stringent, moderately  
stringent, or low stringent conditions. See *e.g.* Ausubel, *et al.*, CURRENT PROTOCOLS IN  
20 MOLECULAR BIOLOGY, John Wiley & Sons, New York, NY, 1993, and below.

The nucleotide sequence determined from the cloning of the human 2155647, 2355875,  
3223867, 3224646, 3482699, or Mamm-X gene allows for the generation of probes and primers  
25 designed for use in identifying and/or cloning 2155647, 2355875, 3223867, 3224646, 3482699,  
or Mamm-X homologues in other cell types, *e.g.* from other tissues, as well as 2155647,  
2355875, 3223867, 3224646, 3482699, or Mamm-X homologues from other mammals. The  
30 probe/primer typically comprises substantially purified oligonucleotide. The oligonucleotide  
typically comprises a region of nucleotide sequence that hybridizes under stringent conditions to  
at least about 12, 25, 50, 100, 150, 200, 250, 300, 350 or 400 consecutive sense strand nucleotide  
20 sequence of SEQ ID NO:1, 3, 5, 7, 9, 11, 25 or 27 or an anti-sense strand nucleotide sequence of  
35 SEQ ID NO:1, 3, 5, 7, 9, 11, 25 or 27 or of a naturally occurring mutant of SEQ ID NO:1, 3, 5,  
7, 9, 11, 25 or 27.

Probes based on the human 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-  
40 X nucleotide sequence can be used to detect transcripts or genomic sequences encoding the  
same or homologous proteins. In various embodiments, the probe further comprises a label  
25 group attached thereto, *e.g.* the label group can be a radioisotope, a fluorescent compound, an  
enzyme, or an enzyme co-factor. Such probes can be used as a part of a diagnostic test kit for  
45 identifying cells or tissue which misexpress a 2155647, 2355875, 3223867, 3224646, 3482699,  
or Mamm-X protein, such as by measuring a level of a 2155647, 2355875, 3223867, 3224646,  
30 3482699, or Mamm-X -encoding nucleic acid in a sample of cells from a subject *e.g.*, detecting  
50 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X mRNA levels or determining

whether a genomic 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X gene has been mutated or deleted.

"A polypeptide having a biologically active portion of 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X " refers to polypeptides exhibiting activity similar, but not necessarily identical to, an activity of a polypeptide of the present invention, including mature forms, as measured in a particular biological assay, with or without dose dependency. A nucleic acid fragment encoding a "biologically active portion of 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X " can be prepared by isolating a portion of SEQ ID NO:1, 3, 5, 7, 9, 11, 25 or 27, that encodes a polypeptide having a 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X biological activity (the biological activities of the 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X proteins are described below), expressing the encoded portion of 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X protein (e.g., by recombinant expression *in vitro*) and assessing the activity of the encoded portion of 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X.

#### **2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X variants**

The invention further encompasses nucleic acid molecules that differ from the nucleotide sequence shown in SEQ ID NO:1, 3, 5, 7, 9, 11, 25 or 27 due to degeneracy of the genetic code and thus encode the same 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X protein as that encoded by the nucleotide sequence shown in SEQ ID NO:1, 3, 5, 7, 9, 11, 25 or 27 . In another embodiment, an isolated nucleic acid molecule of the invention has a nucleotide sequence encoding a protein having an amino acid sequence shown in SEQ ID NO:1, 3, 5, 7, 9, 11, 25 or 27.

In addition to the human 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X nucleotide sequence shown in SEQ ID NO:1, 3, 5, 7, 9, 11, 25 or 27, it will be appreciated by those skilled in the art that DNA sequence polymorphisms that lead to changes in the amino acid sequences of 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X may exist within a population (e.g., the human population). Such genetic polymorphism in the 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X gene may exist among individuals within a population due to natural allelic variation. As used herein, the terms "gene" and "recombinant gene" refer to nucleic acid molecules comprising an open reading frame encoding a 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X protein, preferably a mammalian 2155647,

5 2355875, 3223867, 3224646, 3482699, or Mamm-X protein. Such natural allelic variations can typically result in 1-5% variance in the nucleotide sequence of the 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X gene. Any and all such nucleotide variations and resulting  
10 amino acid polymorphisms in 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X that are the result of natural allelic variation and that do not alter the functional activity of 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X are intended to be within the  
15 scope of the invention.

Moreover, nucleic acid molecules encoding 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X proteins from other species, and thus that have a nucleotide sequence that  
10 differs from the human sequence of SEQ ID NO:1, 3, 5, 7, 9, 11, 25 or 27, are intended to be within the scope of the invention. Nucleic acid molecules corresponding to natural allelic variants and homologues of the 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X cDNAs of the invention can be isolated based on their homology to the human 2155647,  
25 2355875, 3223867, 3224646, 3482699, or Mamm-X nucleic acids disclosed herein using the human cDNAs, or a portion thereof, as a hybridization probe according to standard hybridization techniques under stringent hybridization conditions. For example, a soluble human 2155647,  
30 2355875, 3223867, 3224646, 3482699, or Mamm-X cDNA can be isolated based on its homology to human membrane-bound 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X. Likewise, a membrane-bound human 2155647, 2355875, 3223867, 3224646,  
20 3482699, or Mamm-X cDNA can be isolated based on its homology to soluble human 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X.

Accordingly, in another embodiment, an isolated nucleic acid molecule of the invention is at least 6 nucleotides in length and hybridizes under stringent conditions to the nucleic acid  
40 molecule comprising the nucleotide sequence of SEQ ID NO:1, 3, 5, 7, 9, 11, 25 or 27. In another embodiment, the nucleic acid is at least 10, 25, 50, 100, 250 or 500 nucleotides in length. In another embodiment, an isolated nucleic acid molecule of the invention hybridizes to the coding region. As used herein, the term "hybridizes under stringent conditions" is intended to  
45 describe conditions for hybridization and washing under which nucleotide sequences at least 60% homologous to each other typically remain hybridized to each other.

50 Homologs (*i.e.*, nucleic acids encoding 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X proteins derived from species other than human) or other related sequences (*e.g.*,

5 paralogous) can be obtained by low, moderate or high stringency hybridization with all or a portion of the particular human sequence as a probe using methods well known in the art for nucleic acid hybridization and cloning.

10 Stringent conditions are known to those skilled in the art and can be found in CURRENT  
5 PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6. Preferably, the conditions are such that sequences at least about 65%, 70%, 75%, 85%, 90%, 95%, 98%, or  
15 99% homologous to each other typically remain hybridized to each other. A non-limiting example of stringent hybridization conditions are hybridization in a high salt buffer comprising  
20 6X SSC, 50 mM Tris-HCl (pH 7.5), 1 mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.02% BSA, and 500 mg/ml denatured salmon sperm DNA at 65°C, followed by one or more washes in 0.2X  
25 SSC, 0.01% BSA at 50°C. An isolated nucleic acid molecule of the invention that hybridizes under stringent conditions to the sequence of SEQ ID NO:1, 3, 5, 7, 9, 11, 25 or 27 corresponds to a naturally-occurring nucleic acid molecule. As used herein, a "naturally-occurring" nucleic  
30 acid molecule refers to an RNA or DNA molecule having a nucleotide sequence that occurs in nature (*e.g.*, encodes a natural protein).

In a second embodiment, a nucleic acid sequence that is hybridizable to the nucleic acid  
35 molecule comprising the nucleotide sequence of SEQ ID NO:1, 3, 5, 7, 9, 11, 25 or 27, or fragments, analogs or derivatives thereof, under conditions of moderate stringency is provided. A non-limiting example of moderate stringency hybridization conditions are hybridization in 6X  
40 SSC, 5X Denhardt's solution, 0.5% SDS and 100 mg/ml denatured salmon sperm DNA at 55°C, followed by one or more washes in 1X SSC, 0.1% SDS at 37°C. Other conditions of moderate stringency that may be used are well-known in the art. See, *e.g.*, Ausubel *et al.* (eds.), 1993, CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, NY, and Kriegler, 1990, GENE TRANSFER AND EXPRESSION, A LABORATORY MANUAL, Stockton Press, NY.

25 In a third embodiment, a nucleic acid that is hybridizable to the nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:1, 3, 5, 7, 9, 11, 25 or 27, or fragments,  
45 analogs or derivatives thereof, under conditions of low stringency, is provided. A non-limiting example of low stringency hybridization conditions are hybridization in 35% formamide, 5X SSC, 50 mM Tris-HCl (pH 7.5), 5 mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.2% BSA, 100  
50 mg/ml denatured salmon sperm DNA, 10% (wt/vol) dextran sulfate at 40°C, followed by one or more washes in 2X SSC, 25 mM Tris-HCl (pH 7.4), 5 mM EDTA, and 0.1% SDS at 50°C.

5 Other conditions of low stringency that may be used are well known in the art (*e.g.*, as employed for cross-species hybridizations). See, *e.g.*, Ausubel *et al.* (eds.), 1993, CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, NY, and Kriegler, 1990, GENE TRANSFER AND  
10 EXPRESSION, A LABORATORY MANUAL, Stockton Press, NY; Shilo and Weinberg, 1981, *Proc Natl Acad Sci USA* 78: 6789-6792.

#### Conservative mutations

15 In addition to naturally-occurring allelic variants of the 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X sequence that may exist in the population, the skilled artisan will further appreciate that changes can be introduced by mutation into the nucleotide sequence  
20 of SEQ ID NO:1, 3, 5, 7, 9, 11, 25 or 27, thereby leading to changes in the amino acid sequence of the encoded 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X protein, without altering the functional ability of the 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X protein. For example, nucleotide substitutions leading to amino acid substitutions at  
25 "non-essential" amino acid residues can be made in the sequence of SEQ ID NO:1, 3, 5, 7, 9, 11, 25 or 27. A "non-essential" amino acid residue is a residue that can be altered from the wild-type sequence of 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X without significantly  
30 altering the biological activity, whereas an "essential" amino acid residue is required for biological activity. For example, amino acid residues that are conserved among the 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X proteins of the present invention, are  
20 predicted to be particularly unamenable to alteration.

35 Another aspect of the invention pertains to nucleic acid molecules encoding 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X proteins that contain changes in amino acid residues that are not essential for activity. Such 2155647, 2355875, 3223867, 3224646,  
40 3482699, or Mamm-X proteins differ in amino acid sequence from SEQ ID NO:2, 4, 6, 8, 10, or 12, yet retain biological activity. In one embodiment, the isolated nucleic acid molecule comprises a nucleotide sequence encoding a protein, wherein the protein comprises an amino  
45 acid sequence at least about 45% of whose residues are identical to the amino acid sequence of SEQ ID NO:2, 4, 6, 8, 10, or 12, respectively. Preferably, the protein encoded by the nucleic acid molecule is at least about 60% identical to SEQ ID NO:2, 4, 6, 8, 10, or 12, more preferably  
50 at least about 70% identical to SEQ ID NO:2, 4, 6, 8, 10, or 12, still more preferably at least about 80% identical to SEQ ID NO:2, 4, 6, 8, 10, or 12, even more preferably at least about 90%



5 identical to SEQ ID NO:2, 4, 6, 8, 10, or 12, and most preferably at least about 95% identical to  
SEQ ID NO:2, 4, 6, 8, 10, or 12.

10 An isolated nucleic acid molecule encoding a 2155647, 2355875, 3223867, 3224646,  
3482699, or Mamm-X protein homologous to the protein of SEQ ID NO:2, 4, 6, 8, 10, or 12 can  
5 be created by introducing one or more nucleotide substitutions, additions or deletions into the  
nucleotide sequence of SEQ ID NO:1, 3, 5, 7, 9, 11, 25 or 27 such that one or more amino acid  
15 substitutions, additions or deletions are introduced into the encoded protein.

Mutations can be introduced into SEQ ID NO:1, 3, 5, 7, 9, 11, 25 or 27 by standard  
techniques, such as site-directed mutagenesis and PCR-mediated mutagenesis. Preferably,  
20 10 conservative amino acid substitutions are made at one or more predicted non-essential amino  
acid residues. A "conservative amino acid substitution" is one in which the amino acid residue is  
replaced with an amino acid residue having a similar side chain. Families of amino acid residues  
having similar side chains have been defined in the art. These families include amino acids with  
25 basic side chains (*e.g.*, lysine, arginine, histidine), acidic side chains (*e.g.*, aspartic acid, glutamic  
15 acid), uncharged polar side chains (*e.g.*, glycine, asparagine, glutamine, serine, threonine,  
tyrosine, cysteine), nonpolar side chains (*e.g.*, alanine, valine, leucine, isoleucine, proline,  
30 phenylalanine, methionine, tryptophan), beta-branched side chains (*e.g.*, threonine, valine,  
isoleucine) and aromatic side chains (*e.g.*, tyrosine, phenylalanine, tryptophan, histidine). Thus,  
a predicted nonessential amino acid residue in 2155647, 2355875, 3223867, 3224646, 3482699,  
20 or Mamm-X is replaced with another amino acid residue from the same side chain family.  
35 Alternatively, in another embodiment, mutations can be introduced randomly along all or part of  
a 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X coding sequence, such as by  
saturation mutagenesis, and the resultant mutants can be screened for 2155647, 2355875,  
40 3223867, 3224646, 3482699, or Mamm-X biological activity to identify mutants that retain  
25 activity. Following mutagenesis of SEQ ID NO:1, 3, 5, 7, 9, 11, 25 or 27, the encoded protein  
can be expressed by any recombinant technology known in the art and the activity of the protein  
can be determined.

45 In one embodiment, a mutant 2155647, 2355875, 3223867, 3224646, 3482699, or  
Mamm-X protein can be assayed for (1) the ability to form protein:protein interactions with  
30 other 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X proteins, other cell-surface  
50 proteins, or biologically active portions thereof, (2) complex formation between a mutant

2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X protein and a 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X ligand; (3) the ability of a mutant 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X protein to bind to an intracellular target protein or biologically active portion thereof.

#### **Antisense Polynucleotides**

Another aspect of the invention pertains to isolated antisense nucleic acid molecules that are hybridizable to or complementary to the nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:1, 3, 5, 7, 9, 11, 25 or 27 or fragments, analogs or derivatives thereof. An "antisense" nucleic acid comprises a nucleotide sequence that is complementary to a "sense" nucleic acid encoding a protein, *e.g.*, complementary to the coding strand of a double-stranded cDNA molecule or complementary to an mRNA sequence. In specific aspects, antisense nucleic acid molecules are provided that comprise a sequence complementary to at least about 10, 25, 50, 100, 250 or 500 nucleotides or an entire 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X coding strand, or to only a portion thereof. Nucleic acid molecules encoding fragments, homologs, derivatives and analogs of a 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X protein, or antisense nucleic acids complementary to a 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X nucleic acid sequence of SEQ ID NO:1, 3, 5, 7, 9, 11, 25 or 27 are additionally provided.

In one embodiment, an antisense nucleic acid molecule is antisense to a "coding region" of the coding strand of a nucleotide sequence encoding 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X. The term "coding region" refers to the region of the nucleotide sequence comprising codons which are translated into amino acid residues (*e.g.*, the coding region of human 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X corresponds to nucleotides 148 to 402 of SEQ ID NO:1, corresponds to nucleotides 209 to 610 of SEQ ID NO:3, corresponds to nucleotides 129 to 534 of SEQ ID NO:5, corresponds to nucleotides 301 to 1084 of SEQ ID NO:7, and corresponds to nucleotides 341 to 539 of SEQ ID NO:9. In another embodiment, the antisense nucleic acid molecule is antisense to a "noncoding region" of the coding strand of a nucleotide sequence encoding 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X. The term "noncoding region" refers to 5' and 3' sequences which flank the coding region that are not translated into amino acids (*i.e.*, also referred to as 5' and 3' untranslated regions).

Given the coding strand sequences encoding 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X disclosed herein (*e.g.*, SEQ ID NO:1, 3, 5, 7, 9, 11, 25 or 27), antisense nucleic acids of the invention can be designed according to the rules of Watson and Crick or Hoogsteen base pairing. The antisense nucleic acid molecule can be complementary to the entire coding region of 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X mRNA, but more preferably is an oligonucleotide that is antisense to only a portion of the coding or noncoding region of 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X mRNA. For example, the antisense oligonucleotide can be complementary to the region surrounding the translation start site of 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X mRNA. An antisense oligonucleotide can be, for example, about 5, 10, 15, 20, 25, 30, 35, 40, 45 or 50 nucleotides in length. An antisense nucleic acid of the invention can be constructed using chemical synthesis or enzymatic ligation reactions using procedures known in the art. For example, an antisense nucleic acid (*e.g.*, an antisense oligonucleotide) can be chemically synthesized using naturally occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed between the antisense and sense nucleic acids, *e.g.*, phosphorothioate derivatives and acridine substituted nucleotides can be used.

Examples of modified nucleotides that can be used to generate the antisense nucleic acid include: 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-(carboxyhydroxymethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine. Alternatively, the antisense nucleic acid can be produced biologically using an expression vector into which a nucleic acid has been subcloned in an antisense orientation (*i.e.*, RNA transcribed from the

5 inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest, described further in the following subsection).

10 The antisense nucleic acid molecules of the invention are typically administered to a subject or generated *in situ* such that they hybridize with or bind to cellular mRNA and/or  
5 genomic DNA encoding a 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X protein to thereby inhibit expression of the protein, *e.g.*, by inhibiting transcription and/or translation.  
15 The hybridization can be by conventional nucleotide complementarity to form a stable duplex, or, for example, in the case of an antisense nucleic acid molecule that binds to DNA duplexes, through specific interactions in the major groove of the double helix. An example of a route of  
10 administration of antisense nucleic acid molecules of the invention includes direct injection at a tissue site. Alternatively, antisense nucleic acid molecules can be modified to target selected cells and then administered systemically. For example, for systemic administration, antisense  
20 molecules can be modified such that they specifically bind to receptors or antigens expressed on a selected cell surface, *e.g.*, by linking the antisense nucleic acid molecules to peptides or  
25 antibodies that bind to cell surface receptors or antigens. The antisense nucleic acid molecules can also be delivered to cells using the vectors described herein. To achieve sufficient intracellular concentrations of antisense molecules, vector constructs in which the antisense  
30 nucleic acid molecule is placed under the control of a strong pol II or pol III promoter are preferred.

20 In yet another embodiment, the antisense nucleic acid molecule of the invention is an a-anomeric nucleic acid molecule. An a-anomeric nucleic acid molecule forms specific  
35 double-stranded hybrids with complementary RNA in which, contrary to the usual b-units, the strands run parallel to each other (Gaultier *et al.* (1987) *Nucleic Acids Res* 15: 6625-6641). The antisense nucleic acid molecule can also comprise a 2'-o-methylribonucleotide (Inoue *et al.*  
40 (1987) *Nucleic Acids Res* 15: 6131-6148) or a chimeric RNA-DNA analogue (Inoue *et al.* (1987) *FEBS Lett* 215: 327-330).

#### 45 **Ribozymes and PNA moieties**

In still another embodiment, an antisense nucleic acid of the invention is a ribozyme. Ribozymes are catalytic RNA molecules with ribonuclease activity that are capable of cleaving a  
50 30 single-stranded nucleic acid, such as an mRNA, to which they have a complementary region. Thus, ribozymes (*e.g.*, hammerhead ribozymes (described in Haselhoff and Gerlach (1988)

5 *Nature* 334:585-591)) can be used to catalytically cleave 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X mRNA transcripts to thereby inhibit translation of 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X mRNA. A ribozyme having specificity for a  
10 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X -encoding nucleic acid can be  
5 designed based upon the nucleotide sequence of a 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X cDNA disclosed herein (*i.e.*, SEQ ID NO:1, 3, 5, 7, 9, 11, 25 or 27). For example, a derivative of a Tetrahymena L-19 IVS RNA can be constructed in which the  
15 nucleotide sequence of the active site is complementary to the nucleotide sequence to be cleaved in a 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X -encoding mRNA. See, *e.g.*,  
10 Cech *et al.* U.S. Pat. No. 4,987,071; and Cech *et al.* U.S. Pat. No. 5,116,742. Alternatively,  
20 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X mRNA can be used to select a catalytic RNA having a specific ribonuclease activity from a pool of RNA molecules. See, *e.g.*, Bartel *et al.*, (1993) *Science* 261:1411-1418.

25 Alternatively, 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X gene  
15 expression can be inhibited by targeting nucleotide sequences complementary to the regulatory region of the 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X (*e.g.*, the 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X promoter and/or enhancers) to form triple  
30 helical structures that prevent transcription of the 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X gene in target cells. See generally, Helene. (1991) *Anticancer Drug Des.*  
20 6: 569-84; Helene. *et al.* (1992) *Ann. N.Y. Acad. Sci.* 660:27-36; and Maher (1992) *Bioassays*  
35 14: 807-15.

In various embodiments, the nucleic acids of 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X can be modified at the base moiety, sugar moiety or phosphate backbone  
40 to improve, *e.g.*, the stability, hybridization, or solubility of the molecule. For example, the  
25 deoxyribose phosphate backbone of the nucleic acids can be modified to generate peptide nucleic acids (see Hyrup *et al.* (1996) *Bioorg Med Chem* 4: 5-23). As used herein, the terms  
45 "peptide nucleic acids" or "PNAs" refer to nucleic acid mimics, *e.g.*, DNA mimics, in which the deoxyribose phosphate backbone is replaced by a pseudopeptide backbone and only the four natural nucleobases are retained. The neutral backbone of PNAs has been shown to allow for  
30 specific hybridization to DNA and RNA under conditions of low ionic strength. The synthesis of  
50 PNA oligomers can be performed using standard solid phase peptide synthesis protocols as described in Hyrup *et al.* (1996) above; Perry-O'Keefe *et al.* (1996) *PNAS* 93: 14670-675.

PNAs of 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X can be used in therapeutic and diagnostic applications. For example, PNAs can be used as antisense or antigene agents for sequence-specific modulation of gene expression by, *e.g.*, inducing transcription or translation arrest or inhibiting replication. PNAs of 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X can also be used, *e.g.*, in the analysis of single base pair mutations in a gene by, *e.g.*, PNA directed PCR clamping; as artificial restriction enzymes when used in combination with other enzymes, *e.g.*, S1 nucleases (Hyrup B. (1996) above); or as probes or primers for DNA sequence and hybridization (Hyrup *et al.* (1996), above; Perry-O'Keefe (1996), above).

In another embodiment, PNAs of 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X can be modified, *e.g.*, to enhance their stability or cellular uptake, by attaching lipophilic or other helper groups to PNA, by the formation of PNA-DNA chimeras, or by the use of liposomes or other techniques of drug delivery known in the art. For example, PNA-DNA chimeras of 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X can be generated that may combine the advantageous properties of PNA and DNA. Such chimeras allow DNA recognition enzymes, *e.g.*, RNase H and DNA polymerases, to interact with the DNA portion while the PNA portion would provide high binding affinity and specificity. PNA-DNA chimeras can be linked using linkers of appropriate lengths selected in terms of base stacking, number of bonds between the nucleobases, and orientation (Hyrup (1996) above). The synthesis of PNA-DNA chimeras can be performed as described in Hyrup (1996) above and Finn *et al.* (1996) *Nucl Acids Res* 24: 3357-63. For example, a DNA chain can be synthesized on a solid support using standard phosphoramidite coupling chemistry, and modified nucleoside analogs, *e.g.*, 5'-(4-methoxytrityl)amino-5'-deoxy-thymidine phosphoramidite, can be used between the PNA and the 5' end of DNA (Mag *et al.* (1989) *Nucl Acid Res* 17: 5973-88). PNA monomers are then coupled in a stepwise manner to produce a chimeric molecule with a 5' PNA segment and a 3' DNA segment (Finn *et al.* (1996) above). Alternatively, chimeric molecules can be synthesized with a 5' DNA segment and a 3' PNA segment. See, Petersen *et al.* (1975) *Bioorg Med Chem Lett* 5: 1119-11124.

In other embodiments, the oligonucleotide may include other appended groups such as peptides (*e.g.*, for targeting host cell receptors *in vivo*), or agents facilitating transport across the cell membrane (see, *e.g.*, Letsinger *et al.*, 1989, *Proc. Natl. Acad. Sci. U.S.A.* 86:6553-6556; Lemaitre *et al.*, 1987, *Proc. Natl. Acad. Sci.* 84:648-652; PCT Publication No. W088/09810) or

the blood-brain barrier (see, e.g., PCT Publication No. W089/10134). In addition, oligonucleotides can be modified with hybridization triggered cleavage agents (See, e.g., Krol *et al.*, 1988, *BioTechniques* 6:958-976) or intercalating agents. (See, e.g., Zon, 1988, *Pharm. Res.* 5: 539-549). To this end, the oligonucleotide may be conjugated to another molecule, e.g., a peptide, a hybridization triggered cross-linking agent, a transport agent, a hybridization-triggered cleavage agent, etc.

**2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X proteins**

One aspect of the invention pertains to isolated 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X proteins, and biologically active portions thereof, or derivatives, fragments, analogs or homologs thereof. Also provided are polypeptide fragments suitable for use as immunogens to raise anti-2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X antibodies. In one embodiment, native 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X proteins can be isolated from cells or tissue sources by an appropriate purification scheme using standard protein purification techniques. In another embodiment, 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X proteins are produced by recombinant DNA techniques. Alternative to recombinant expression, a 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X protein or polypeptide can be synthesized chemically using standard peptide synthesis techniques.

An "isolated" or "purified" protein or biologically active portion thereof is substantially free of cellular material or other contaminating proteins from the cell or tissue source from which the 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X protein is derived, or substantially free from chemical precursors or other chemicals when chemically synthesized. The language "substantially free of cellular material" includes preparations of 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X protein in which the protein is separated from cellular components of the cells from which it is isolated or recombinantly produced. In one embodiment, the language "substantially free of cellular material" includes preparations of 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X protein having less than about 30% (by dry weight) of non-2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X protein (also referred to herein as a "contaminating protein"), more preferably less than about 20% of non-2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X protein, still more preferably less than about 10% of non-2155647, 2355875, 3223867, 3224646, 3482699, or

5 Mamm-X protein, and most preferably less than about 5% non-2155647, 2355875, 3223867,  
3224646, 3482699, or Mamm-X protein. When the 2155647, 2355875, 3223867, 3224646,  
3482699, or Mamm-X protein or biologically active portion thereof is recombinantly produced,  
10 it is also preferably substantially free of culture medium, *i.e.*, culture medium represents less  
5 than about 20%, more preferably less than about 10%, and most preferably less than about 5% of  
the volume of the protein preparation.

15 The language "substantially free of chemical precursors or other chemicals" includes  
preparations of 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X protein in which  
the protein is separated from chemical precursors or other chemicals that are involved in the  
10 synthesis of the protein. In one embodiment, the language "substantially free of chemical  
20 precursors or other chemicals" includes preparations of 2155647, 2355875, 3223867, 3224646,  
3482699, or Mamm-X protein having less than about 30% (by dry weight) of chemical  
precursors or non-2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X chemicals,  
25 more preferably less than about 20% chemical precursors or non-2155647, 2355875, 3223867,  
15 3224646, 3482699, or Mamm-X chemicals, still more preferably less than about 10% chemical  
precursors or non-2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X chemicals, and  
30 most preferably less than about 5% chemical precursors or non-2155647, 2355875, 3223867,  
3224646, 3482699, or Mamm-X chemicals.

Biologically active portions of a 2155647, 2355875, 3223867, 3224646, 3482699, or  
20 Mamm-X protein include peptides comprising amino acid sequences sufficiently homologous to  
35 or derived from the amino acid sequence of the 2155647, 2355875, 3223867, 3224646,  
3482699, or Mamm-X protein, *e.g.*, the amino acid sequence shown in SEQ ID NO:2, 4, 6, 8,  
10, that include fewer amino acids than the full length 2155647, 2355875, 3223867, 3224646,  
40 3482699, or Mamm-X proteins, and exhibit at least one activity of a 2155647, 2355875,  
25 3223867, 3224646, 3482699, or Mamm-X protein. Typically, biologically active portions  
comprise a domain or motif with at least one activity of the 2155647, 2355875, 3223867,  
3224646, 3482699, or Mamm-X protein. A biologically active portion of a 2155647, 2355875,  
45 3223867, 3224646, 3482699, or Mamm-X protein can be a polypeptide which is, for example,  
10, 25, 50, 100 or more amino acids in length.

30 Moreover, other biologically active portions, in which other regions of the protein are  
50 deleted, can be prepared by recombinant techniques and evaluated for one or more of the



functional activities of a native 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X protein.

In an embodiment, the 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X protein has an amino acid sequence shown in SEQ ID NO:2, 4, 6, 8, 10. In other embodiments, the 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X protein is substantially homologous to SEQ ID NO:2, 4, 6, 8, 10 and retains the functional activity of the protein of SEQ ID NO:2, 4, 6, 8, 10 yet differs in amino acid sequence due to natural allelic variation or mutagenesis, as described in detail below. Accordingly, in another embodiment, the 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X protein is a protein that comprises an amino acid sequence at least about 45% homologous to the amino acid sequence of SEQ ID NO:2, 4, 6, 8, 10 and retains the functional activity of the 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X proteins of SEQ ID NO:2, 4, 6, 8, 10

#### Determining similarity between two or more sequences

To determine the percent similarity of two amino acid sequences or of two nucleic acids, the sequences are aligned for optimal comparison purposes (*e.g.*, gaps can be introduced in the sequence of a first amino acid or nucleic acid sequence for optimal alignment with a second amino or nucleic acid sequence). The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are homologous at that position (*i.e.*, as used herein amino acid or nucleic acid "similarity" is equivalent to amino acid or nucleic acid "identity").

The nucleic acid sequence similarity may be determined as the degree of identity between two sequences. The homology may be determined using computer programs known in the art, such as GAP software provided in the GCG program package. See, *Needleman and Wunsch* 1970 *J Mol Biol* 48: 443-453. Using GCG GAP software with the following settings for nucleic acid sequence comparison: GAP creation penalty of 5.0 and GAP extension penalty of 0.3, the coding region of the analogous nucleic acid sequences referred to above exhibits a degree of identity preferably of at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99%, with the CDS (encoding) part of the DNA sequence shown in SEQ ID NO:1, 3, 5, 7, 9.

The term "sequence identity" refers to the degree to which two polynucleotide or polypeptide sequences are identical on a residue-by-residue basis over a particular region of

5 comparison. The term "percentage of sequence identity" is calculated by comparing two  
optimally aligned sequences over that region of comparison, determining the number of  
10 positions at which the identical nucleic acid base (*e.g.*, A, T, C, G, U, or I, in the case of nucleic  
acids) occurs in both sequences to yield the number of matched positions, dividing the number  
5 of matched positions by the total number of positions in the region of comparison (*i.e.*, the  
window size), and multiplying the result by 100 to yield the percentage of sequence identity. The  
15 term "substantial identity" as used herein denotes a characteristic of a polynucleotide sequence,  
wherein the polynucleotide comprises a sequence that has at least 80 percent sequence identity,  
preferably at least 85 percent identity and often 90 to 95 percent sequence identity, more usually  
10 at least 99 percent sequence identity as compared to a reference sequence over a comparison  
20 region.

#### Chimeric and fusion proteins

25 The invention also provides 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-  
X chimeric or fusion proteins. As used herein, a 2155647, 2355875, 3223867, 3224646,  
15 3482699, or Mamm-X "chimeric protein" or "fusion protein" comprises a 2155647, 2355875,  
3223867, 3224646, 3482699, or Mamm-X polypeptide operatively linked to a non-2155647,  
30 2355875, 3223867, 3224646, 3482699, or Mamm-X polypeptide. A "2155647, 2355875,  
3223867, 3224646, 3482699, or Mamm-X polypeptide" refers to a polypeptide having an amino  
acid sequence corresponding to 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X ,  
20 whereas a "non-2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X polypeptide"  
35 refers to a polypeptide having an amino acid sequence corresponding to a protein that is not  
substantially homologous to the 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X  
protein, *e.g.*, a protein that is different from the 2155647, 2355875, 3223867, 3224646, 3482699,  
40 or Mamm-X protein and that is derived from the same or a different organism. Within a  
25 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X fusion protein the 2155647,  
2355875, 3223867, 3224646, 3482699, or Mamm-X polypeptide can correspond to all or a  
portion of a 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X protein. In one  
45 embodiment, a 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X fusion protein  
comprises at least one biologically active portion of a 2155647, 2355875, 3223867, 3224646,  
30 3482699, or Mamm-X protein. In another embodiment, a 2155647, 2355875, 3223867,  
50 3224646, 3482699, or Mamm-X fusion protein comprises at least two biologically active  
portions of a 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X protein. In yet

5 another embodiment, a 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X fusion protein comprises at least three biologically active portions of a 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X protein. Within the fusion protein, the term "operatively linked"  
10 is intended to indicate that the 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X polypeptide and the non-2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X polypeptide are fused in-frame to each other. The non-2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X polypeptide can be fused to the N-terminus or C-terminus of the  
15 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X polypeptide.

For example, in one embodiment a 2155647, 2355875, 3223867, 3224646, 3482699, or  
10 Mamm-X fusion protein comprises a 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X domain linked to the extracellular domain of a second protein. Such fusion proteins can be further utilized in screening assays for compounds which modulate 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X activity.

25 In yet another embodiment, the fusion protein is a GST-2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X fusion protein in which the 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X sequences are fused to the C-terminus of the GST (*i.e.*, glutathione S-transferase) sequences. Such fusion proteins can facilitate the purification of recombinant 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X.

30 In another embodiment, the fusion protein is a 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X protein containing a heterologous signal sequence at its N-terminus. For example, the native 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X signal sequence can be removed and replaced with a signal sequence from another protein. In certain host cells (*e.g.*, mammalian host cells), expression and/or secretion of 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X can be increased through use of a heterologous signal  
40 sequence.  
25

45 In yet another embodiment, the fusion protein is a 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X-immunoglobulin fusion protein in which the 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X sequences are fused to sequences derived from a member of the immunoglobulin protein family. The 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X-immunoglobulin fusion proteins of the invention can be  
50 incorporated into pharmaceutical compositions and administered to a subject to inhibit an

5 interaction between a 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X ligand and  
a 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X protein on the surface of a cell,  
to thereby suppress 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X -mediated  
10 signal transduction *in vivo*. The 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X  
5 -immunoglobulin fusion proteins can be used to affect the bioavailability of a 2155647,  
2355875, 3223867, 3224646, 3482699, or Mamm-X cognate ligand. Inhibition of the 2155647,  
2355875, 3223867, 3224646, 3482699, or Mamm-X ligand/2155647, 2355875, 3223867,  
15 3224646, 3482699, or Mamm-X interaction may be useful therapeutically for both the treatment  
of proliferative and differentiative disorders, as well as modulating (*e.g.* promoting or inhibiting)  
10 cell survival. Moreover, the 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X  
20 -immunoglobulin fusion proteins of the invention can be used as immunogens to produce  
anti-2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X antibodies in a subject, to  
purify 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X ligands, and in screening  
25 assays to identify molecules that inhibit the interaction of 2155647, 2355875, 3223867,  
15 3224646, 3482699, or Mamm-X with a 2155647, 2355875, 3223867, 3224646, 3482699, or  
Mamm-X ligand.

30 A 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X chimeric or fusion  
protein of the invention can be produced by standard recombinant DNA techniques. For  
example, DNA fragments coding for the different polypeptide sequences are ligated together  
20 in-frame in accordance with conventional techniques, *e.g.*, by employing blunt-ended or  
35 stagger-ended termini for ligation, restriction enzyme digestion to provide for appropriate  
termini, filling-in of cohesive ends as appropriate, alkaline phosphatase treatment to avoid  
undesirable joining, and enzymatic ligation. In another embodiment, the fusion gene can be  
synthesized by conventional techniques including automated DNA synthesizers. Alternatively,  
40 25 PCR amplification of gene fragments can be carried out using anchor primers that give rise to  
complementary overhangs between two consecutive gene fragments that can subsequently be  
annealed and reamplified to generate a chimeric gene sequence (see, for example, Ausubel *et al.*  
45 (eds.) CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, 1992). Moreover,  
many expression vectors are commercially available that already encode a fusion moiety (*e.g.*, a  
30 GST polypeptide). A 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X -encoding  
50 nucleic acid can be cloned into such an expression vector such that the fusion moiety is linked  
in-frame to the 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X protein.

### Agonists and antagonists

The present invention also pertains to variants of the 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X proteins that function as either 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X agonists (mimetics) or as 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X antagonists. Variants of the 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X protein can be generated by mutagenesis, *e.g.*, discrete point mutation or truncation of the 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X protein. An agonist of the 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X protein can retain substantially the same, or a subset of, the biological activities of the naturally occurring form of the 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X protein. An antagonist of the 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X protein can inhibit one or more of the activities of the naturally occurring form of the 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X protein by, for example, competitively binding to a downstream or upstream member of a cellular signaling cascade which includes the 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X protein. Thus, specific biological effects can be elicited by treatment with a variant of limited function. In one embodiment, treatment of a subject with a variant having a subset of the biological activities of the naturally occurring form of the protein has fewer side effects in a subject relative to treatment with the naturally occurring form of the 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X proteins.

Variants of the 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X protein that function as either 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X agonists (mimetics) or as 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X antagonists can be identified by screening combinatorial libraries of mutants, *e.g.*, truncation mutants, of the 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X protein for 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X protein agonist or antagonist activity. In one embodiment, a variegated library of 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X variants is generated by combinatorial mutagenesis at the nucleic acid level and is encoded by a variegated gene library. A variegated library of 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X variants can be produced by, for example, enzymatically ligating a mixture of synthetic oligonucleotides into gene sequences such that a degenerate set of potential 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X sequences is expressible as individual polypeptides, or alternatively, as a set of larger fusion proteins (*e.g.*, for phage

display) containing the set of 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X sequences therein. There are a variety of methods which can be used to produce libraries of potential 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X variants from a degenerate oligonucleotide sequence. Chemical synthesis of a degenerate gene sequence can be performed in an automatic DNA synthesizer, and the synthetic gene then ligated into an appropriate expression vector. Use of a degenerate set of genes allows for the provision, in one mixture, of all of the sequences encoding the desired set of potential 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X sequences. Methods for synthesizing degenerate oligonucleotides are known in the art (see, e.g., Narang (1983) *Tetrahedron* 39:3; Itakura *et al.* (1984) *Annu Rev Biochem* 53:323; Itakura *et al.* (1984) *Science* 198:1056; Ike *et al.* (1983) *Nucl Acid Res* 11:477.

#### Polypeptide libraries

In addition, libraries of fragments of the 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X protein coding sequence can be used to generate a variegated population of 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X fragments for screening and subsequent selection of variants of a 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X protein. In one embodiment, a library of coding sequence fragments can be generated by treating a double stranded PCR fragment of a 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X coding sequence with a nuclease under conditions wherein nicking occurs only about once per molecule, denaturing the double stranded DNA, renaturing the DNA to form double stranded DNA that can include sense/antisense pairs from different nicked products, removing single stranded portions from reformed duplexes by treatment with S1 nuclease, and ligating the resulting fragment library into an expression vector. By this method, an expression library can be derived which encodes N-terminal and internal fragments of various sizes of the 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X protein.

Several techniques are known in the art for screening gene products of combinatorial libraries made by point mutations or truncation, and for screening cDNA libraries for gene products having a selected property. Such techniques are adaptable for rapid screening of the gene libraries generated by the combinatorial mutagenesis of 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X proteins. The most widely used techniques, which are amenable to high throughput analysis, for screening large gene libraries typically include cloning the gene

5 library into replicable expression vectors, transforming appropriate cells with the resulting  
library of vectors, and expressing the combinatorial genes under conditions in which detection of  
a desired activity facilitates isolation of the vector encoding the gene whose product was  
10 detected. Recursive ensemble mutagenesis (REM), a new technique that enhances the frequency  
5 of functional mutants in the libraries, can be used in combination with the screening assays to  
identify 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X variants (Arkin and  
Yourvan (1992) PNAS 89:7811-7815; Delgrave *et al.* (1993) Protein Engineering 6:327-331).

**Anti-2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X antibodies**

An isolated 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X protein, or a  
20 10 portion or fragment thereof, can be used as an immunogen to generate antibodies that bind  
2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X using standard techniques for  
polyclonal and monoclonal antibody preparation. The full-length 2155647, 2355875, 3223867,  
25 3224646, 3482699, or Mamm-X protein can be used or, alternatively, the invention provides  
antigenic peptide fragments of 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X  
15 for use as immunogens. The antigenic peptide of 2155647, 2355875, 3223867, 3224646,  
3482699, or Mamm-X comprises at least 8 amino acid residues of the amino acid sequence  
shown in SEQ ID NO: 2, 4, 6, 8, 10 and encompasses an epitope of 2155647, 2355875,  
30 3223867, 3224646, 3482699, or Mamm-X such that an antibody raised against the peptide forms  
a specific immune complex with 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X.  
35 20 Preferably, the antigenic peptide comprises at least 10 amino acid residues, more preferably at  
least 15 amino acid residues, even more preferably at least 20 amino acid residues, and most  
preferably at least 30 amino acid residues. Preferred epitopes encompassed by the antigenic  
peptide are regions of 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X that are  
40 located on the surface of the protein, *e.g.*, hydrophilic regions. A hydrophobicity analysis of the  
25 human 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X protein sequence indicates  
that the regions between amino acids 80-108 (2155647); 25-70 and 90-134 (2355875); 70-135  
45 (3223867); 30-60 and 200-261 (3224646); 20-66 (3482699); and 25-95 (Mamm-X); are  
particularly hydrophilic and, therefore, are likely to encode surface residues useful for targeting  
antibody production.

50 30 As disclosed herein, 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X  
protein sequence of SEQ ID NO: 2, 4, 6, 8, 10 or derivatives, fragments, analogs or homologs

5 thereof, may be utilized as immunogens in the generation of antibodies that immunospecifically-bind these protein components. The term "antibody" as used herein refers to immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, *i.e.*, molecules that contain an antigen binding site that specifically binds (immunoreacts with) 10 an antigen, such as 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X. Such antibodies include, but are not limited to, polyclonal, monoclonal, chimeric, single chain,  $F_{ab}$  and  $F_{(ab)_2}$  fragments, and an  $F_{ab}$  expression library. In a specific embodiment, antibodies to human 15 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X proteins are disclosed. Various procedures known within the art may be used for the production of polyclonal or monoclonal 20 antibodies to a 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X protein sequence of SEQ ID NO: 2, 4, 6, 8, 10 or derivative, fragment, analog or homolog thereof. Some of these proteins are discussed below.

For the production of polyclonal antibodies, various suitable host animals (*e.g.*, rabbit, 25 goat, mouse or other mammal) may be immunized by injection with the native protein, or a synthetic variant thereof, or a derivative of the foregoing. An appropriate immunogenic preparation can contain, for example, recombinantly expressed 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X protein or a chemically synthesized 2155647, 2355875, 30 3223867, 3224646, 3482699, or Mamm-X polypeptide. The preparation can further include an adjuvant. Various adjuvants used to increase the immunological response include, but are not limited to, Freund's (complete and incomplete), mineral gels (*e.g.*, aluminum hydroxide), surface 35 active substances (*e.g.*, lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, dinitrophenol, etc.), human adjuvants such as *Bacille Calmette-Guerin* and *Corynebacterium parvum*, or similar immunostimulatory agents. If desired, the antibody molecules directed 40 against 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X can be isolated from the mammal (*e.g.*, from the blood) and further purified by well known techniques, such as protein A 25 chromatography to obtain the IgG fraction.

45 The term "monoclonal antibody" or "monoclonal antibody composition", as used herein, refers to a population of antibody molecules that contain only one species of an antigen binding site capable of immunoreacting with a particular epitope of 2155647, 2355875, 3223867, 30 3224646, 3482699, or Mamm-X. A monoclonal antibody composition thus typically displays a single binding affinity for a particular 2155647, 2355875, 3223867, 3224646, 3482699, or



5 Mamm-X protein with which it immunoreacts. For preparation of monoclonal antibodies directed towards a particular 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X protein, or derivatives, fragments, analogs or homologs thereof, any technique that provides for the production of antibody molecules by continuous cell line culture may be utilized. Such 10 techniques include, but are not limited to, the hybridoma technique (see Kohler & Milstein, 1975 *Nature* 256: 495-497); the trioma technique; the human B-cell hybridoma technique (see Kozbor, *et al.*, 1983 *Immunol Today* 4: 72) and the EBV hybridoma technique to produce human 15 monoclonal antibodies (see Cole, *et al.*, 1985 In: MONOCLONAL ANTIBODIES AND CANCER THERAPY, Alan R. Liss, Inc., pp. 77-96). Human monoclonal antibodies may be utilized in the practice of the present invention and may be produced by using human hybridomas (see Cote, *et al.*, 1983. *Proc Natl Acad Sci USA* 80: 2026-2030) or by transforming human B-cells with 20 Epstein Barr Virus *in vitro* (see Cole, *et al.*, 1985 In: MONOCLONAL ANTIBODIES AND CANCER THERAPY, Alan R. Liss, Inc., pp. 77-96).

25 According to the invention, techniques can be adapted for the production of single-chain antibodies specific to a 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X protein (see *e.g.*, U.S. Patent No. 4,946,778). In addition, methodologies can be adapted for the construction of  $F_{ab}$  expression libraries (see *e.g.*, Huse, *et al.*, 1989 *Science* 246: 1275-1281) to 30 allow rapid and effective identification of monoclonal  $F_{ab}$  fragments with the desired specificity for a 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X protein or derivatives, fragments, analogs or homologs thereof. Non-human antibodies can be "humanized" by 35 techniques well known in the art. See *e.g.*, U.S. Patent No. 5,225,539. Antibody fragments that contain the idiotypes to a 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X protein may be produced by techniques known in the art including, but not limited to: (i) an  $F_{(ab)2}$  fragment produced by pepsin digestion of an antibody molecule; (ii) an  $F_{ab}$  fragment generated 40 by reducing the disulfide bridges of an  $F_{(ab)2}$  fragment; (iii) an  $F_{ab}$  fragment generated by the treatment of the antibody molecule with papain and a reducing agent and (iv)  $F_v$  fragments.

45 Additionally, recombinant anti-2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X antibodies, such as chimeric and humanized monoclonal antibodies, comprising both human and non-human portions, which can be made using standard recombinant DNA 50 techniques, are within the scope of the invention. Such chimeric and humanized monoclonal antibodies can be produced by recombinant DNA techniques known in the art, for example using

5 methods described in PCT International Application No. PCT/US86/02269; European Patent  
Application No. 184,187; European Patent Application No. 171,496; European Patent  
Application No. 173,494; PCT International Publication No. WO 86/01533; U.S. Pat. No.  
10 4,816,567; European Patent Application No. 125,023; Better *et al.* (1988) *Science*  
5 240:1041-1043; Liu *et al.* (1987) *PNAS* 84:3439-3443; Liu *et al.* (1987) *J Immunol.*  
139:3521-3526; Sun *et al.* (1987) *PNAS* 84:214-218; Nishimura *et al.* (1987) *Cancer Res*  
47:999-1005; Wood *et al.* (1985) *Nature* 314:446-449; Shaw *et al.* (1988) *J Natl Cancer Inst*  
15 80:1553-1559; Morrison (1985) *Science* 229:1202-1207; Oi *et al.* (1986) *BioTechniques* 4:214;  
U.S. Pat. No. 5,225,539; Jones *et al.* (1986) *Nature* 321:552-525; Verhoeven *et al.* (1988)  
10 *Science* 239:1534; and Beidler *et al.* (1988) *J Immunol* 141:4053-4060.

20 In one embodiment, methodologies for the screening of antibodies that possess the  
desired specificity include, but are not limited to, enzyme-linked immunosorbent assay (ELISA)  
and other immunologically-mediated techniques known within the art. In a specific embodiment,  
25 selection of antibodies that are specific to a particular domain of a 2155647, 2355875, 3223867,  
15 3224646, 3482699, or Mamm-X protein is facilitated by generation of hybridomas that bind to  
the fragment of a 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X protein  
possessing such a domain. Antibodies that are specific for a domain within a 2155647, 2355875,  
30 3223867, 3224646, 3482699, or Mamm-X protein, or derivatives, fragments, analogs or  
homologs thereof, are also provided herein.

35 20 Anti-2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X antibodies may be  
used in methods known within the art relating to the localization and/or quantitation of a  
2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X protein (*e.g.*, for use in measuring  
levels of the 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X protein within  
40 appropriate physiological samples, for use in diagnostic methods, for use in imaging the protein,  
25 and the like). In a given embodiment, antibodies for 2155647, 2355875, 3223867, 3224646,  
3482699, or Mamm-X proteins, or derivatives, fragments, analogs or homologs thereof, that  
45 contain the antibody derived binding domain, are utilized as pharmacologically-active  
compounds [hereinafter "Therapeutics"].

50 30 An anti-2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X antibody (*e.g.*,  
monoclonal antibody) can be used to isolate 2155647, 2355875, 3223867, 3224646, 3482699, or  
Mamm-X by standard techniques, such as affinity chromatography or immunoprecipitation. An

anti-2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X antibody can facilitate the purification of natural 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X from cells and of recombinantly produced 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X expressed in host cells. Moreover, an anti-2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X antibody can be used to detect 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X protein (e.g., in a cellular lysate or cell supernatant) in order to evaluate the abundance and pattern of expression of the 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X protein. Anti-2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X antibodies can be used diagnostically to monitor protein levels in tissue as part of a clinical testing procedure, e.g., to, for example, determine the efficacy of a given treatment regimen. Detection can be facilitated by coupling (*i.e.*, physically linking) the antibody to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, b-galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin, and examples of suitable radioactive material include  $^{125}\text{I}$ ,  $^{131}\text{I}$ ,  $^{35}\text{S}$  or  $^3\text{H}$ .

#### **2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X Recombinant Expression Vectors and Host Cells**

Another aspect of the invention pertains to vectors, preferably expression vectors, containing a nucleic acid encoding 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X protein, or derivatives, fragments, analogs or homologs thereof. As used herein, the term "vector" refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of vector is a "plasmid", which refers to a circular double stranded DNA loop into which additional DNA segments can be ligated. Another type of vector is a viral vector, wherein additional DNA segments can be ligated into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors having a bacterial origin of replication and episomal mammalian vectors).

5 Other vectors (e.g., non-episomal mammalian vectors) are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are  
10 operatively linked. Such vectors are referred to herein as "expression vectors". In general, expression vectors of utility in recombinant DNA techniques are often in the form of plasmids. In the present specification, "plasmid" and "vector" can be used interchangeably as the plasmid is the most commonly used form of vector. However, the invention is intended to include such  
15 other forms of expression vectors, such as viral vectors (e.g., replication defective retroviruses, adenoviruses and adeno-associated viruses), which serve equivalent functions.

10 The recombinant expression vectors of the invention comprise a nucleic acid of the invention in a form suitable for expression of the nucleic acid in a host cell, which means that the recombinant expression vectors include one or more regulatory sequences, selected on the basis of the host cells to be used for expression, that is operatively linked to the nucleic acid  
25 sequence to be expressed. Within a recombinant expression vector, "operably linked" is intended to mean that the nucleotide sequence of interest is linked to the regulatory sequence(s) in a manner that allows for expression of the nucleotide sequence (e.g., in an *in vitro* transcription/translation system or in a host cell when the vector is introduced into the host cell). The term "regulatory sequence" is intended to include promoters, enhancers and other  
30 expression control elements (e.g., polyadenylation signals). Such regulatory sequences are described, for example, in Goeddel; GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990). Regulatory sequences include those that direct constitutive expression of a nucleotide sequence in many types of host cell and those that direct expression of the nucleotide sequence only in certain host cells (e.g.,  
40 tissue-specific regulatory sequences). It will be appreciated by those skilled in the art that the design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression of protein desired, etc. The expression vectors of the invention can be introduced into host cells to thereby produce proteins or peptides, including  
45 fusion proteins or peptides, encoded by nucleic acids as described herein (e.g., 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X proteins, mutant forms of 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X, fusion proteins, etc.).  
30

50 The recombinant expression vectors of the invention can be designed for expression of 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X in prokaryotic or eukaryotic cells.

5 For example, 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X can be expressed in  
bacterial cells such as *E. coli*, insect cells (using baculovirus expression vectors) yeast cells or  
mammalian cells. Suitable host cells are discussed further in Goeddel, GENE EXPRESSION  
10 TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990).

5 Alternatively, the recombinant expression vector can be transcribed and translated *in vitro*, for  
example using T7 promoter regulatory sequences and T7 polymerase.

15 Expression of proteins in prokaryotes is most often carried out in *E. coli* with vectors  
containing constitutive or inducible promoters directing the expression of either fusion or  
non-fusion proteins. Fusion vectors add a number of amino acids to a protein encoded therein,  
usually to the amino terminus of the recombinant protein. Such fusion vectors typically serve  
20 three purposes: (1) to increase expression of recombinant protein; (2) to increase the solubility of  
the recombinant protein; and (3) to aid in the purification of the recombinant protein by acting as  
a ligand in affinity purification. Often, in fusion expression vectors, a proteolytic cleavage site is  
introduced at the junction of the fusion moiety and the recombinant protein to enable separation  
25 of the recombinant protein from the fusion moiety subsequent to purification of the fusion  
protein. Such enzymes, and their cognate recognition sequences, include Factor Xa, thrombin  
and enterokinase. Typical fusion expression vectors include pGEX (Pharmacia Biotech Inc;  
Smith and Johnson (1988) *Gene* 67:31-40), pMAL (New England Biolabs, Beverly, Mass.) and  
pRIT5 (Pharmacia, Piscataway, N.J.) that fuse glutathione S-transferase (GST), maltose E  
30 binding protein, or protein A, respectively, to the target recombinant protein.

35 Examples of suitable inducible non-fusion *E. coli* expression vectors include pTrc  
(Amrann *et al.*, (1988) *Gene* 69:301-315) and pET 11d (Studier *et al.*, GENE EXPRESSION  
TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990)  
40 60-89).

25 One strategy to maximize recombinant protein expression in *E. coli* is to express the  
protein in a host bacteria with an impaired capacity to proteolytically cleave the recombinant  
protein. See, Gottesman, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185,  
45 Academic Press, San Diego, Calif. (1990) 119-128. Another strategy is to alter the nucleic acid  
sequence of the nucleic acid to be inserted into an expression vector so that the individual  
30 codons for each amino acid are those preferentially utilized in *E. coli* (Wada *et al.*, (1992)

5 *Nucleic Acids Res.* 20:2111-2118). Such alteration of nucleic acid sequences of the invention can be carried out by standard DNA synthesis techniques.

10 In another embodiment, the 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X expression vector is a yeast expression vector. Examples of vectors for expression in yeast *S. cerevisiae* include pYepSec1 (Baldari, *et al.*, (1987) *EMBO J* 6:229-234), pMFa (Kurjan and Herskowitz, (1982) *Cell* 30:933-943), pJRY88 (Schultz *et al.*, (1987) *Gene* 54:113-123), pYES2 (Invitrogen Corporation, San Diego, Calif.), and picZ (Invitrogen Corp, San Diego, Calif.).

15 Alternatively, 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X can be expressed in insect cells using baculovirus expression vectors. Baculovirus vectors available for expression of proteins in cultured insect cells (*e.g.*, SF9 cells) include the pAc series (Smith *et al.* (1983) *Mol Cell Biol* 3:2156-2165) and the pVL series (Lucklow and Summers (1989) *Virology* 170:31-39).

25 In yet another embodiment, a nucleic acid of the invention is expressed in mammalian cells using a mammalian expression vector. Examples of mammalian expression vectors include pCDM8 (Seed (1987) *Nature* 329:840) and pMT2PC (Kaufman *et al.* (1987) *EMBO J* 6: 187-195). When used in mammalian cells, the expression vector's control functions are often provided by viral regulatory elements. For example, commonly used promoters are derived from polyoma, Adenovirus 2, cytomegalovirus and Simian Virus 40. For other suitable expression systems for both prokaryotic and eukaryotic cells. See, *e.g.*, Chapters 16 and 17 of Sambrook *et al.*, *MOLECULAR CLONING: A LABORATORY MANUAL*. 2nd ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989.

35 In another embodiment, the recombinant mammalian expression vector is capable of directing expression of the nucleic acid preferentially in a particular cell type (*e.g.*, tissue-specific regulatory elements are used to express the nucleic acid). Tissue-specific regulatory elements are known in the art. Non-limiting examples of suitable tissue-specific promoters include the albumin promoter (liver-specific; Pinkert *et al.* (1987) *Genes Dev* 1:268-277), lymphoid-specific promoters (Calame and Eaton (1988) *Adv Immunol* 43:235-275), in particular promoters of T cell receptors (Winoto and Baltimore (1989) *EMBO J* 8:729-733) and immunoglobulins (Banerji *et al.* (1983) *Cell* 33:729-740; Queen and Baltimore (1983) *Cell* 33:741-748), neuron-specific promoters (*e.g.*, the neurofilament promoter; Byrne and Ruddle (1989) *PNAS* 86:5473-5477), pancreas-specific promoters (Edlund *et al.* (1985) *Science*

5 230:912-916), and mammary gland-specific promoters (e.g., milk whey promoter; U.S. Pat. No. 4,873,316 and European Application Publication No. 264,166). Developmentally-regulated promoters are also encompassed, e.g., the murine hox promoters (Kessel and Gruss (1990) *Science* 249:374-379) and the  $\alpha$ -fetoprotein promoter (Campes and Tilghman (1989) *Genes Dev* 3:537-546).

15 The invention further provides a recombinant expression vector comprising a DNA molecule of the invention cloned into the expression vector in an antisense orientation. That is, the DNA molecule is operatively linked to a regulatory sequence in a manner that allows for expression (by transcription of the DNA molecule) of an RNA molecule that is antisense to 20 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X mRNA. Regulatory sequences operatively linked to a nucleic acid cloned in the antisense orientation can be chosen that direct the continuous expression of the antisense RNA molecule in a variety of cell types, for instance viral promoters and/or enhancers, or regulatory sequences can be chosen that direct constitutive, 25 tissue specific or cell type specific expression of antisense RNA. The antisense expression vector can be in the form of a recombinant plasmid, phagemid or attenuated virus in which antisense nucleic acids are produced under the control of a high efficiency regulatory region, the activity of which can be determined by the cell type into which the vector is introduced. For a discussion 30 of the regulation of gene expression using antisense genes see Weintraub *et al.*, "Antisense RNA as a molecular tool for genetic analysis," Reviews--Trends in Genetics, Vol. 1(1) 1986.

35 Another aspect of the invention pertains to host cells into which a recombinant expression vector of the invention has been introduced. The terms "host cell" and "recombinant host cell" are used interchangeably herein. It is understood that such terms refer not only to the particular subject cell but to the progeny or potential progeny of such a cell. Because certain 40 modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included 25 within the scope of the term as used herein.

45 A host cell can be any prokaryotic or eukaryotic cell. For example, 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X protein can be expressed in bacterial cells such as *E. coli*, insect cells, yeast or mammalian cells (such as Chinese hamster ovary cells (CHO) or COS 30 cells). Other suitable host cells are known to those skilled in the art.

5 Vector DNA can be introduced into prokaryotic or eukaryotic cells via conventional transformation or transfection techniques. As used herein, the terms "transformation" and "transfection" are intended to refer to a variety of art-recognized techniques for introducing  
10 foreign nucleic acid (*e.g.*, DNA) into a host cell, including calcium phosphate or calcium chloride co-precipitation, DEAE-dextran-mediated transfection, lipofection, or electroporation. Suitable methods for transforming or transfecting host cells can be found in Sambrook, *et al.* (MOLECULAR CLONING: A LABORATORY MANUAL, 2nd ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989), and other laboratory manuals.

10 For stable transfection of mammalian cells, it is known that, depending upon the expression vector and transfection technique used, only a small fraction of cells may integrate the foreign DNA into their genome. In order to identify and select these integrants, a gene that encodes a selectable marker (*e.g.*, resistance to antibiotics) is generally introduced into the host  
20 cells along with the gene of interest. Various selectable markers include those that confer resistance to drugs, such as G418, hygromycin and methotrexate. Nucleic acid encoding a selectable marker can be introduced into a host cell on the same vector as that encoding 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X or can be introduced on a  
30 separate vector. Cells stably transfected with the introduced nucleic acid can be identified by drug selection (*e.g.*, cells that have incorporated the selectable marker gene will survive, while the other cells die).

35 A host cell of the invention, such as a prokaryotic or eukaryotic host cell in culture, can be used to produce (*i.e.*, express) 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X protein. Accordingly, the invention further provides methods for producing 2155647, 2355875, 40 3223867, 3224646, 3482699, or Mamm-X protein using the host cells of the invention. In one embodiment, the method comprises culturing the host cell of invention (into which a recombinant expression vector encoding 2155647, 2355875, 3223867, 3224646, 3482699, or  
25 Mamm-X has been introduced) in a suitable medium such that 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X protein is produced. In another embodiment, the method further comprises isolating 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X from the  
30 medium or the host cell.



### Transgenic animals

The host cells of the invention can also be used to produce nonhuman transgenic animals. For example, in one embodiment, a host cell of the invention is a fertilized oocyte or an embryonic stem cell into which 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X -coding sequences have been introduced. Such host cells can then be used to create non-human transgenic animals in which exogenous 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X sequences have been introduced into their genome or homologous recombinant animals in which endogenous 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X sequences have been altered. Such animals are useful for studying the function and/or activity of 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X and for identifying and/or evaluating modulators of 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X activity. As used herein, a "transgenic animal" is a non-human animal, preferably a mammal, more preferably a rodent such as a rat or mouse, in which one or more of the cells of the animal includes a transgene. Other examples of transgenic animals include non-human primates, sheep, dogs, cows, goats, chickens, amphibians, etc. A transgene is exogenous DNA that is integrated into the genome of a cell from which a transgenic animal develops and that remains in the genome of the mature animal, thereby directing the expression of an encoded gene product in one or more cell types or tissues of the transgenic animal. As used herein, a "homologous recombinant animal" is a non-human animal, preferably a mammal, more preferably a mouse, in which an endogenous 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X gene has been altered by homologous recombination between the endogenous gene and an exogenous DNA molecule introduced into a cell of the animal, *e.g.*, an embryonic cell of the animal, prior to development of the animal.

A transgenic animal of the invention can be created by introducing 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X -encoding nucleic acid into the male pronuclei of a fertilized oocyte, *e.g.*, by microinjection, retroviral infection, and allowing the oocyte to develop in a pseudopregnant female foster animal. The human 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X cDNA sequence of SEQ ID NO: 1, 3, 5, 7, 9 can be introduced as a transgene into the genome of a non-human animal. Alternatively, a nonhuman homologue of the human 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X gene, such as a mouse 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X gene, can be isolated based on hybridization to the human 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X

5 cDNA (described further above) and used as a transgene. Intronic sequences and  
polyadenylation signals can also be included in the transgene to increase the efficiency of  
expression of the transgene. A tissue-specific regulatory sequence(s) can be operably linked to  
10 the 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X transgene to direct expression  
5 of 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X protein to particular cells.  
Methods for generating transgenic animals via embryo manipulation and microinjection,  
particularly animals such as mice, have become conventional in the art and are described, for  
15 example, in U.S. Pat. Nos. 4,736,866; 4,870,009; and 4,873,191; and Hogan 1986, In:  
MANIPULATING THE MOUSE EMBRYO, Cold Spring Harbor Laboratory Press, Cold Spring  
10 Harbor, N.Y. Similar methods are used for production of other transgenic animals. A transgenic  
founder animal can be identified based upon the presence of the 2155647, 2355875, 3223867,  
20 3224646, 3482699, or Mamm-X transgene in its genome and/or expression of 2155647,  
2355875, 3223867, 3224646, 3482699, or Mamm-X mRNA in tissues or cells of the animals. A  
transgenic founder animal can then be used to breed additional animals carrying the transgene.  
25 Moreover, transgenic animals carrying a transgene encoding 2155647, 2355875, 3223867,  
3224646, 3482699, or Mamm-X can further be bred to other transgenic animals carrying other  
transgenes.

30 To create a homologous recombinant animal, a vector is prepared which contains at least  
a portion of a 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X gene into which a  
20 deletion, addition or substitution has been introduced to thereby alter, *e.g.*, functionally disrupt,  
the 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X gene. The 2155647, 2355875,  
35 3223867, 3224646, 3482699, or Mamm-X gene can be a human gene (*e.g.*, the cDNA of SEQ  
ID NO: 1, 3, 5, 7, 9) but more preferably, is a non-human homologue of a human 2155647,  
40 2355875, 3223867, 3224646, 3482699, or Mamm-X gene. For example, a mouse homologue of  
25 human 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X gene of SEQ ID NO: 1, 3,  
5, 7, 9 can be used to construct a homologous recombination vector suitable for altering an  
endogenous 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X gene in the mouse  
45 genome. In one embodiment, the vector is designed such that, upon homologous recombination,  
the endogenous 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X gene is  
30 functionally disrupted (*i.e.*, no longer encodes a functional protein; also referred to as a "knock  
out" vector).  
50

Alternatively, the vector can be designed such that, upon homologous recombination, the endogenous 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X gene is mutated or otherwise altered but still encodes functional protein (*e.g.*, the upstream regulatory region can be altered to thereby alter the expression of the endogenous 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X protein). In the homologous recombination vector, the altered portion of the 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X gene is flanked at its 5' and 3' ends by additional nucleic acid of the 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X gene to allow for homologous recombination to occur between the exogenous 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X gene carried by the vector and an endogenous 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X gene in an embryonic stem cell. The additional flanking 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X nucleic acid is of sufficient length for successful homologous recombination with the endogenous gene. Typically, several kilobases of flanking DNA (both at the 5' and 3' ends) are included in the vector. See *e.g.*, Thomas *et al.* (1987) *Cell* 51:503 for a description of homologous recombination vectors. The vector is introduced into an embryonic stem cell line (*e.g.*, by electroporation) and cells in which the introduced 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X gene has homologously recombined with the endogenous 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X gene are selected (see *e.g.*, Li *et al.* (1992) *Cell* 69:915).

The selected cells are then injected into a blastocyst of an animal (*e.g.*, a mouse) to form aggregation chimeras. See *e.g.*, Bradley 1987, In: TERATOCARCINOMAS AND EMBRYONIC STEM CELLS: A PRACTICAL APPROACH, Robertson, ed. IRL, Oxford, pp. 113-152. A chimeric embryo can then be implanted into a suitable pseudopregnant female foster animal and the embryo brought to term. Progeny harboring the homologously recombined DNA in their germ cells can be used to breed animals in which all cells of the animal contain the homologously recombined DNA by germline transmission of the transgene. Methods for constructing homologous recombination vectors and homologous recombinant animals are described further in Bradley (1991) *Curr Opin Biotechnol* 2:823-829; PCT International Publication Nos.: WO 90/11354; WO 91/01140; WO 92/0968; and WO 93/04169.

In another embodiment, transgenic non-humans animals can be produced that contain selected systems that allow for regulated expression of the transgene. One example of such a system is the cre/loxP recombinase system of bacteriophage P1. For a description of the cre/loxP

5 recombinase system, see, e.g., Lakso *et al.* (1992) *PNAS* 89:6232-6236. Another example of a  
10 recombinase system is the FLP recombinase system of *Saccharomyces cerevisiae* (O'Gorman *et al.* (1991) *Science* 251:1351-1355. If a cre/loxP recombinase system is used to regulate  
15 expression of the transgene, animals containing transgenes encoding both the Cre recombinase  
and a selected protein are required. Such animals can be provided through the construction of  
"double" transgenic animals, e.g., by mating two transgenic animals, one containing a transgene  
10 encoding a selected protein and the other containing a transgene encoding a recombinase.

15 Clones of the non-human transgenic animals described herein can also be produced  
according to the methods described in Wilmut *et al.* (1997) *Nature* 385:810-813. In brief, a cell,  
20 e.g., a somatic cell, from the transgenic animal can be isolated and induced to exit the growth  
cycle and enter G<sub>0</sub> phase. The quiescent cell can then be fused, e.g., through the use of electrical  
pulses, to an enucleated oocyte from an animal of the same species from which the quiescent cell  
25 is isolated. The reconstructed oocyte is then cultured such that it develops to morula or  
blastocyte and then transferred to pseudopregnant female foster animal. The offspring borne of  
15 this female foster animal will be a clone of the animal from which the cell, e.g., the somatic cell,  
is isolated.

### 30 **Pharmaceutical Compositions**

The 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X nucleic acid  
molecules, 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X proteins, and  
35 20 anti-2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X antibodies (also referred to  
herein as "active compounds") of the invention, and derivatives, fragments, analogs and  
homologs thereof, can be incorporated into pharmaceutical compositions suitable for  
administration. Such compositions typically comprise the nucleic acid molecule, protein, or  
40 antibody and a pharmaceutically acceptable carrier. As used herein, "pharmaceutically  
25 acceptable carrier" is intended to include any and all solvents, dispersion media, coatings,  
antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like,  
45 compatible with pharmaceutical administration. The use of such media and agents for  
pharmaceutically active substances is well known in the art. Except insofar as any conventional  
media or agent is incompatible with the active compound, use thereof in the compositions is  
50 30 contemplated. Supplementary active compounds can also be incorporated into the compositions.

5 A pharmaceutical composition of the invention is formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral, *e.g.*, intravenous, intradermal, subcutaneous, oral (*e.g.*, inhalation), transdermal (topical),  
10 transmucosal, and rectal administration. Solutions or suspensions used for parenteral,  
5 intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl  
15 parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates, and agents for the adjustment of tonicity such as sodium chloride or dextrose. The pH can be adjusted with  
10 acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.

Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions  
25 (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of  
15 sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL™ (BASF, Parsippany, N.J.) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be fluid  
30 to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as  
20 bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example,  
35 by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can  
40 be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as manitol, sorbitol, sodium chloride in  
45 the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum  
30 monostearate and gelatin.

50 Sterile injectable solutions can be prepared by incorporating the active compound (*e.g.*, a 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X protein or anti-2155647,

5 2355875, 3223867, 3224646, 3482699, or Mamm-X antibody) in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active  
10 compound into a sterile vehicle that contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, methods of preparation are vacuum drying and freeze-drying that yields a powder of the active ingredient plus any additional desired ingredient from a previously  
15 sterile-filtered solution thereof.

Oral compositions generally include an inert diluent or an edible carrier. They can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic  
10 administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash, wherein the compound in the fluid carrier is applied orally and swished and expectorated or swallowed. Pharmaceutically compatible binding agents, and/or adjuvant  
25 materials can be included as part of the composition. The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent  
30 such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.

For administration by inhalation, the compounds are delivered in the form of an aerosol spray from pressured container or dispenser which contains a suitable propellant, *e.g.*, a gas such  
40 as carbon dioxide, or a nebulizer.

25 Systemic administration can also be by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for  
45 example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be accomplished through the use of nasal sprays or suppositories. For transdermal administration, the active compounds are formulated into  
30 ointments, salves, gels, or creams as generally known in the art.

5 The compounds can also be prepared in the form of suppositories (*e.g.*, with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas for rectal delivery.

10 In one embodiment, the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible  
5 polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. The materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes  
15 targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Pat. No. 4,522,811.

25 It is especially advantageous to formulate oral or parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit  
15 containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms of the invention are dictated by and directly dependent on the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and  
30 the limitations inherent in the art of compounding such an active compound for the treatment of individuals.

35 The nucleic acid molecules of the invention can be inserted into vectors and used as gene therapy vectors. Gene therapy vectors can be delivered to a subject by, for example, intravenous injection, local administration (see U.S. Pat. No. 5,328,470) or by stereotactic injection (see *e.g.*,  
40 Chen *et al.* (1994) *PNAS* 91:3054-3057). The pharmaceutical preparation of the gene therapy vector can include the gene therapy vector in an acceptable diluent, or can comprise a slow release matrix in which the gene delivery vehicle is imbedded. Alternatively, where the complete  
45 gene delivery vector can be produced intact from recombinant cells, *e.g.*, retroviral vectors, the pharmaceutical preparation can include one or more cells that produce the gene delivery system.

50 30 The pharmaceutical compositions can be included in a container, pack, or dispenser together with instructions for administration.

## Uses and Methods of the Invention

The nucleic acid molecules, proteins, protein homologues, and antibodies described herein can be used in one or more of the following methods: (a) screening assays; (b) detection assays (*e.g.*, chromosomal mapping, tissue typing, forensic biology), (c) predictive medicine (*e.g.*, diagnostic assays, prognostic assays, monitoring clinical trials, and pharmacogenomics); and (d) methods of treatment (*e.g.*, therapeutic and prophylactic). A 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X protein interacts with other cellular proteins and can thus be used to (i) modulation of protein activity; (ii) regulation of cellular proliferation; (iii) regulation of cellular differentiation; and (iv) regulation of cell survival.

The isolated nucleic acid molecules of the invention can be used to express 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X protein (*e.g.*, via a recombinant expression vector in a host cell in gene therapy applications), to detect 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X mRNA (*e.g.*, in a biological sample) or a genetic lesion in a 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X gene, and to modulate 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X activity, as described further below. In addition, the 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X proteins can be used to screen drugs or compounds that modulate the 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X activity or expression as well as to treat disorders characterized by insufficient or excessive production of 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X protein or production of 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X protein forms that have decreased or aberrant activity compared to 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X wild type protein (*e.g.* proliferative disorders such as cancer or preclampsia). In addition, the anti-2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X antibodies of the invention can be used to detect and isolate 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X proteins and modulate 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X activity.

This invention further pertains to novel agents identified by the above described screening assays and uses thereof for treatments as described herein.

### Screening Assays

The invention provides a method (also referred to herein as a "screening assay") for identifying modulators, *i.e.*, candidate or test compounds or agents (*e.g.*, peptides,



5 peptidomimetics, small molecules or other drugs) that bind to 2155647, 2355875, 3223867,  
3224646, 3482699, or Mamm-X proteins or have a stimulatory or inhibitory effect on, for  
example, 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X expression or 2155647,  
10 2355875, 3223867, 3224646, 3482699, or Mamm-X activity.

5 In one embodiment, the invention provides assays for screening candidate or test  
compounds which bind to or modulate the activity of the membrane-bound form of a 2155647,  
15 2355875, 3223867, 3224646, 3482699, or Mamm-X protein or polypeptide or biologically  
active portion thereof. The test compounds of the present invention can be obtained using any of  
the numerous approaches in combinatorial library methods known in the art, including:  
10 biological libraries; spatially addressable parallel solid phase or solution phase libraries;  
20 synthetic library methods requiring deconvolution; the "one-bead one-compound" library  
method; and synthetic library methods using affinity chromatography selection. The biological  
library approach is limited to peptide libraries, while the other four approaches are applicable to  
25 peptide, non-peptide oligomer or small molecule libraries of compounds (Lam (1997)  
15 *Anticancer Drug Des* 12:145).

Examples of methods for the synthesis of molecular libraries can be found in the art, for  
example in: DeWitt *et al.* (1993) *Proc Natl Acad Sci U.S.A.* 90:6909; Erb *et al.* (1994) *Proc Natl*  
30 *Acad Sci U.S.A.* 91:11422; Zuckermann *et al.* (1994) *J Med Chem* 37:2678; Cho *et al.* (1993)  
*Science* 261:1303; Carrell *et al.* (1994) *Angew Chem Int Ed Engl* 33:2059; Carell *et al.* (1994)  
20 *Angew Chem Int Ed Engl* 33:2061; and Gallop *et al.* (1994) *J Med Chem* 37:1233.

35 Libraries of compounds may be presented in solution (e.g., Houghten (1992)  
*Biotechniques* 13:412-421), or on beads (Lam (1991) *Nature* 354:82-84), on chips (Fodor (1993)  
*Nature* 364:555-556), bacteria (Ladner U.S. Pat. No. 5,223,409), spores (Ladner USP '409),  
40 plasmids (Cull *et al.* (1992) *Proc Natl Acad Sci USA* 89:1865-1869) or on phage (Scott and  
25 Smith (1990) *Science* 249:386-390; Devlin (1990) *Science* 249:404-406; Cwirla *et al.* (1990)  
*Proc Natl Acad Sci U.S.A.* 87:6378-6382; Felici (1991) *J Mol Biol* 222:301-310; Ladner above.).

45 In one embodiment, an assay is a cell-based assay in which a cell which expresses a  
membrane-bound form of 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X  
protein, or a biologically active portion thereof, on the cell surface is contacted with a test  
50 30 compound and the ability of the test compound to bind to a 2155647, 2355875, 3223867,  
3224646, 3482699, or Mamm-X protein determined. The cell, for example, can of mammalian

5 origin or a yeast cell. Determining the ability of the test compound to bind to the 2155647,  
2355875, 3223867, 3224646, 3482699, or Mamm-X protein can be accomplished, for example,  
by coupling the test compound with a radioisotope or enzymatic label such that binding of the  
10 test compound to the 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X protein or  
5 biologically active portion thereof can be determined by detecting the labeled compound in a  
complex. For example, test compounds can be labeled with  $^{125}\text{I}$ ,  $^{35}\text{S}$ ,  $^{14}\text{C}$ , or  $^3\text{H}$ , either directly or  
indirectly, and the radioisotope detected by direct counting of radioemission or by scintillation  
15 counting. Alternatively, test compounds can be enzymatically labeled with, for example,  
horseradish peroxidase, alkaline phosphatase, or luciferase, and the enzymatic label detected by  
10 determination of conversion of an appropriate substrate to product. In one embodiment, the  
assay comprises contacting a cell which expresses a membrane-bound form of 2155647,  
2355875, 3223867, 3224646, 3482699, or Mamm-X protein, or a biologically active portion  
thereof, on the cell surface with a known compound which binds 2155647, 2355875, 3223867,  
25 3224646, 3482699, or Mamm-X to form an assay mixture, contacting the assay mixture with a  
15 test compound, and determining the ability of the test compound to interact with a 2155647,  
2355875, 3223867, 3224646, 3482699, or Mamm-X protein, wherein determining the ability of  
the test compound to interact with a 2155647, 2355875, 3223867, 3224646, 3482699, or  
30 Mamm-X protein comprises determining the ability of the test compound to preferentially bind  
to 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X or a biologically active portion  
20 thereof as compared to the known compound.

35 In another embodiment, an assay is a cell-based assay comprising contacting a cell  
expressing a membrane-bound form of 2155647, 2355875, 3223867, 3224646, 3482699, or  
Mamm-X protein, or a biologically active portion thereof, on the cell surface with a test  
40 compound and determining the ability of the test compound to modulate (*e.g.*, stimulate or  
25 inhibit) the activity of the 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X protein  
or biologically active portion thereof. Determining the ability of the test compound to modulate  
the activity of 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X or a biologically  
45 active portion thereof can be accomplished, for example, by determining the ability of the  
2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X protein to bind to or interact with  
30 a 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X target molecule. As used herein,  
a "target molecule" is a molecule with which a 2155647, 2355875, 3223867, 3224646, 3482699,  
50 or Mamm-X protein binds or interacts in nature, for example, a molecule on the surface of a cell

5 which expresses a 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X protein, a molecule on the surface of a second cell, a molecule in the extracellular milieu, a molecule associated with the internal surface of a cell membrane or a cytoplasmic molecule. A 2155647,  
10 2355875, 3223867, 3224646, 3482699, or Mamm-X target molecule can be a non-2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X molecule or a 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X protein or polypeptide of the present invention. In one  
15 embodiment, a 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X target molecule is a component of a signal transduction pathway that facilitates transduction of an extracellular signal (*e.g.* a signal generated by binding of a compound to a membrane-bound 2155647,  
20 2355875, 3223867, 3224646, 3482699, or Mamm-X molecule) through the cell membrane and into the cell. The target, for example, can be a second intercellular protein that has catalytic activity or a protein that facilitates the association of downstream signaling molecules with 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X.

25 Determining the ability of the 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X protein to bind to or interact with a 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X target molecule can be accomplished by one of the methods described above for  
15 determining direct binding. In one embodiment, determining the ability of the 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X protein to bind to or interact with a 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X target molecule can be  
20 accomplished by determining the activity of the target molecule. For example, the activity of the target molecule can be determined by detecting induction of a cellular second messenger of the target (*i.e.* intracellular  $Ca^{2+}$ , diacylglycerol,  $IP_3$ , etc.), detecting catalytic/enzymatic activity of the target an appropriate substrate, detecting the induction of a reporter gene (comprising a  
25 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X -responsive regulatory element operatively linked to a nucleic acid encoding a detectable marker, *e.g.*, luciferase), or detecting a cellular response, for example, cell survival, cellular differentiation, or cell proliferation.

30 In yet another embodiment, an assay of the present invention is a cell-free assay comprising contacting a 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X protein or biologically active portion thereof with a test compound and determining the ability of the test  
35 compound to bind to the 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X protein or biologically active portion thereof. Binding of the test compound to the 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X protein can be determined either directly or indirectly

5 as described above. In one embodiment, the assay comprises contacting the 2155647, 2355875,  
3223867, 3224646, 3482699, or Mamm-X protein or biologically active portion thereof with a  
known compound which binds 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X to  
10 form an assay mixture, contacting the assay mixture with a test compound, and determining the  
5 ability of the test compound to interact with a 2155647, 2355875, 3223867, 3224646, 3482699,  
or Mamm-X protein, wherein determining the ability of the test compound to interact with a  
2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X protein comprises determining  
15 the ability of the test compound to preferentially bind to 2155647, 2355875, 3223867, 3224646,  
3482699, or Mamm-X or biologically active portion thereof as compared to the known  
10 compound.

20 In another embodiment, an assay is a cell-free assay comprising contacting 2155647,  
2355875, 3223867, 3224646, 3482699, or Mamm-X protein or biologically active portion  
thereof with a test compound and determining the ability of the test compound to modulate (*e.g.*  
25 stimulate or inhibit) the activity of the 2155647, 2355875, 3223867, 3224646, 3482699, or  
15 Mamm-X protein or biologically active portion thereof. Determining the ability of the test  
compound to modulate the activity of 2155647, 2355875, 3223867, 3224646, 3482699, or  
Mamm-X can be accomplished, for example, by determining the ability of the 2155647,  
30 2355875, 3223867, 3224646, 3482699, or Mamm-X protein to bind to a 2155647, 2355875,  
3223867, 3224646, 3482699, or Mamm-X target molecule by one of the methods described  
20 above for determining direct binding. In an alternative embodiment, determining the ability of  
the test compound to modulate the activity of 2155647, 2355875, 3223867, 3224646, 3482699,  
35 or Mamm-X can be accomplished by determining the ability of the 2155647, 2355875, 3223867,  
3224646, 3482699, or Mamm-X protein further modulate a 2155647, 2355875, 3223867,  
3224646, 3482699, or Mamm-X target molecule. For example, the catalytic/enzymatic activity  
40 of the target molecule on an appropriate substrate can be determined as previously described.  
25

In yet another embodiment, the cell-free assay comprises contacting the 2155647,  
45 2355875, 3223867, 3224646, 3482699, or Mamm-X protein or biologically active portion  
thereof with a known compound which binds 2155647, 2355875, 3223867, 3224646, 3482699,  
or Mamm-X to form an assay mixture, contacting the assay mixture with a test compound, and  
30 determining the ability of the test compound to interact with a 2155647, 2355875, 3223867,  
3224646, 3482699, or Mamm-X protein, wherein determining the ability of the test compound  
50 to interact with a 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X protein

comprises determining the ability of the 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X protein to preferentially bind to or modulate the activity of a 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X target molecule.

The cell-free assays of the present invention are amenable to use of both the soluble form or the membrane-bound form of 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X. In the case of cell-free assays comprising the membrane-bound form of 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X, it may be desirable to utilize a solubilizing agent such that the membrane-bound form of 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X is maintained in solution. Examples of such solubilizing agents include non-ionic detergents such as n-octylglucoside, n-dodecylglucoside, n-dodecylmaltoside, octanoyl-N-methylglucamide, decanoyl-N-methylglucamide, Triton® X-100, Triton® X-114, Thesit®, Isotridecypoly(ethylene glycol ether), 3-(3-cholamidopropyl)dimethylamminiol-1-propane sulfonate (CHAPS), 3-(3-cholamidopropyl)dimethylamminiol-2-hydroxy-1-propane sulfonate (CHAPSO), or N-dodecyl-N,N-dimethyl-3-ammonio-1-propane sulfonate.

In more than one embodiment of the above assay methods of the present invention, it may be desirable to immobilize either 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X or its target molecule to facilitate separation of complexed from uncomplexed forms of one or both of the proteins, as well as to accommodate automation of the assay. Binding of a test compound to 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X, or interaction of 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X with a target molecule in the presence and absence of a candidate compound, can be accomplished in any vessel suitable for containing the reactants. Examples of such vessels include microtiter plates, test tubes, and micro-centrifuge tubes. In one embodiment, a fusion protein can be provided that adds a domain that allows one or both of the proteins to be bound to a matrix. For example, GST-2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X fusion proteins or GST-target fusion proteins can be adsorbed onto glutathione sepharose beads (Sigma Chemical, St. Louis, MO) or glutathione derivatized microtiter plates, that are then combined with the test compound or the test compound and either the non-adsorbed target protein or 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X protein, and the mixture is incubated under conditions conducive to complex formation (e.g., at physiological conditions for salt and pH). Following incubation, the beads or microtiter plate wells are washed to remove any unbound components, the matrix immobilized in the case of beads, complex determined either directly or indirectly, for

5 example, as described above. Alternatively, the complexes can be dissociated from the matrix, and the level of 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X binding or activity determined using standard techniques.

10 Other techniques for immobilizing proteins on matrices can also be used in the screening assays of the invention. For example, either 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X or its target molecule can be immobilized utilizing conjugation of biotin and streptavidin. Biotinylated 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X or target molecules can be prepared from biotin-NHS (N-hydroxy-succinimide) using techniques well known in the art (*e.g.*, biotinylation kit, Pierce Chemicals, Rockford, Ill.), and immobilized 10 in the wells of streptavidin-coated 96 well plates (Pierce Chemical). Alternatively, antibodies reactive with 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X or target molecules, but which do not interfere with binding of the 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X protein to its target molecule, can be derivatized to the wells of the plate, and unbound target or 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X trapped in the 25 wells by antibody conjugation. Methods for detecting such complexes, in addition to those described above for the GST-immobilized complexes, include immunodetection of complexes using antibodies reactive with the 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X or target molecule, as well as enzyme-linked assays that rely on detecting an enzymatic activity associated with the 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X or target 20 molecule.

35 In another embodiment, modulators of 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X expression are identified in a method wherein a cell is contacted with a candidate compound and the expression of 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X mRNA or protein in the cell is determined. The level of expression of 2155647, 2355875, 40 3223867, 3224646, 3482699, or Mamm-X mRNA or protein in the presence of the candidate compound is compared to the level of expression of 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X mRNA or protein in the absence of the candidate compound. The candidate compound can then be identified as a modulator of 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X expression based on this comparison. For example, when 45 expression of 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X mRNA or protein is greater (statistically significantly greater) in the presence of the candidate compound than in its absence, the candidate compound is identified as a stimulator of 2155647, 2355875, 3223867, 50

5 3224646, 3482699, or Mamm-X mRNA or protein expression. Alternatively, when expression  
of 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X mRNA or protein is less  
(statistically significantly less) in the presence of the candidate compound than in its absence,  
10 the candidate compound is identified as an inhibitor of 2155647, 2355875, 3223867, 3224646,  
5 3482699, or Mamm-X mRNA or protein expression. The level of 2155647, 2355875, 3223867,  
3224646, 3482699, or Mamm-X mRNA or protein expression in the cells can be determined by  
methods described herein for detecting 2155647, 2355875, 3223867, 3224646, 3482699, or  
15 Mamm-X mRNA or protein.

In yet another aspect of the invention, the 2155647, 2355875, 3223867, 3224646,  
10 3482699, or Mamm-X proteins can be used as "bait proteins" in a two-hybrid assay or three  
20 hybrid assay (see, e.g., U.S. Pat. No. 5,283,317; Zervos *et al.* (1993) Cell 72:223-232; Madura *et al.* (1993) J Biol Chem 268:12046-12054; Bartel *et al.* (1993) Biotechniques 14:920-924;  
Iwabuchi *et al.* (1993) Oncogene 8:1693-1696; and Brent WO94/10300), to identify other  
25 proteins that bind to or interact with 2155647, 2355875, 3223867, 3224646, 3482699, or  
15 Mamm-X ("2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X -binding proteins" or  
"2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X -bp") and modulate 2155647,  
2355875, 3223867, 3224646, 3482699, or Mamm-X activity. Such 2155647, 2355875, 3223867,  
30 3224646, 3482699, or Mamm-X -binding proteins are also likely to be involved in the  
propagation of signals by the 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X  
20 proteins as, for example, upstream or downstream elements of the 2155647, 2355875, 3223867,  
35 3224646, 3482699, or Mamm-X pathway.

The two-hybrid system is based on the modular nature of most transcription factors,  
which consist of separable DNA-binding and activation domains. Briefly, the assay utilizes two  
40 different DNA constructs. In one construct, the gene that codes for 2155647, 2355875, 3223867,  
25 3224646, 3482699, or Mamm-X is fused to a gene encoding the DNA binding domain of a  
known transcription factor (e.g., GAL-4). In the other construct, a DNA sequence, from a library  
of DNA sequences, that encodes an unidentified protein ("prey" or "sample") is fused to a gene  
45 that codes for the activation domain of the known transcription factor. If the "bait" and the  
"prey" proteins are able to interact, *in vivo*, forming a 2155647, 2355875, 3223867, 3224646,  
30 3482699, or Mamm-X -dependent complex, the DNA-binding and activation domains of the  
transcription factor are brought into close proximity. This proximity allows transcription of a  
50 reporter gene (e.g., LacZ) that is operably linked to a transcriptional regulatory site responsive to

the transcription factor. Expression of the reporter gene can be detected and cell colonies containing the functional transcription factor can be isolated and used to obtain the cloned gene that encodes the protein which interacts with 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X.

This invention further pertains to novel agents identified by the above-described screening assays and uses thereof for treatments as described herein.

#### Detection Assays

Portions or fragments of the cDNA sequences identified herein (and the corresponding complete gene sequences) can be used in numerous ways as polynucleotide reagents. For example, these sequences can be used to: (i) map their respective genes on a chromosome; and, thus, locate gene regions associated with genetic disease; (ii) identify an individual from a minute biological sample (tissue typing); and (iii) aid in forensic identification of a biological sample. These applications are described in the subsections below.

#### Chromosome Mapping

Once the sequence (or a portion of the sequence) of a gene has been isolated, this sequence can be used to map the location of the gene on a chromosome. This process is called chromosome mapping. Accordingly, portions or fragments of the 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X, sequences, described herein, can be used to map the location of the 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X genes, respectively, on a chromosome. The mapping of the 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X sequences to chromosomes is an important first step in correlating these sequences with genes associated with disease.

Briefly, 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X genes can be mapped to chromosomes by preparing PCR primers (preferably 15-25 bp in length) from the 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X sequences. Computer analysis of the 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X, sequences can be used to rapidly select primers that do not span more than one exon in the genomic DNA, thus complicating the amplification process. These primers can then be used for PCR screening of somatic cell hybrids containing individual human chromosomes. Only those hybrids containing



5 the human gene corresponding to the 2155647, 2355875, 3223867, 3224646, 3482699, or  
Mamm-X sequences will yield an amplified fragment.

10 Somatic cell hybrids are prepared by fusing somatic cells from different mammals (e.g.,  
human and mouse cells). As hybrids of human and mouse cells grow and divide, they gradually  
5 lose human chromosomes in random order, but retain the mouse chromosomes. By using media  
in which mouse cells cannot grow, because they lack a particular enzyme, but in which human  
15 cells can, the one human chromosome that contains the gene encoding the needed enzyme will  
be retained. By using various media, panels of hybrid cell lines can be established. Each cell line  
in a panel contains either a single human chromosome or a small number of human  
10 chromosomes, and a full set of mouse chromosomes, allowing easy mapping of individual genes  
20 to specific human chromosomes. (D'Eustachio *et al.* (1983) *Science* 220:919-924). Somatic cell  
hybrids containing only fragments of human chromosomes can also be produced by using  
human chromosomes with translocations and deletions.

25 PCR mapping of somatic cell hybrids is a rapid procedure for assigning a particular  
15 sequence to a particular chromosome. Three or more sequences can be assigned per day using a  
single thermal cycler. Using the 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X  
30 sequences to design oligonucleotide primers, sublocalization can be achieved with panels of  
fragments from specific chromosomes.

35 Fluorescence *in situ* hybridization (FISH) of a DNA sequence to a metaphase  
20 chromosomal spread can further be used to provide a precise chromosomal location in one step.  
Chromosome spreads can be made using cells whose division has been blocked in metaphase by  
a chemical like colcemid that disrupts the mitotic spindle. The chromosomes can be treated  
briefly with trypsin, and then stained with Giemsa. A pattern of light and dark bands develops on  
40 each chromosome, so that the chromosomes can be identified individually. The FISH technique  
25 can be used with a DNA sequence as short as 500 or 600 bases. However, clones larger than  
1,000 bases have a higher likelihood of binding to a unique chromosomal location with  
sufficient signal intensity for simple detection. Preferably 1,000 bases, and more preferably  
45 2,000 bases, will suffice to get good results at a reasonable amount of time. For a review of this  
technique, see Verma *et al.*, HUMAN CHROMOSOMES: A MANUAL OF BASIC TECHNIQUES  
30 (Pergamon Press, New York 1988).

5 Reagents for chromosome mapping can be used individually to mark a single  
chromosome or a single site on that chromosome, or panels of reagents can be used for marking  
multiple sites and/or multiple chromosomes. Reagents corresponding to noncoding regions of  
10 the genes actually are preferred for mapping purposes. Coding sequences are more likely to be  
conserved within gene families, thus increasing the chance of cross hybridizations during  
15 chromosomal mapping.

15 Once a sequence has been mapped to a precise chromosomal location, the physical  
position of the sequence on the chromosome can be correlated with genetic map data. Such data  
are found, for example, in McKusick, MENDELIAN INHERITANCE IN MAN, available on-line  
10 through Johns Hopkins University Welch Medical Library). The relationship between genes and  
disease, mapped to the same chromosomal region, can then be identified through linkage  
20 analysis (co-inheritance of physically adjacent genes), described in, for example, Egeland *et al.*  
(1987) *Nature*, 325:783-787.

25 Moreover, differences in the DNA sequences between individuals affected and  
unaffected with a disease associated with the 2155647, 2355875, 3223867, 3224646, 3482699,  
15 or Mamm-X gene, can be determined. If a mutation is observed in some or all of the affected  
individuals but not in any unaffected individuals, then the mutation is likely to be the causative  
30 agent of the particular disease. Comparison of affected and unaffected individuals generally  
involves first looking for structural alterations in the chromosomes, such as deletions or  
translocations that are visible from chromosome spreads or detectable using PCR based on that  
20 DNA sequence. Ultimately, complete sequencing of genes from several individuals can be  
performed to confirm the presence of a mutation and to distinguish mutations from  
35 polymorphisms.

#### 40 Tissue Typing

25 The 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X sequences of the  
present invention can also be used to identify individuals from minute biological samples. In this  
45 technique, an individual's genomic DNA is digested with one or more restriction enzymes, and  
probed on a Southern blot to yield unique bands for identification. The sequences of the present  
invention are useful as additional DNA markers for RFLP ("restriction fragment length  
50 polymorphisms," described in U.S. Pat. No. 5,272,057).

Furthermore, the sequences of the present invention can be used to provide an alternative technique that determines the actual base-by-base DNA sequence of selected portions of an individual's genome. Thus, the 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X sequences described herein can be used to prepare two PCR primers from the 5' and 3' ends of the sequences. These primers can then be used to amplify an individual's DNA and subsequently sequence it.

Panels of corresponding DNA sequences from individuals, prepared in this manner, can provide unique individual identifications, as each individual will have a unique set of such DNA sequences due to allelic differences. The sequences of the present invention can be used to obtain such identification sequences from individuals and from tissue. The 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X sequences of the invention uniquely represent portions of the human genome. Allelic variation occurs to some degree in the coding regions of these sequences, and to a greater degree in the noncoding regions. It is estimated that allelic variation between individual humans occurs with a frequency of about once per each 500 bases. Much of the allelic variation is due to single nucleotide polymorphisms (SNPs), which include restriction fragment length polymorphisms (RFLPs).

Each of the sequences described herein can, to some degree, be used as a standard against which DNA from an individual can be compared for identification purposes. Because greater numbers of polymorphisms occur in the noncoding regions, fewer sequences are necessary to differentiate individuals. The noncoding sequences of SEQ ID NO: 1, 3, 5, 7, 9 can comfortably provide positive individual identification with a panel of perhaps 10 to 1,000 primers that each yield a noncoding amplified sequence of 100 bases. If predicted coding sequences, such as those in SEQ ID NO: 1, 3, 5, 7, 9 are used, a more appropriate number of primers for positive individual identification would be 500-2,000.

#### **Predictive Medicine**

The present invention also pertains to the field of predictive medicine in which diagnostic assays, prognostic assays, pharmacogenomics, and monitoring clinical trials are used for prognostic (predictive) purposes to thereby treat an individual prophylactically. Accordingly, one aspect of the present invention relates to diagnostic assays for determining 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X protein and/or nucleic acid expression as well as 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X activity, in the context of

5 a biological sample (e.g., blood, serum, cells, tissue) to thereby determine whether an individual  
is afflicted with a disease or disorder, or is at risk of developing a disorder, associated with  
aberrant 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X expression or activity.  
10 The invention also provides for prognostic (or predictive) assays for determining whether an  
5 individual is at risk of developing a disorder associated with 2155647, 2355875, 3223867,  
3224646, 3482699, or Mamm-X protein, nucleic acid expression or activity. For example,  
mutations in a 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X gene can be  
15 assayed in a biological sample. Such assays can be used for prognostic or predictive purpose to  
thereby prophylactically treat an individual prior to the onset of a disorder characterized by or  
10 associated with 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X protein, nucleic  
20 acid expression or activity.

Another aspect of the invention provides methods for determining 2155647, 2355875,  
3223867, 3224646, 3482699, or Mamm-X protein, nucleic acid expression or 2155647,  
25 2355875, 3223867, 3224646, 3482699, or Mamm-X activity in an individual to thereby select  
15 appropriate therapeutic or prophylactic agents for that individual (referred to herein as  
"pharmacogenomics"). Pharmacogenomics allows for the selection of agents (e.g., drugs) for  
therapeutic or prophylactic treatment of an individual based on the genotype of the individual  
30 (e.g., the genotype of the individual examined to determine the ability of the individual to  
respond to a particular agent.)

20 Yet another aspect of the invention pertains to monitoring the influence of agents (e.g.,  
35 drugs, compounds) on the expression or activity of 2155647, 2355875, 3223867, 3224646,  
3482699, or Mamm-X in clinical trials.

These and other agents are described in further detail in the following sections.

#### 40 Diagnostic Assays

25 An exemplary method for detecting the presence or absence of 2155647, 2355875,  
3223867, 3224646, 3482699, or Mamm-X in a biological sample involves obtaining a biological  
45 sample from a test subject and contacting the biological sample with a compound or an agent  
capable of detecting 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X protein or  
nucleic acid (e.g., mRNA, genomic DNA) that encodes 2155647, 2355875, 3223867, 3224646,  
50 30 3482699, or Mamm-X protein such that the presence of 2155647, 2355875, 3223867, 3224646,  
3482699, or Mamm-X is detected in the biological sample. An agent for detecting 2155647,

5 2355875, 3223867, 3224646, 3482699, or Mamm-X mRNA or genomic DNA is a labeled  
nucleic acid probe capable of hybridizing to 2155647, 2355875, 3223867, 3224646, 3482699, or  
10 Mamm-X mRNA or genomic DNA. The nucleic acid probe can be, for example, a full-length  
2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X nucleic acid, such as the nucleic  
5 acid of SEQ ID NO: 1, 3, 5, 7, 9, or a portion thereof, such as an oligonucleotide of at least 15,  
30, 50, 100, 250 or 500 nucleotides in length and sufficient to specifically hybridize under  
stringent conditions to 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X mRNA or  
15 genomic DNA. Other suitable probes for use in the diagnostic assays of the invention are  
described herein.

10 An agent for detecting 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X  
20 protein is an antibody capable of binding to 2155647, 2355875, 3223867, 3224646, 3482699, or  
Mamm-X protein, preferably an antibody with a detectable label. Antibodies can be polyclonal,  
or more preferably, monoclonal. An intact antibody, or a fragment thereof (*e.g.*, Fab or F(ab')<sub>2</sub>)  
25 can be used. The term "labeled", with regard to the probe or antibody, is intended to encompass  
15 direct labeling of the probe or antibody by coupling (*i.e.*, physically linking) a detectable  
substance to the probe or antibody, as well as indirect labeling of the probe or antibody by  
reactivity with another reagent that is directly labeled. Examples of indirect labeling include  
30 detection of a primary antibody using a fluorescently labeled secondary antibody and  
end-labeling of a DNA probe with biotin such that it can be detected with fluorescently labeled  
20 streptavidin. The term "biological sample" is intended to include tissues, cells and biological  
35 fluids isolated from a subject, as well as tissues, cells and fluids present within a subject. That is,  
the detection method of the invention can be used to detect 2155647, 2355875, 3223867,  
3224646, 3482699, or Mamm-X mRNA, protein, or genomic DNA in a biological sample *in*  
40 *vitro* as well as *in vivo*. For example, *in vitro* techniques for detection of 2155647, 2355875,  
25 3223867, 3224646, 3482699, or Mamm-X mRNA include Northern hybridizations and *in situ*  
hybridizations. *In vitro* techniques for detection of 2155647, 2355875, 3223867, 3224646,  
3482699, or Mamm-X protein include enzyme linked immunosorbent assays (ELISAs), Western  
45 blots, immunoprecipitations and immunofluorescence. *In vitro* techniques for detection of  
2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X genomic DNA include Southern  
30 hybridizations. Furthermore, *in vivo* techniques for detection of 2155647, 2355875, 3223867,  
3224646, 3482699, or Mamm-X protein include introducing into a subject a labeled  
50 anti-2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X antibody. For example, the

antibody can be labeled with a radioactive marker whose presence and location in a subject can be detected by standard imaging techniques.

In one embodiment, the biological sample contains protein molecules from the test subject. Alternatively, the biological sample can contain mRNA molecules from the test subject or genomic DNA molecules from the test subject. A preferred biological sample is a peripheral blood leukocyte sample isolated by conventional means from a subject.

In another embodiment, the methods further involve obtaining a control biological sample from a control subject, contacting the control sample with a compound or agent capable of detecting 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X protein, mRNA, or genomic DNA, such that the presence of 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X protein, mRNA or genomic DNA is detected in the biological sample, and comparing the presence of 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X protein, mRNA or genomic DNA in the control sample with the presence of 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X protein, mRNA or genomic DNA in the test sample.

The invention also encompasses kits for detecting the presence of 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X in a biological sample. For example, the kit can comprise: a labeled compound or agent capable of detecting 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X protein or mRNA in a biological sample; means for determining the amount of 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X in the sample; and means for comparing the amount of 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X in the sample with a standard. The compound or agent can be packaged in a suitable container. The kit can further comprise instructions for using the kit to detect 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X protein or nucleic acid.

#### Prognostic Assays

The diagnostic methods described herein can furthermore be utilized to identify subjects having or at risk of developing a disease or disorder associated with aberrant 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X expression or activity. For example, the assays described herein, such as the preceding diagnostic assays or the following assays, can be utilized to identify a subject having or at risk of developing a disorder associated with 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X protein, nucleic acid expression or activity such as cancer or fibrotic disorders. Alternatively, the prognostic assays can be utilized to

5 identify a subject having or at risk for developing a disease or disorder. Thus, the present  
invention provides a method for identifying a disease or disorder associated with aberrant  
2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X expression or activity in which a  
10 test sample is obtained from a subject and 2155647, 2355875, 3223867, 3224646, 3482699, or  
5 Mamm-X protein or nucleic acid (*e.g.*, mRNA, genomic DNA) is detected, wherein the presence  
of 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X protein or nucleic acid is  
diagnostic for a subject having or at risk of developing a disease or disorder associated with  
15 aberrant 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X expression or activity.  
As used herein, a "test sample" refers to a biological sample obtained from a subject of interest.  
10 For example, a test sample can be a biological fluid (*e.g.*, serum), cell sample, or tissue.

20 Furthermore, the prognostic assays described herein can be used to determine whether a  
subject can be administered an agent (*e.g.*, an agonist, antagonist, peptidomimetic, protein,  
peptide, nucleic acid, small molecule, or other drug candidate) to treat a disease or disorder  
25 associated with aberrant 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X  
15 expression or activity. For example, such methods can be used to determine whether a subject  
can be effectively treated with an agent for a disorder, such as cancer or preclampsia. Thus, the  
present invention provides methods for determining whether a subject can be effectively treated  
30 with an agent for a disorder associated with aberrant 2155647, 2355875, 3223867, 3224646,  
3482699, or Mamm-X expression or activity in which a test sample is obtained and 2155647,  
20 2355875, 3223867, 3224646, 3482699, or Mamm-X protein or nucleic acid is detected (*e.g.*,  
35 wherein the presence of 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X protein  
or nucleic acid is diagnostic for a subject that can be administered the agent to treat a disorder  
associated with aberrant 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X  
40 expression or activity.)

25 The methods of the invention can also be used to detect genetic lesions in a 2155647,  
2355875, 3223867, 3224646, 3482699, or Mamm-X gene, thereby determining if a subject with  
the lesioned gene is at risk for a disorder characterized by aberrant cell proliferation and/or  
45 differentiation. In various embodiments, the methods include detecting, in a sample of cells from  
the subject, the presence or absence of a genetic lesion characterized by at least one of an  
30 alteration affecting the integrity of a gene encoding a 2155647, 2355875, 3223867, 3224646,  
50 3482699, or Mamm-X -protein, or the mis-expression of the 2155647, 2355875, 3223867,  
3224646, 3482699, or Mamm-X gene. For example, such genetic lesions can be detected by

ascertaining the existence of at least one of (1) a deletion of one or more nucleotides from a 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X gene; (2) an addition of one or more nucleotides to a 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X gene; (3) a substitution of one or more nucleotides of a 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X gene; (4) a chromosomal rearrangement of a 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X gene; (5) an alteration in the level of a messenger RNA transcript of a 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X gene; (6) aberrant modification of a 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X gene, such as of the methylation pattern of the genomic DNA, (7) the presence of a non-wild type splicing pattern of a messenger RNA transcript of a 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X gene; (8) a non-wild type level of a 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X -protein, (9) allelic loss of a 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X gene, and (10) inappropriate post-translational modification of a 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X -protein. As described herein, there are a large number of assay techniques known in the art which can be used for detecting lesions in a 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X gene. A preferred biological sample is a peripheral blood leukocyte sample isolated by conventional means from a subject. However, any biological sample containing nucleated cells may be used, including, for example, buccal mucosal cells.

In certain embodiments, detection of the lesion involves the use of a probe/primer in a polymerase chain reaction (PCR) (see, e.g., U.S. Pat. Nos. 4,683,195 and 4,683,202), such as anchor PCR or RACE PCR, or, alternatively, in a ligation chain reaction (LCR) (see, e.g., Landegran *et al.* (1988) *Science* 241:1077-1080; and Nakazawa *et al.* (1994) *PNAS* 91:360-364), the latter of which can be particularly useful for detecting point mutations in the 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X -gene (see Abravaya *et al.* (1995) *Nucl Acids Res* 23:675-682). This method can include the steps of collecting a sample of cells from a patient, isolating nucleic acid (e.g., genomic, mRNA or both) from the cells of the sample, contacting the nucleic acid sample with one or more primers that specifically hybridize to a 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X gene under conditions such that hybridization and amplification of the 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X gene (if present) occurs, and detecting the presence or absence of an amplification product, or detecting the size of the amplification product and comparing the length to a control sample. It is anticipated that PCR and/or LCR may be desirable to use as a preliminary



5 amplification step in conjunction with any of the techniques used for detecting mutations described herein.

10 Alternative amplification methods include: self sustained sequence replication (Guatelli *et al.*, 1990, *Proc Natl Acad Sci USA* 87:1874-1878), transcriptional amplification system  
5 (Kwoh, *et al.*, 1989, *Proc Natl Acad Sci USA* 86:1173-1177), Q-Beta Replicase (Lizardi *et al.*, 1988, *BioTechnology* 6:1197), or any other nucleic acid amplification method, followed by the  
15 detection of the amplified molecules using techniques well known to those of skill in the art. These detection schemes are especially useful for the detection of nucleic acid molecules if such molecules are present in very low numbers.

20 In an alternative embodiment, mutations in a 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X gene from a sample cell can be identified by alterations in restriction enzyme cleavage patterns. For example, sample and control DNA is isolated, amplified  
25 (optionally), digested with one or more restriction endonucleases, and fragment length sizes are determined by gel electrophoresis and compared. Differences in fragment length sizes between  
15 sample and control DNA indicates mutations in the sample DNA. Moreover, the use of sequence specific ribozymes (see, for example, U.S. Pat. No. 5,493,531) can be used to score for the  
30 presence of specific mutations by development or loss of a ribozyme cleavage site.

In other embodiments, genetic mutations in 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X can be identified by hybridizing a sample and control nucleic acids, *e.g.*,  
20 DNA or RNA, to high density arrays containing hundreds or thousands of oligonucleotides probes (Cronin *et al.* (1996) *Human Mutation* 7: 244-255; Kozal *et al.* (1996) *Nature Medicine*  
35 2: 753-759). For example, genetic mutations in 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X can be identified in two dimensional arrays containing light-generated DNA probes  
40 as described in Cronin *et al.* above. Briefly, a first hybridization array of probes can be used to scan through long stretches of DNA in a sample and control to identify base changes between  
25 the sequences by making linear arrays of sequential overlapping probes. This step allows the identification of point mutations. This step is followed by a second hybridization array that  
45 allows the characterization of specific mutations by using smaller, specialized probe arrays complementary to all variants or mutations detected. Each mutation array is composed of  
30 parallel probe sets, one complementary to the wild-type gene and the other complementary to the mutant gene.

5 In yet another embodiment, any of a variety of sequencing reactions known in the art can be used to directly sequence the 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X gene and detect mutations by comparing the sequence of the sample 2155647, 2355875, 10 3223867, 3224646, 3482699, or Mamm-X with the corresponding wild-type (control) sequence. Examples of sequencing reactions include those based on techniques developed by Maxim and 5 Gilbert (1977) *PNAS* 74:560 or Sanger (1977) *PNAS* 74:5463. It is also contemplated that any of a variety of automated sequencing procedures can be utilized when performing the diagnostic assays (Naeve *et al.*, (1995) *Biotechniques* 19:448), including sequencing by mass spectrometry 15 (see, e.g., PCT International Publ. No. WO 94/16101; Cohen *et al.* (1996) *Adv Chromatogr* 36:127-162; and Griffin *et al.* (1993) *Appl Biochem Biotechnol* 38:147-159).

20 Other methods for detecting mutations in the 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X gene include methods in which protection from cleavage agents is used to detect mismatched bases in RNA/RNA or RNA/DNA heteroduplexes (Myers *et al.* (1985) 25 *Science* 230:1242). In general, the art technique of "mismatch cleavage" starts by providing heteroduplexes of formed by hybridizing (labeled) RNA or DNA containing the wild-type 15 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X sequence with potentially mutant RNA or DNA obtained from a tissue sample. The double-stranded duplexes are treated with an agent that cleaves single-stranded regions of the duplex such as which will exist due to basepair 30 mismatches between the control and sample strands. For instance, RNA/DNA duplexes can be treated with RNase and DNA/DNA hybrids treated with S1 nuclease to enzymatically digesting the mismatched regions. In other embodiments, either DNA/DNA or RNA/DNA duplexes can 20 be treated with hydroxylamine or osmium tetroxide and with piperidine in order to digest mismatched regions. After digestion of the mismatched regions, the resulting material is then 35 separated by size on denaturing polyacrylamide gels to determine the site of mutation. See, for example, Cotton *et al* (1988) *Proc Natl Acad Sci USA* 85:4397; Saleeba *et al* (1992) *Methods Enzymol* 217:286-295. In an embodiment, the control DNA or RNA can be labeled for detection.

45 In still another embodiment, the mismatch cleavage reaction employs one or more proteins that recognize mismatched base pairs in double-stranded DNA (so called "DNA mismatch repair" enzymes) in defined systems for detecting and mapping point mutations in 30 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X cDNAs obtained from samples of cells. For example, the mutY enzyme of *E. coli* cleaves A at G/A mismatches and the thymidine 50 DNA glycosylase from HeLa cells cleaves T at G/T mismatches (Hsu *et al.* (1994)

5 *Carcinogenesis* 15:1657-1662). According to an exemplary embodiment, a probe based on a  
2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X sequence, *e.g.*, a wild-type  
2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X sequence, is hybridized to a  
10 cDNA or other DNA product from a test cell(s). The duplex is treated with a DNA mismatch  
5 repair enzyme, and the cleavage products, if any, can be detected from electrophoresis protocols  
or the like. See, for example, U.S. Pat. No. 5,459,039.

15 In other embodiments, alterations in electrophoretic mobility will be used to identify  
mutations in 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X genes. For example,  
single strand conformation polymorphism (SSCP) may be used to detect differences in  
10 electrophoretic mobility between mutant and wild type nucleic acids (Orita *et al.* (1989) *Proc*  
20 *Natl Acad Sci USA*: 86:2766, see also Cotton (1993) *Mutat Res* 285:125-144; Hayashi (1992)  
*Genet Anal Tech Appl* 9:73-79). Single-stranded DNA fragments of sample and control  
2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X nucleic acids will be denatured  
25 and allowed to renature. The secondary structure of single-stranded nucleic acids varies  
15 according to sequence, the resulting alteration in electrophoretic mobility enables the detection  
of even a single base change. The DNA fragments may be labeled or detected with labeled  
probes. The sensitivity of the assay may be enhanced by using RNA (rather than DNA), in which  
30 the secondary structure is more sensitive to a change in sequence. In one embodiment, the  
subject method utilizes heteroduplex analysis to separate double stranded heteroduplex  
20 molecules on the basis of changes in electrophoretic mobility (Keen *et al.* (1991) *Trends Genet*  
7:5).

35 In yet another embodiment the movement of mutant or wild-type fragments in  
polyacrylamide gels containing a gradient of denaturant is assayed using denaturing gradient gel  
40 electrophoresis (DGGE) (Myers *et al.* (1985) *Nature* 313:495). When DGGE is used as the  
25 method of analysis, DNA will be modified to insure that it does not completely denature, for  
example by adding a GC clamp of approximately 40 bp of high-melting GC-rich DNA by PCR.  
In a further embodiment, a temperature gradient is used in place of a denaturing gradient to  
45 identify differences in the mobility of control and sample DNA (Rosenbaum and Reissner  
(1987) *Biophys Chem* 265:12753).

30 Examples of other techniques for detecting point mutations include, but are not limited  
50 to, selective oligonucleotide hybridization, selective amplification, or selective primer extension.

5 For example, oligonucleotide primers may be prepared in which the known mutation is placed centrally and then hybridized to target DNA under conditions that permit hybridization only if a perfect match is found (Saiki *et al.* (1986) *Nature* 324:163); Saiki *et al.* (1989) *Proc Natl Acad. Sci USA* 86:6230). Such allele specific oligonucleotides are hybridized to PCR amplified target.  
10 DNA or a number of different mutations when the oligonucleotides are attached to the hybridizing membrane and hybridized with labeled target DNA.

15 Alternatively, allele specific amplification technology that depends on selective PCR amplification may be used in conjunction with the instant invention. Oligonucleotides used as primers for specific amplification may carry the mutation of interest in the center of the molecule (so that amplification depends on differential hybridization) (Gibbs *et al.* (1989) *Nucleic Acids Res* 17:2437-2448) or at the extreme 3' end of one primer where, under appropriate conditions, mismatch can prevent, or reduce polymerase extension (Prossner (1993) *Tibtech* 11:238). In addition it may be desirable to introduce a novel restriction site in the region of the mutation to create cleavage-based detection (Gasparini *et al.* (1992) *Mol Cell Probes* 6:1).  
25 It is anticipated that in certain embodiments amplification may also be performed using Taq ligase for amplification (Barany (1991) *Proc Natl Acad Sci USA* 88:189). In such cases, ligation will occur only if there is a perfect match at the 3' end of the 5' sequence, making it possible to detect the presence of a known mutation at a specific site by looking for the presence or absence of amplification.

20 The methods described herein may be performed, for example, by utilizing pre-packaged diagnostic kits comprising at least one probe nucleic acid or antibody reagent described herein, which may be conveniently used, *e.g.*, in clinical settings to diagnose patients exhibiting symptoms or family history of a disease or illness involving a 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X gene.  
40

25 Furthermore, any cell type or tissue, preferably peripheral blood leukocytes, in which 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X is expressed may be utilized in the prognostic assays described herein. However, any biological sample containing nucleated cells may be used, including, for example, buccal mucosal cells.  
45

#### Pharmacogenomics

30 Agents, or modulators that have a stimulatory or inhibitory effect on 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X activity (*e.g.*, 2155647, 2355875, 3223867, 3224646,  
50

5 3482699, or Mamm-X gene expression), as identified by a screening assay described herein can  
be administered to individuals to treat (prophylactically or therapeutically) disorders (*e.g.*, cancer  
or gestational disorders) associated with aberrant 2155647, 2355875, 3223867, 3224646,  
10 3482699, or Mamm-X activity. In conjunction with such treatment, the pharmacogenomics (*i.e.*,  
5 the study of the relationship between an individual's genotype and that individual's response to a  
foreign compound or drug) of the individual may be considered. Differences in metabolism of  
therapeutics can lead to severe toxicity or therapeutic failure by altering the relation between  
15 dose and blood concentration of the pharmacologically active drug. Thus, the  
pharmacogenomics of the individual permits the selection of effective agents (*e.g.*, drugs) for  
10 prophylactic or therapeutic treatments based on a consideration of the individual's genotype.  
Such pharmacogenomics can further be used to determine appropriate dosages and therapeutic  
20 regimens. Accordingly, the activity of 2155647, 2355875, 3223867, 3224646, 3482699, or  
Mamm-X protein, expression of 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X  
25 nucleic acid, or mutation content of 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-  
15 X genes in an individual can be determined to thereby select appropriate agent(s) for therapeutic  
or prophylactic treatment of the individual.

Pharmacogenomics deals with clinically significant hereditary variations in the response  
30 to drugs due to altered drug disposition and abnormal action in affected persons. See *e.g.*,  
Eichelbaum, *Clin Exp Pharmacol Physiol*, 1996, 23:983-985 and Linder, *Clin Chem*, 1997,  
20 43:254-266. In general, two types of pharmacogenetic conditions can be differentiated. Genetic  
35 conditions transmitted as a single factor altering the way drugs act on the body (altered drug  
action) or genetic conditions transmitted as single factors altering the way the body acts on drugs  
(altered drug metabolism). These pharmacogenetic conditions can occur either as rare defects or  
40 as polymorphisms. For example, glucose-6-phosphate dehydrogenase (G6PD) deficiency is a  
25 common inherited enzymopathy in which the main clinical complication is haemolysis after  
ingestion of oxidant drugs (anti-malarials, sulfonamides, analgesics, nitrofurans) and  
consumption of fava beans.

45 As an illustrative embodiment, the activity of drug metabolizing enzymes is a major  
determinant of both the intensity and duration of drug action. The discovery of genetic  
30 polymorphisms of drug metabolizing enzymes (*e.g.*, N-acetyltransferase 2 (NAT 2) and  
50 cytochrome P450 enzymes CYP2D6 and CYP2C19) has provided an explanation as to why  
some patients do not obtain the expected drug effects or show exaggerated drug response and

5 serious toxicity after taking the standard and safe dose of a drug. These polymorphisms are  
expressed in two phenotypes in the population, the extensive metabolizer (EM) and poor  
10 metabolizer (PM). The prevalence of PM is different among different populations. For example,  
the gene coding for CYP2D6 is highly polymorphic and several mutations have been identified  
5 in PM, which all lead to the absence of functional CYP2D6. Poor metabolizers of CYP2D6 and  
CYP2C19 quite frequently experience exaggerated drug response and side effects when they  
15 receive standard doses. If a metabolite is the active therapeutic moiety, PM show no therapeutic  
response, as demonstrated for the analgesic effect of codeine mediated by its CYP2D6-formed  
metabolite morphine. The other extreme are the so called ultra-rapid metabolizers who do not  
10 respond to standard doses. Recently, the molecular basis of ultra-rapid metabolism has been  
20 identified to be due to CYP2D6 gene amplification.

Thus, the activity of 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X  
protein, expression of 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X nucleic  
25 acid, or mutation content of 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X  
genes in an individual can be determined to thereby select appropriate agent(s) for therapeutic or  
15 prophylactic treatment of the individual. In addition, pharmacogenetic studies can be used to  
apply genotyping of polymorphic alleles encoding drug-metabolizing enzymes to the  
30 identification of an individual's drug responsiveness phenotype. This knowledge, when applied  
to dosing or drug selection, can avoid adverse reactions or therapeutic failure and thus enhance  
20 therapeutic or prophylactic efficiency when treating a subject with a 2155647, 2355875,  
35 3223867, 3224646, 3482699, or Mamm-X modulator, such as a modulator identified by one of  
the exemplary screening assays described herein.

#### Monitoring of Effects During Clinical Trials

40 Monitoring the influence of agents (*e.g.*, drugs, compounds) on the expression or activity  
25 of 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X (*e.g.*, the ability to modulate  
aberrant cell proliferation and/or differentiation) can be applied not only in basic drug screening,  
45 but also in clinical trials. For example, the effectiveness of an agent determined by a screening  
assay as described herein to increase 2155647, 2355875, 3223867, 3224646, 3482699, or  
Mamm-X gene expression, protein levels, or upregulate 2155647, 2355875, 3223867, 3224646,  
30 3482699, or Mamm-X activity, can be monitored in clinical trials of subjects exhibiting  
50 decreased 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X gene expression,

5 protein levels, or downregulated 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X  
activity. Alternatively, the effectiveness of an agent determined by a screening assay to decrease  
2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X gene expression, protein levels,  
10 or downregulate 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X activity, can be  
5 monitored in clinical trials of subjects exhibiting increased 2155647, 2355875, 3223867,  
3224646, 3482699, or Mamm-X gene expression, protein levels, or upregulated 2155647,  
2355875, 3223867, 3224646, 3482699, or Mamm-X activity. In such clinical trials, the  
15 expression or activity of 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X and,  
preferably, other genes that have been implicated in, for example, a cellular proliferation  
10 disorder can be used as a "read out" or markers of the immune responsiveness of a particular  
20 cell.

For example, and not by way of limitation, genes, including 2155647, 2355875,  
3223867, 3224646, 3482699, or Mamm-X, that are modulated in cells by treatment with an  
25 agent (*e.g.*, compound, drug or small molecule) that modulates 2155647, 2355875, 3223867,  
15 3224646, 3482699, or Mamm-X activity (*e.g.*, identified in a screening assay as described  
herein) can be identified. Thus, to study the effect of agents on cellular proliferation disorders,  
for example, in a clinical trial, cells can be isolated and RNA prepared and analyzed for the  
30 levels of expression of 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X and other  
genes implicated in the disorder. The levels of gene expression (*i.e.*, a gene expression pattern)  
20 can be quantified by Northern blot analysis or RT-PCR, as described herein, or alternatively by  
35 measuring the amount of protein produced, by one of the methods as described herein, or by  
measuring the levels of activity of 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-  
X or other genes. In this way, the gene expression pattern can serve as a marker, indicative of the  
40 physiological response of the cells to the agent. Accordingly, this response state may be  
25 determined before, and at various points during, treatment of the individual with the agent.

In one embodiment, the present invention provides a method for monitoring the  
effectiveness of treatment of a subject with an agent (*e.g.*, an agonist, antagonist, protein,  
45 peptide, peptidomimetic, nucleic acid, small molecule, or other drug candidate identified by the  
screening assays described herein) comprising the steps of (i) obtaining a pre-administration  
30 sample from a subject prior to administration of the agent; (ii) detecting the level of expression  
of a 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X protein, mRNA, or genomic  
50 DNA in the preadministration sample; (iii) obtaining one or more post-administration samples

5 from the subject; (iv) detecting the level of expression or activity of the 2155647, 2355875,  
3223867, 3224646, 3482699, or Mamm-X protein, mRNA, or genomic DNA in the  
post-administration samples; (v) comparing the level of expression or activity of the 2155647,  
10 2355875, 3223867, 3224646, 3482699, or Mamm-X protein, mRNA, or genomic DNA in the  
5 pre-administration sample with the 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-  
X protein, mRNA, or genomic DNA in the post administration sample or samples; and (vi)  
altering the administration of the agent to the subject accordingly. For example, increased  
15 administration of the agent may be desirable to increase the expression or activity of 2155647,  
2355875, 3223867, 3224646, 3482699, or Mamm-X to higher levels than detected, *i.e.*, to  
10 increase the effectiveness of the agent. Alternatively, decreased administration of the agent may  
be desirable to decrease expression or activity of 2155647, 2355875, 3223867, 3224646,  
20 3482699, or Mamm-X to lower levels than detected, *i.e.*, to decrease the effectiveness of the  
agent.

#### 25 **Methods of Treatment**

15 The present invention provides for both prophylactic and therapeutic methods of treating  
a subject at risk of (or susceptible to) a disorder or having a disorder associated with aberrant  
30 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X expression or activity.

#### **Disorders**

20 Diseases and disorders that are characterized by increased (relative to a subject not  
35 suffering from the disease or disorder) levels or biological activity may be treated with  
Therapeutics that antagonize (*i.e.*, reduce or inhibit) activity. Therapeutics that antagonize  
activity may be administered in a therapeutic or prophylactic manner. Therapeutics that may be  
40 utilized include, but are not limited to, (i) an aforementioned peptide, or analogs, derivatives,  
fragments or homologs thereof; (ii) antibodies to an aforementioned peptide; (iii) nucleic acids  
25 encoding an aforementioned peptide; (iv) administration of antisense nucleic acid and nucleic  
acids that are "dysfunctional" (*i.e.*, due to a heterologous insertion within the coding sequences  
45 of coding sequences to an aforementioned peptide) are utilized to "knockout" endogenous  
function of an aforementioned peptide by homologous recombination (see, *e.g.*, Capecchi, 1989.  
*Science* 244: 1288-1292); or (v) modulators (*i.e.*, inhibitors, agonists and antagonists, including  
50 additional peptide mimetic of the invention or antibodies specific to a peptide of the invention)  
that alter the interaction between an aforementioned peptide and its binding partner.



5 Diseases and disorders that are characterized by decreased (relative to a subject not  
suffering from the disease or disorder) levels or biological activity may be treated with  
Therapeutics that increase (*i.e.*, are agonists to) activity. Therapeutics that upregulate activity  
10 may be administered in a therapeutic or prophylactic manner. Therapeutics that may be utilized  
5 include, but are not limited to, an aforementioned peptide, or analogs, derivatives, fragments or  
homologs thereof; or an agonist that increases bioavailability.

15 Increased or decreased levels can be readily detected by quantifying peptide and/or RNA,  
by obtaining a patient tissue sample (*e.g.*, from biopsy tissue) and assaying it *in vitro* for RNA or  
peptide levels, structure and/or activity of the expressed peptides (or mRNAs of an  
10 aforementioned peptide). Methods that are well-known within the art include, but are not limited  
20 to, immunoassays (*e.g.*, by Western blot analysis, immunoprecipitation followed by sodium  
dodecyl sulfate (SDS) polyacrylamide gel electrophoresis, immunocytochemistry, etc.) and/or  
hybridization assays to detect expression of mRNAs (*e.g.*, Northern assays, dot blots, *in situ*  
25 hybridization, etc.).

#### 15 **Prophylactic Methods**

In one aspect, the invention provides a method for preventing, in a subject, a disease or  
30 condition associated with an aberrant 2155647, 2355875, 3223867, 3224646, 3482699, or  
Mamm-X expression or activity, by administering to the subject an agent that modulates  
2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X expression or at least one  
20 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X activity. Subjects at risk for a  
35 disease that is caused or contributed to by aberrant 2155647, 2355875, 3223867, 3224646,  
3482699, or Mamm-X expression or activity can be identified by, for example, any or a  
combination of diagnostic or prognostic assays as described herein. Administration of a  
40 prophylactic agent can occur prior to the manifestation of symptoms characteristic of the  
25 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X aberrancy, such that a disease or  
disorder is prevented or, alternatively, delayed in its progression. Depending on the type of  
45 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X aberrancy, for example, a  
2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X agonist or 2155647, 2355875,  
3223867, 3224646, 3482699, or Mamm-X antagonist agent can be used for treating the subject.  
30 The appropriate agent can be determined based on screening assays described herein. The  
50 prophylactic methods of the present invention are further discussed in the following subsections.

### Therapeutic Methods

Another aspect of the invention pertains to methods of modulating 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X expression or activity for therapeutic purposes. The modulatory method of the invention involves contacting a cell with an agent that modulates one or more of the activities of 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X protein activity associated with the cell. An agent that modulates 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X protein activity can be an agent as described herein, such as a nucleic acid or a protein, a naturally-occurring cognate ligand of a 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X protein, a peptide, a 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X peptidomimetic, or other small molecule. In one embodiment, the agent stimulates one or more 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X protein activity. Examples of such stimulatory agents include active 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X protein and a nucleic acid molecule encoding 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X that has been introduced into the cell. In another embodiment, the agent inhibits one or more 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X protein activity. Examples of such inhibitory agents include antisense 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X nucleic acid molecules and anti-2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X antibodies. These modulatory methods can be performed *in vitro* (e.g., by culturing the cell with the agent) or, alternatively, *in vivo* (e.g., by administering the agent to a subject). As such, the present invention provides methods of treating an individual afflicted with a disease or disorder characterized by aberrant expression or activity of a 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X protein or nucleic acid molecule. In one embodiment, the method involves administering an agent (e.g., an agent identified by a screening assay described herein), or combination of agents that modulates (e.g., upregulates or downregulates) 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X expression or activity. In another embodiment, the method involves administering a 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X protein or nucleic acid molecule as therapy to compensate for reduced or aberrant 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X expression or activity.

Stimulation of 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X activity is desirable in situations in which 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X is abnormally downregulated and/or in which increased 2155647, 2355875, 3223867, 3224646,

5 3482699, or Mamm-X activity is likely to have a beneficial effect. One example of such a  
situation is where a subject has a disorder characterized by aberrant cell proliferation and/or  
differentiation (*e.g.*, cancer). Another example of such a situation is where the subject has a  
10 gestational disease (*e.g.*, preclampsia).

#### 5 Malignancies

An aforementioned protein or polynucleotide of the invention may be involved in the  
15 regulation of cell proliferation. Accordingly, Therapeutics of the present invention may be useful  
in the therapeutic or prophylactic treatment of diseases or disorders that are associated with cell  
hyperproliferation and/or loss of control of cell proliferation (*e.g.*, cancers, malignancies and  
20 tumors). For a review of such hyperproliferation disorders, see *e.g.*, Fishman, *et al.*, 1985.  
MEDICINE, 2nd ed., J.B. Lippincott Co., Philadelphia, PA.

Therapeutics of the present invention may be assayed by any method known within the  
25 art for efficacy in treating or preventing malignancies and related disorders. Such assays include,  
but are not limited to, *in vitro* assays utilizing transformed cells or cells derived from the  
15 patient's tumor, as well as *in vivo* assays using animal models of cancer or malignancies.  
Potentially effective Therapeutics are those that, for example, inhibit the proliferation of  
30 tumor-derived or transformed cells in culture or cause a regression of tumors in animal models,  
in comparison to the controls.

In the practice of the present invention, once a malignancy or cancer has been shown to  
35 20 be amenable to treatment by modulating (*i.e.*, inhibiting, antagonizing or agonizing) activity,  
that cancer or malignancy may subsequently be treated or prevented by the administration of a  
Therapeutic that serves to modulate protein function.

#### 40 Premalignant conditions

The Therapeutics of the present invention that are effective in the therapeutic or  
25 prophylactic treatment of cancer or malignancies may also be administered for the treatment of  
45 pre-malignant conditions and/or to prevent the progression of a pre-malignancy to a neoplastic  
or malignant state. Such prophylactic or therapeutic use is indicated in conditions known or  
suspected of preceding progression to neoplasia or cancer, in particular, where non-neoplastic  
50 cell growth consisting of hyperplasia, metaplasia or, most particularly, dysplasia has occurred.

5 For a review of such abnormal cell growth see *e.g.*, Robbins & Angell, 1976. BASIC  
PATHOLOGY, 2nd ed., W.B. Saunders Co., Philadelphia, PA.

10 Hyperplasia is a form of controlled cell proliferation involving an increase in cell number  
in a tissue or organ, without significant alteration in its structure or function. For example, it has  
15 been demonstrated that endometrial hyperplasia often precedes endometrial cancer. Metaplasia is  
a form of controlled cell growth in which one type of mature or fully differentiated cell  
15 substitutes for another type of mature cell. Metaplasia may occur in epithelial or connective  
tissue cells. Dysplasia is generally considered a precursor of cancer, and is found mainly in the  
epithelia. Dysplasia is the most disorderly form of non-neoplastic cell growth, and involves a  
20 10 loss in individual cell uniformity and in the architectural orientation of cells. Dysplasia  
characteristically occurs where there exists chronic irritation or inflammation, and is often found  
in the cervix, respiratory passages, oral cavity, and gall bladder.

25 Alternatively, or in addition to the presence of abnormal cell growth characterized as  
hyperplasia, metaplasia, or dysplasia, the presence of one or more characteristics of a  
15 transformed or malignant phenotype displayed either *in vivo* or *in vitro* within a cell sample  
derived from a patient, is indicative of the desirability of prophylactic/therapeutic administration  
30 of a Therapeutic that possesses the ability to modulate activity of An aforementioned protein.  
Characteristics of a transformed phenotype include, but are not limited to: (i) morphological  
changes; (ii) looser substratum attachment; (iii) loss of cell-to-cell contact inhibition; (iv) loss of  
35 20 anchorage dependence; (v) protease release; (vi) increased sugar transport; (vii) decreased serum  
requirement; (viii) expression of fetal antigens, (ix) disappearance of the 250 kDal cell-surface  
protein, and the like. See *e.g.*, Richards, *et al.*, 1986. MOLECULAR PATHOLOGY, W.B. Saunders  
Co., Philadelphia, PA.

40 In a specific embodiment of the present invention, a patient that exhibits one or more of  
25 the following predisposing factors for malignancy is treated by administration of an effective  
amount of a Therapeutic: (i) a chromosomal translocation associated with a malignancy (*e.g.*, the  
45 Philadelphia chromosome (*bcr/abl*) for chronic myelogenous leukemia and t(14;18) for  
follicular lymphoma, etc.); (ii) familial polyposis or Gardner's syndrome (possible forerunners of  
colon cancer); (iii) monoclonal gammopathy of undetermined significance (a possible precursor  
50 30 of multiple myeloma) and (iv) a first degree kinship with persons having a cancer or  
pre-cancerous disease showing a Mendelian (genetic) inheritance pattern (*e.g.*, familial polyposis

5 of the colon, Gardner's syndrome, hereditary exostosis, polyendocrine adenomatosis,  
Peutz-Jeghers syndrome, neurofibromatosis of Von Recklinghausen, medullary thyroid  
10 carcinoma with amyloid production and pheochromocytoma, retinoblastoma, carotid body  
tumor, cutaneous melanocarcinoma, intraocular melanocarcinoma, xeroderma pigmentosum,  
15 ataxia telangiectasia, Chediak-Higashi syndrome, albinism, Fanconi's aplastic anemia and  
Bloom's syndrome).

15 In another embodiment, a Therapeutic of the present invention is administered to a  
human patient to prevent the progression to breast, colon, lung, pancreatic, or uterine cancer, or  
melanoma or sarcoma.

#### 20 10 **Hyperproliferative and dysproliferative disorders**

In one embodiment of the present invention, a Therapeutic is administered in the  
therapeutic or prophylactic treatment of hyperproliferative or benign dysproliferative disorders.  
25 The efficacy in treating or preventing hyperproliferative diseases or disorders of a Therapeutic of  
the present invention may be assayed by any method known within the art. Such assays include  
15 *in vitro* cell proliferation assays, *in vitro* or *in vivo* assays using animal models of  
hyperproliferative diseases or disorders, or the like. Potentially effective Therapeutics may, for  
30 example, promote cell proliferation in culture or cause growth or cell proliferation in animal  
models in comparison to controls.

35 Specific embodiments of the present invention are directed to the treatment or prevention  
20 of cirrhosis of the liver (a condition in which scarring has overtaken normal liver regeneration  
processes); treatment of keloid (hypertrophic scar) formation causing disfiguring of the skin in  
which the scarring process interferes with normal renewal; psoriasis (a common skin condition  
40 characterized by excessive proliferation of the skin and delay in proper cell fate determination);  
benign tumors; fibrocystic conditions and tissue hypertrophy (*e.g.*, benign prostatic  
25 hypertrophy).

#### 45 **Neurodegenerative disorders**

2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X protein may be implicated  
in the deregulation of cellular maturation and apoptosis, which are both characteristic of  
50 neurodegenerative disease. Accordingly, Therapeutics of the invention, particularly but not

5 limited to those that modulate (or supply) activity of an aforementioned protein, may be  
effective in treating or preventing neurodegenerative disease. Therapeutics of the present  
invention that modulate the activity of an aforementioned protein involved in neurodegenerative  
10 disorders can be assayed by any method known in the art for efficacy in treating or preventing  
5 such neurodegenerative diseases and disorders. Such assays include *in vitro* assays for regulated  
cell maturation or inhibition of apoptosis or *in vivo* assays using animal models of  
neurodegenerative diseases or disorders, or any of the assays described below. Potentially  
15 effective Therapeutics, for example but not by way of limitation, promote regulated cell  
maturation and prevent cell apoptosis in culture, or reduce neurodegeneration in animal models  
10 in comparison to controls.

20 Once a neurodegenerative disease or disorder has been shown to be amenable to  
treatment by modulation activity, that neurodegenerative disease or disorder can be treated or  
prevented by administration of a Therapeutic that modulates activity. Such diseases include all  
25 degenerative disorders involved with aging, especially osteoarthritis and neurodegenerative  
15 disorders.

#### 30 Disorders related to organ transplantation

2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X may be implicated in  
disorders related to organ transplantation, in particular but not limited to organ rejection.  
Therapeutics of the invention, particularly those that modulate (or supply) activity, may be  
35 20 effective in treating or preventing diseases or disorders related to organ transplantation.  
Therapeutics of the invention (particularly Therapeutics that modulate the levels or activity of an  
aforementioned protein) can be assayed by any method known in the art for efficacy in treating  
40 or preventing such diseases and disorders related to organ transplantation. Such assays include *in*  
*vitro* assays for using cell culture models as described below, or *in vivo* assays using animal  
25 models of diseases and disorders related to organ transplantation, see *e.g.*, below. Potentially  
effective Therapeutics, for example but not by way of limitation, reduce immune rejection  
45 responses in animal models in comparison to controls.

Accordingly, once diseases and disorders related to organ transplantation are shown to be  
50 amenable to treatment by modulation of activity, such diseases or disorders can be treated or  
30 prevented by administration of a Therapeutic that modulates activity.

### Cardiovascular Disease

2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X may be implicated in cardiovascular disorders, including in atherosclerotic plaque formation. Diseases such as cardiovascular disease, including cerebral thrombosis or hemorrhage, ischemic heart or renal disease, peripheral vascular disease, or thrombosis of other major vessel, and other diseases, including diabetes mellitus, hypertension, hypothyroidism, cholesterol ester storage disease, systemic lupus erythematosus, homocysteinemia, and familial protein or lipid processing diseases, and the like, are either directly or indirectly associated with atherosclerosis. Accordingly, Therapeutics of the invention, particularly those that modulate (or supply) activity or formation may be effective in treating or preventing atherosclerosis-associated diseases or disorders. Therapeutics of the invention (particularly Therapeutics that modulate the levels or activity) can be assayed by any method known in the art, including those described below, for efficacy in treating or preventing such diseases and disorders.

A vast array of animal and cell culture models exist for processes involved in atherosclerosis. A limited and non-exclusive list of animal models includes knockout mice for premature atherosclerosis (Kurabayashi and Yazaki, 1996, *Int. Angiol.* 15: 187-194), transgenic mouse models of atherosclerosis (Kappel *et al.*, 1994, *FASEB J.* 8: 583-592), antisense oligonucleotide treatment of animal models (Callow, 1995, *Curr. Opin. Cardiol.* 10: 569-576), transgenic rabbit models for atherosclerosis (Taylor, 1997, *Ann. N.Y. Acad. Sci.* 811: 146-152), hypercholesterolemic animal models (Rosenfeld, 1996, *Diabetes Res. Clin. Pract.* 30 Suppl.: 1-11), hyperlipidemic mice (Paigen *et al.*, 1994, *Curr. Opin. Lipidol.* 5: 258-264), and inhibition of lipoxygenase in animals (Sigal *et al.*, 1994, *Ann. N.Y. Acad. Sci.* 714: 211-224). In addition, *in vitro* cell models include but are not limited to monocytes exposed to low density lipoprotein (Frostedgard *et al.*, 1996, *Atherosclerosis* 121: 93-103), cloned vascular smooth muscle cells (Suttles *et al.*, 1995, *Exp. Cell Res.* 218: 331-338), endothelial cell-derived chemoattractant exposed T cells (Katz *et al.*, 1994, *J. Leukoc. Biol.* 55: 567-573), cultured human aortic endothelial cells (Farber *et al.*, 1992, *Am. J. Physiol.* 262: H1088-1085), and foam cell cultures (Libby *et al.*, 1996, *Curr Opin Lipidol* 7: 330-335). Potentially effective Therapeutics, for example but not by way of limitation, reduce foam cell formation in cell culture models, or reduce atherosclerotic plaque formation in hypercholesterolemic mouse models of atherosclerosis in comparison to controls.

Accordingly, once an atherosclerosis-associated disease or disorder has been shown to be amenable to treatment by modulation of activity or formation, that disease or disorder can be treated or prevented by administration of a Therapeutic that modulates activity.

#### Cytokine and Cell Proliferation/Differentiation Activity

A 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X protein of the present invention may exhibit cytokine, cell proliferation (either inducing or inhibiting) or cell differentiation (either inducing or inhibiting) activity or may induce production of other cytokines in certain cell populations. Many protein factors discovered to date, including all known cytokines, have exhibited activity in one or more factor dependent cell proliferation assays, and hence the assays serve as a convenient confirmation of cytokine activity. The activity of a protein of the present invention is evidenced by any one of a number of routine factor dependent cell proliferation assays for cell lines including, without limitation, 32D, DA2, DA1G, T10, B9, B9/11, BaF3, MC9/G, M+ (preB M+), 2E8, RB5, DA1, 123, T1165, HT2, CTLL2, TF-1, Mo7e and CMK.

The activity of a protein of the invention may, among other means, be measured by the following methods: Assays for T-cell or thymocyte proliferation include without limitation those described in: CURRENT PROTOCOLS IN IMMUNOLOGY, Ed by Coligan *et al.*, Greene Publishing Associates and Wiley-Interscience (Chapter 3 and Chapter 7); Takai *et al.*, *J Immunol* 137:3494-3500, 1986; Bertagnolli *et al.*, *J Immunol* 145:1706-1712, 1990; Bertagnolli *et al.*, *Cell Immunol* 133:327-341, 1991; Bertagnolli, *et al.*, *J Immunol* 149:3778-3783, 1992; Bowman *et al.*, *J Immunol* 152:1756-1761, 1994.

Assays for cytokine production and/or proliferation of spleen cells, lymph node cells or thymocytes include, without limitation, those described by Kruisbeek and Shevach, In: CURRENT PROTOCOLS IN IMMUNOLOGY. Coligan *et al.*, eds. Vol 1, pp. 3.12.1-14, John Wiley and Sons, Toronto 1994; and by Schreiber, In: CURRENT PROTOCOLS IN IMMUNOLOGY. Coligan eds. Vol. 1 pp. 6.8.1-8, John Wiley and Sons, Toronto 1994.

Assays for proliferation and differentiation of hematopoietic and lymphopoietic cells include, without limitation, those described by Bottomly *et al.*, In: CURRENT PROTOCOLS IN IMMUNOLOGY. Coligan *et al.*, eds. Vol 1 pp. 6.3.1-6.3.12, John Wiley and Sons, Toronto 1991; deVries *et al.*, *J Exp Med* 173:1205-1211, 1991; Moreau *et al.*, *Nature* 336:690-692, 1988; Greenberger *et al.*, *Proc Natl Acad Sci U.S.A.* 80:2931-2938, 1983; Nordan, In: CURRENT



5 PROTOCOLS IN IMMUNOLOGY. Coligan *et al.*, eds. Vol 1 pp. 6.6.1-5, John Wiley and Sons,  
Toronto 1991; Smith *et al.*, *Proc Natl Acad Sci U.S.A.* 83:1857-1861, 1986; Measurement of  
human Interleukin 11-Bennett, *et al.* In: CURRENT PROTOCOLS IN IMMUNOLOGY. Coligan *et al.*,  
10 eds. Vol 1 pp. 6.15.1 John Wiley and Sons, Toronto 1991; Ciarletta, *et al.*, In: CURRENT  
5 PROTOCOLS IN IMMUNOLOGY. Coligan *et al.*, eds. Vol 1 pp. 6.13.1, John Wiley and Sons,  
Toronto 1991.

15 Assays for T-cell clone responses to antigens (which will identify, among others,  
proteins that affect APC-T cell interactions as well as direct T-cell effects by measuring  
proliferation and cytokine production) include, without limitation, those described In: CURRENT  
10 PROTOCOLS IN IMMUNOLOGY. Coligan *et al.*, eds., Greene Publishing Associates and  
20 Wiley-Interscience (Chapter 3Chapter 6, Chapter 7); Weinberger *et al.*, *Proc Natl Acad Sci USA*  
77:6091-6095, 1980; Weinberger *et al.*, *Eur J Immun* 11:405-411, 1981; Takai *et al.*, *J Immunol*  
137:3494-3500, 1986; Takai *et al.*, *J Immunol* 140:508-512, 1988.

#### 25 Immune Stimulating or Suppressing Activity

15 A 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X protein of the present  
invention may also exhibit immune stimulating or immune suppressing activity, including  
30 without limitation the activities for which assays are described herein. A protein may be useful  
in the treatment of various immune deficiencies and disorders (including severe combined  
immunodeficiency (SCID)), *e.g.*, in regulating (up or down) growth and proliferation of T and/or  
20 B lymphocytes, as well as effecting the cytolytic activity of NK cells and other cell populations.  
35 These immune deficiencies may be genetic or be caused by viral (*e.g.*, HIV) as well as bacterial  
or fungal infections, or may result from autoimmune disorders. More specifically, infectious  
diseases caused by viral, bacterial, fungal or other infection may be treatable using a protein of  
40 the present invention, including infections by HIV, hepatitis viruses, herpesviruses,  
25 mycobacteria, Leishmania species., malaria species. and various fungal infections such as  
candidiasis. Of course, in this regard, a protein of the present invention may also be useful where  
a boost to the immune system generally may be desirable, *i.e.*, in the treatment of cancer.

45 Autoimmune disorders which may be treated using a protein of the present invention  
include, for example, connective tissue disease, multiple sclerosis, systemic lupus  
30 erythematosus, rheumatoid arthritis, autoimmune pulmonary inflammation, Guillain-Barre  
50 syndrome, autoimmune thyroiditis, insulin dependent diabetes mellitus, myasthenia gravis,

5 graft-versus-host disease and autoimmune inflammatory eye disease. Such a protein of the  
present invention may also be useful in the treatment of allergic reactions and conditions, such  
as asthma (particularly allergic asthma) or other respiratory problems. Other conditions, in which  
10 immune suppression is desired (including, for example, organ transplantation), may also be  
5 treatable using a protein of the present invention.

Using the proteins of the invention it may also be possible to immune responses, in a  
15 number of ways. Down regulation may be in the form of inhibiting or blocking an immune  
response already in progress or may involve preventing the induction of an immune response.  
The functions of activated T cells may be inhibited by suppressing T cell responses or by  
10 inducing specific tolerance in T cells, or both. Immunosuppression of T cell responses is  
20 generally an active, non-antigen-specific, process which requires continuous exposure of the T  
cells to the suppressive agent. Tolerance, which involves inducing non-responsiveness or energy  
in T cells, is distinguishable from immunosuppression in that it is generally antigen-specific and  
25 persists after exposure to the tolerizing agent has ceased. Operationally, tolerance can be  
15 demonstrated by the lack of a T cell response upon re-exposure to specific antigen in the absence  
of the tolerizing agent.

Down regulating or preventing one or more antigen functions (including without  
30 limitation B lymphocyte antigen functions (such as, for example, B7), *e.g.*, preventing high level  
lymphokine synthesis by activated T cells, will be useful in situations of tissue, skin and organ  
20 transplantation and in graft-versus-host disease (GVHD). For example, blockage of T cell  
35 function should result in reduced tissue destruction in tissue transplantation. Typically, in tissue  
transplants, rejection of the transplant is initiated through its recognition as foreign by T cells,  
followed by an immune reaction that destroys the transplant. The administration of a molecule  
40 which inhibits or blocks interaction of a B7 lymphocyte antigen with its natural ligand(s) on  
25 immune cells (such as a soluble, monomeric form of a peptide having B7-2 activity alone or in  
conjunction with a monomeric form of a peptide having an activity of another B lymphocyte  
antigen (*e.g.*, B7-1, B7-3) or blocking antibody), prior to transplantation can lead to the binding  
45 of the molecule to the natural ligand(s) on the immune cells without transmitting the  
corresponding costimulatory signal. Blocking B lymphocyte antigen function in this matter  
30 prevents cytokine synthesis by immune cells, such as T cells, and thus acts as an  
50 immunosuppressant. Moreover, the lack of costimulation may also be sufficient to energize the  
T cells, thereby inducing tolerance in a subject. Induction of long-term tolerance by B

lymphocyte antigen-blocking reagents may avoid the necessity of repeated administration of these blocking reagents. To achieve sufficient immunosuppression or tolerance in a subject, it may also be necessary to block the function of B lymphocyte antigens.

The efficacy of particular blocking reagents in preventing organ transplant rejection or GVHD can be assessed using animal models that are predictive of efficacy in humans. Examples of appropriate systems which can be used include allogeneic cardiac grafts in rats and xenogeneic pancreatic islet cell grafts in mice, both of which have been used to examine the immunosuppressive effects of CTLA4Ig fusion proteins *in vivo* as described in Lenschow *et al.*, Science 257:789-792 (1992) and Turka *et al.*, Proc Natl Acad Sci USA, 89:11102-11105 (1992). In addition, murine models of GVHD (see Paul ed., FUNDAMENTAL IMMUNOLOGY, Raven Press, New York, 1989, pp. 846-847) can be used to determine the effect of blocking B lymphocyte antigen function *in vivo* on the development of that disease.

Blocking antigen function may also be therapeutically useful for treating autoimmune diseases. Many autoimmune disorders are the result of inappropriate activation of T cells that are reactive against self tissue and which promote the production of cytokines and auto-antibodies involved in the pathology of the diseases. Preventing the activation of autoreactive T cells may reduce or eliminate disease symptoms. Administration of reagents which block costimulation of T cells by disrupting receptor:ligand interactions of B lymphocyte antigens can be used to inhibit T cell activation and prevent production of auto-antibodies or T cell-derived cytokines which may be involved in the disease process. Additionally, blocking reagents may induce antigen-specific tolerance of autoreactive T cells which could lead to long-term relief from the disease. The efficacy of blocking reagents in preventing or alleviating autoimmune disorders can be determined using a number of well-characterized animal models of human autoimmune diseases. Examples include murine experimental autoimmune encephalitis, systemic lupus erythematosus in MRL/lpr/lpr mice or NZB hybrid mice, murine autoimmune collagen arthritis, diabetes mellitus in NOD mice and BB rats, and murine experimental myasthenia gravis (see Paul ed., FUNDAMENTAL IMMUNOLOGY, Raven Press, New York, 1989, pp. 840-856).

Upregulation of an antigen function (preferably a B lymphocyte antigen function), as a means of up regulating immune responses, may also be useful in therapy. Upregulation of immune responses may be in the form of enhancing an existing immune response or eliciting an initial immune response. For example, enhancing an immune response through stimulating B

5 lymphocyte antigen function may be useful in cases of viral infection. In addition, systemic viral diseases such as influenza, the common cold, and encephalitis might be alleviated by the administration of stimulatory forms of B lymphocyte antigens systemically.

10 Alternatively, anti-viral immune responses may be enhanced in an infected patient by removing T cells from the patient, costimulating the T cells *in vitro* with viral antigen-pulsed APCs either expressing a peptide of the present invention or together with a stimulatory form of a soluble peptide of the present invention and reintroducing the *in vitro* activated T cells into the patient. Another method of enhancing anti-viral immune responses would be to isolate infected cells from a patient, transfect them with a nucleic acid encoding a protein of the present invention as described herein such that the cells express all or a portion of the protein on their surface, and reintroduce the transfected cells into the patient. The infected cells would now be capable of delivering a costimulatory signal to, and thereby activate, T cells *in vivo*.

25 In another application, up regulation or enhancement of antigen function (preferably B lymphocyte antigen function) may be useful in the induction of tumor immunity. Tumor cells (e.g., sarcoma, melanoma, lymphoma, leukemia, neuroblastoma, carcinoma) transfected with a nucleic acid encoding at least one peptide of the present invention can be administered to a subject to overcome tumor-specific tolerance in the subject. If desired, the tumor cell can be transfected to express a combination of peptides. For example, tumor cells obtained from a patient can be transfected *ex vivo* with an expression vector directing the expression of a peptide having B7-2-like activity alone, or in conjunction with a peptide having B7-1-like activity and/or B7-3-like activity. The transfected tumor cells are returned to the patient to result in expression of the peptides on the surface of the transfected cell. Alternatively, gene therapy techniques can be used to target a tumor cell for transfection *in vivo*.

40 The presence of the peptide of the present invention having the activity of a B lymphocyte antigen(s) on the surface of the tumor cell provides the necessary costimulation signal to T cells to induce a T cell mediated immune response against the transfected tumor cells. In addition, tumor cells which lack MHC class I or MHC class II molecules, or which fail to reexpress sufficient amounts of MHC class I or MHC class II molecules, can be transfected with nucleic acid encoding all or a portion of (e.g., a cytoplasmic-domain truncated portion) of an MHC class I a chain protein and b 2 microglobulin protein or an MHC class II a chain protein and an MHC class II b chain protein to thereby express MHC class I or MHC class II proteins on

the cell surface. Expression of the appropriate class I or class II MHC in conjunction with a peptide having the activity of a B lymphocyte antigen (e.g., B7-1, B7-2, B7-3) induces a T cell mediated immune response against the transfected tumor cell. Optionally, a gene encoding an antisense construct which blocks expression of an MHC class II associated protein, such as the invariant chain, can also be cotransfected with a DNA encoding a peptide having the activity of a B lymphocyte antigen to promote presentation of tumor associated antigens and induce tumor specific immunity. Thus, the induction of a T cell mediated immune response in a human subject may be sufficient to overcome tumor-specific tolerance in the subject.

The activity of a protein of the invention may, among other means, be measured by the following methods: Suitable assays for thymocyte or splenocyte cytotoxicity include, without limitation, those described in: CURRENT PROTOCOLS IN IMMUNOLOGY. Coligan *et al.*, eds. Greene Publishing Associates and Wiley-Interscience (Chapter 3, Chapter 7); Herrmann *et al.*, *Proc Natl Acad Sci USA* 78:2488-2492, 1981; Herrmann *et al.*, *J Immunol* 128:1968-1974, 1982; Handa *et al.*, *J Immunol* 135:1564-1572, 1985; Takai *et al.*, *J Immunol* 137:3494-3500, 1986; Takai *et al.*, *J Immunol* 140:508-512, 1988; Herrmann *et al.*, *Proc Natl Acad Sci USA* 78:2488-2492, 1981; Herrmann *et al.*, *J Immunol* 128:1968-1974, 1982; Handa *et al.*, *J Immunol* 135:1564-1572, 1985; Takai *et al.*, *J Immunol* 137:3494-3500, 1986; Bowman *et al.*, *J Virology* 61:1992-1998; Takai *et al.*, *J Immunol* 140:508-512, 1988; Bertagnolli *et al.*, *Cell Immunol* 133:327-341, 1991; Brown *et al.*, *J Immunol* 153:3079-3092, 1994.

Assays for T-cell-dependent immunoglobulin responses and isotype switching (which will identify, among others, proteins that modulate T-cell dependent antibody responses and that affect Th1/Th2 profiles) include, without limitation, those described in: Maliszewski, *J Immunol* 144:3028-3033, 1990; and Mond and Brunswick In: CURRENT PROTOCOLS IN IMMUNOLOGY. Coligan *et al.*, eds. Vol 1 pp. 3.8.1-3.8.16, John Wiley and Sons, Toronto 1994.

Mixed lymphocyte reaction (MLR) assays (which will identify, among others, proteins that generate predominantly Th1 and CTL responses) include, without limitation, those described in: CURRENT PROTOCOLS IN IMMUNOLOGY. Coligan *et al.*, eds. Greene Publishing Associates and Wiley-Interscience (Chapter 3, Chapter 7); Takai *et al.*, *J Immunol* 137:3494-3500, 1986; Takai *et al.*, *J Immunol* 140:508-512, 1988; Bertagnolli *et al.*, *J Immunol* 149:3778-3783, 1992.

Dendritic cell-dependent assays (which will identify, among others, proteins expressed by dendritic cells that activate naive T-cells) include, without limitation, those described in: Guery *et al.*, *J Immunol* 134:536-544, 1995; Inaba *et al.*, *J Exp Med* 173:549-559, 1991; Macatonia *et al.*, *J Immunol* 154:5071-5079, 1995; Porgador *et al.*, *J Exp Med* 182:255-260, 1995; Nair *et al.*, *J Virol* 67:4062-4069, 1993; Huang *et al.*, *Science* 264:961-965, 1994; Macatonia *et al.*, *J Exp Med* 169:1255-1264, 1989; Bhardwaj *et al.*, *J Clin Invest* 94:797-807, 1994; and Inaba *et al.*, *J Exp Med* 172:631-640, 1990.

Assays for lymphocyte survival/apoptosis (which will identify, among others, proteins that prevent apoptosis after superantigen induction and proteins that regulate lymphocyte homeostasis) include, without limitation, those described in: Darzynkiewicz *et al.*, *Cytometry* 13:795-808, 1992; Gorczyca *et al.*, *Leukemia* 7:659-670, 1993; Gorczyca *et al.*, *Cancer Res* 53:1945-1951, 1993; Itoh *et al.*, *Cell* 66:233-243, 1991; Zacharchuk, *J Immunol* 145:4037-4045, 1990; Zamai *et al.*, *Cytometry* 14:891-897, 1993; Gorczyca *et al.*, *Internat J Oncol* 1:639-648, 1992.

Assays for proteins that influence early steps of T-cell commitment and development include, without limitation, those described in: Antica *et al.*, *Blood* 84:111-117, 1994; Fine *et al.*, *Cell Immunol* 155: 111-122, 1994; Galy *et al.*, *Blood* 85:2770-2778, 1995; Toki *et al.*, *Proc Nat Acad Sci USA* 88:7548-7551, 1991.

#### Hematopoiesis Regulating Activity

A 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X protein of the present invention may be useful in regulation of hematopoiesis and, consequently, in the treatment of myeloid or lymphoid cell deficiencies. Even marginal biological activity in support of colony forming cells or of factor-dependent cell lines indicates involvement in regulating hematopoiesis, *e.g.* in supporting the growth and proliferation of erythroid progenitor cells alone or in combination with other cytokines, thereby indicating utility, for example, in treating various anemias or for use in conjunction with irradiation/chemotherapy to stimulate the production of erythroid precursors and/or erythroid cells; in supporting the growth and proliferation of myeloid cells such as granulocytes and monocytes/macrophages (*i.e.*, traditional CSF activity) useful, for example, in conjunction with chemotherapy to prevent or treat consequent myelo-suppression; in supporting the growth and proliferation of megakaryocytes and consequently of platelets thereby allowing prevention or treatment of various platelet

5 disorders such as thrombocytopenia, and generally for use in place of or complimentary to  
platelet transfusions; and/or in supporting the growth and proliferation of hematopoietic stem  
cells which are capable of maturing to any and all of the above-mentioned hematopoietic cells  
10 and therefore find therapeutic utility in various stem cell disorders (such as those usually treated  
5 with transplantation, including, without limitation, aplastic anemia and paroxysmal nocturnal  
hemoglobinuria), as well as in repopulating the stem cell compartment post  
15 irradiation/chemotherapy, either *in vivo* or *ex vivo* (i.e., in conjunction with bone marrow  
transplantation or with peripheral progenitor cell transplantation (homologous or heterologous))  
as normal cells or genetically manipulated for gene therapy.

10 The activity of a protein of the invention may, among other means, be measured by  
20 suitable assays. Suitable assays for proliferation and differentiation of various hematopoietic  
lines are cited above.

25 Assays for embryonic stem cell differentiation (which will identify, among others,  
proteins that influence embryonic differentiation hematopoiesis) include, without limitation,  
15 those described in: Johansson *et al.* *Cell Biol* 15:141-151, 1995; Keller *et al.*, *Mol Cell Biol*  
13:473-486, 1993; McClanahan *et al.*, *Blood* 81:2903-2915, 1993.

30 Assays for stem cell survival and differentiation (which will identify, among others,  
proteins that regulate lympho-hematopoiesis) include, without limitation, those described in:  
Methylcellulose colony forming assays, Freshney, M. G. In CULTURE OF HEMATOPOIETIC CELLS.  
20 Freshney, *et al.* eds. Vol pp. 265-268, Wiley-Liss, Inc., New York, N.Y. 1994; Hirayama *et al.*,  
35 *Proc Natl Acad Sci USA* 89:5907-5911, 1992; McNiece and Briddeli. In CULTURE OF  
HEMATOPOIETIC CELLS. Freshney, *et al.* eds. Vol pp. 23-39, Wiley-Liss, Inc., New York, N.Y.  
1994; Neben *et al.*, *Exp Hematol* 22:353-359, 1994; Ploemacher In CULTURE OF HEMATOPOIETIC  
40 CELLS. Freshney, *et al.* eds. Vol pp. 1-21, Wiley-Liss, Inc., New York, N.Y. 1994; Spoonceret  
25 *al.*, In CULTURE OF HEMATOPOIETIC CELLS. Freshney, *et al.* eds. Vol pp. 163-179, Wiley-Liss,  
Inc., New York, N.Y. 1994; Sutherland, In CULTURE OF HEMATOPOIETIC CELLS. Freshney, *et al.*  
45 eds. Vol pp. 139-162, Wiley-Liss, Inc., New York, N.Y. 1994.

#### Tissue Growth Activity

A 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X protein of the present  
50 30 invention also may have utility in compositions used for bone, cartilage, tendon, ligament and/or

5 nerve tissue growth or regeneration, as well as for wound healing and tissue repair and replacement, and in the treatment of burns, incisions and ulcers.

10 A protein of the present invention, which induces cartilage and/or bone growth in circumstances where bone is not normally formed, has application in the healing of bone  
5 fractures and cartilage damage or defects in humans and other animals. Such a preparation employing a protein of the invention may have prophylactic use in closed as well as open  
15 fracture reduction and also in the improved fixation of artificial joints. De novo bone formation induced by an osteogenic agent contributes to the repair of congenital, trauma induced, or oncologic resection induced craniofacial defects, and also is useful in cosmetic plastic surgery.

20 10 A protein of this invention may also be used in the treatment of periodontal disease, and in other tooth repair processes. Such agents may provide an environment to attract bone-forming cells, stimulate growth of bone-forming cells or induce differentiation of progenitors of bone-forming cells. A protein of the invention may also be useful in the treatment of  
25 osteoporosis or osteoarthritis, such as through stimulation of bone and/or cartilage repair or by  
15 blocking inflammation or processes of tissue destruction (collagenase activity, osteoclast activity, etc.) mediated by inflammatory processes.

30 Another category of tissue regeneration activity that may be attributable to the protein of the present invention is tendon/ligament formation. A protein of the present invention, which induces tendon/ligament-like tissue or other tissue formation in circumstances where such tissue  
35 20 is not normally formed, has application in the healing of tendon or ligament tears, deformities and other tendon or ligament defects in humans and other animals. Such a preparation employing a tendon/ligament-like tissue inducing protein may have prophylactic use in preventing damage to tendon or ligament tissue, as well as use in the improved fixation of  
40 tendon or ligament to bone or other tissues, and in repairing defects to tendon or ligament tissue.  
25 De novo tendon/ligament-like tissue formation induced by a composition of the present invention contributes to the repair of congenital, trauma induced, or other tendon or ligament  
45 defects of other origin, and is also useful in cosmetic plastic surgery for attachment or repair of tendons or ligaments. The compositions of the present invention may provide an environment to attract tendon- or ligament-forming cells, stimulate growth of tendon- or ligament-forming cells,  
30 induce differentiation of progenitors of tendon- or ligament-forming cells, or induce growth of tendon/ligament cells or progenitors *ex vivo* for return *in vivo* to effect tissue repair. The  
50



5 compositions of the invention may also be useful in the treatment of tendonitis, carpal tunnel syndrome and other tendon or ligament defects. The compositions may also include an appropriate matrix and/or sequestering agent as a carrier as is well known in the art.

10 The protein of the present invention may also be useful for proliferation of neural cells and for regeneration of nerve and brain tissue, *i.e.* for the treatment of central and peripheral nervous system diseases and neuropathies, as well as mechanical and traumatic disorders, which involve degeneration, death or trauma to neural cells or nerve tissue. More specifically, a protein  
15 may be used in the treatment of diseases of the peripheral nervous system, such as peripheral nerve injuries, peripheral neuropathy and localized neuropathies, and central nervous system diseases, such as Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and Shy-Drager syndrome. Further conditions which may be treated in accordance  
20 with the present invention include mechanical and traumatic disorders, such as spinal cord disorders, head trauma and cerebrovascular diseases such as stroke. Peripheral neuropathies resulting from chemotherapy or other medical therapies may also be treatable using a protein of  
25 the invention.

30 Proteins of the invention may also be useful to promote better or faster closure of non-healing wounds, including without limitation pressure ulcers, ulcers associated with vascular insufficiency, surgical and traumatic wounds, and the like.

35 It is expected that a protein of the present invention may also exhibit activity for generation or regeneration of other tissues, such as organs (including, for example, pancreas, liver, intestine, kidney, skin, endothelium), muscle (smooth, skeletal or cardiac) and vascular (including vascular endothelium) tissue, or for promoting the growth of cells comprising such tissues. Part of the desired effects may be by inhibition or modulation of fibrotic scarring to  
40 allow normal tissue to regenerate. A protein of the invention may also exhibit angiogenic activity.

45 A protein of the present invention may also be useful for gut protection or regeneration and treatment of lung or liver fibrosis, reperfusion injury in various tissues, and conditions resulting from systemic cytokine damage.

50 A protein of the present invention may also be useful for promoting or inhibiting differentiation of tissues described above from precursor tissues or cells; or for inhibiting the growth of tissues described above.

5 The activity of a protein of the invention may, among other means, be measured by the following methods:

Assays for tissue generation activity include, without limitation, those described in:

10 International Patent Publication No. WO95/16035 (bone, cartilage, tendon); International Patent  
5 Publication No. WO95/05846 (nerve, neuronal); International Patent Publication No.  
WO91/07491 (skin, endothelium).

15 Assays for wound healing activity include, without limitation, those described in: Winter,  
*Epidermal Wound Healing*, pp. 71-112 (Maibach, H I and Rovee, D T, eds.), Year Book Medical  
Publishers, Inc., Chicago, as modified by Eaglstein and Menz, J. Invest. Dermatol 71:382-84  
10 (1978).

#### 20 Activin/Inhibin Activity

A 2155647, 2355875, 3223867, 3224646, 3482699, or Mamm-X protein of the present  
25 invention may also exhibit activin- or inhibin-related activities. Inhibins are characterized by  
their ability to inhibit the release of follicle stimulating hormone (FSH), while activins are  
15 characterized by their ability to stimulate the release of follicle stimulating hormone (FSH).  
Thus, a protein of the present invention, alone or in heterodimers with a member of the inhibin a  
30 family, may be useful as a contraceptive based on the ability of inhibins to decrease fertility in  
female mammals and decrease spermatogenesis in male mammals. Administration of sufficient  
amounts of other inhibins can induce infertility in these mammals. Alternatively, the protein of  
35 20 the invention, as a homodimer or as a heterodimer with other protein subunits of the inhibin-b  
group, may be useful as a fertility inducing therapeutic, based upon the ability of activin  
molecules in stimulating FSH release from cells of the anterior pituitary. See, for example, U.S.  
40 Pat. No. 4,798,885. A protein of the invention may also be useful for advancement of the onset  
of fertility in sexually immature mammals, so as to increase the lifetime reproductive  
25 performance of domestic animals such as cows, sheep and pigs.

45 The activity of a protein of the invention may, among other means, be measured by the following methods:

Assays for activin/inhibin activity include, without limitation, those described in: Vale *et al.*,  
Endocrinology 91:562-572, 1972; Ling *et al.*, Nature 321:779-782, 1986; Vale *et al.*, Nature  
50 30 321:776-779, 1986; Mason *et al.*, Nature 318:659-663, 1985; Forage *et al.*, Proc Natl Acad Sci  
USA 83:3091-3095, 1986.

**Chemotactic/Chemokinetic Activity**

A protein of the present invention may have chemotactic or chemokinetic activity (e.g., act as a chemokine) for mammalian cells, including, for example, monocytes, fibroblasts, neutrophils, T-cells, mast cells, eosinophils, epithelial and/or endothelial cells. Chemotactic and chemokinetic proteins can be used to mobilize or attract a desired cell population to a desired site of action. Chemotactic or chemokinetic proteins provide particular advantages in treatment of wounds and other trauma to tissues, as well as in treatment of localized infections. For example, attraction of lymphocytes, monocytes or neutrophils to tumors or sites of infection may result in improved immune responses against the tumor or infecting agent.

A protein or peptide has chemotactic activity for a particular cell population if it can stimulate, directly or indirectly, the directed orientation or movement of such cell population. Preferably, the protein or peptide has the ability to directly stimulate directed movement of cells. Whether a particular protein has chemotactic activity for a population of cells can be readily determined by employing such protein or peptide in any known assay for cell chemotaxis.

The activity of a protein of the invention may, among other means, be measured by following methods. Assays for chemotactic activity (which will identify proteins that induce or prevent chemotaxis) consist of assays that measure the ability of a protein to induce the migration of cells across a membrane as well as the ability of a protein to induce the adhesion of one cell population to another cell population. Suitable assays for movement and adhesion include, without limitation, those described in: CURRENT PROTOCOLS IN IMMUNOLOGY, Coligan *et al.*, eds. (Chapter 6.12, Measurement of alpha and beta Chemokines 6.12.1-6.12.28); Taub *et al.* *J Clin Invest* 95:1370-1376, 1995; Lind *et al.* *APMIS* 103:140-146, 1995; Muller *et al.* *Eur J Immunol* 25: 1744-1748; Gruber *et al.* *J Immunol* 152:5860-5867, 1994; Johnston *et al.* *J Immunol* 153: 1762-1768, 1994.

**Hemostatic and Thrombolytic Activity**

A protein of the invention may also exhibit hemostatic or thrombolytic activity. As a result, such a protein is expected to be useful in treatment of various coagulation disorders (including hereditary disorders, such as hemophilias) or to enhance coagulation and other hemostatic events in treating wounds resulting from trauma, surgery or other causes. A protein of the invention may also be useful for dissolving or inhibiting formation of thromboses and for

5 treatment and prevention of conditions resulting therefrom (such as, for example, infarction of cardiac and central nervous system vessels (*e.g.*, stroke).

10 The activity of a protein of the invention may, among other means, be measured by the following methods. Assay for hemostatic and thrombolytic activity include, without limitation,  
5 those described in: Linet *et al.*, J. Clin. Pharmacol. 26:131-140, 1986; Burdick *et al.*, Thrombosis Res. 45:413-419, 1987; Humphrey *et al.*, Fibrinolysis 5:71-79 (1991); Schaub, Prostaglandins 35:467-474, 1988.  
15

#### Receptor/Ligand Activity

20 A protein of the present invention may also demonstrate activity as a receptor, receptor ligand or inhibitor or agonist of receptor/ligand interactions. Examples of such receptors and  
10 ligands include, without limitation, cytokine receptors and their ligands, receptor kinases and their ligands, receptor phosphatases and their ligands, receptors involved in cell—cell  
25 interactions and their ligands (including without limitation, cellular adhesion molecules (such as selectins, integrins and their ligands) and receptor/ligand pairs involved in antigen presentation,  
15 antigen recognition and development of cellular and humoral immune responses). Receptors and ligands are also useful for screening of potential peptide or small molecule inhibitors of the  
30 relevant receptor/ligand interaction. A protein of the present invention (including, without limitation, fragments of receptors and ligands) may themselves be useful as inhibitors of receptor/ligand interactions.

35 20 The activity of a protein of the invention may, among other means, be measured by the following methods. Suitable assays for receptor-ligand activity include without limitation those described in: CURRENT PROTOCOLS IN IMMUNOLOGY, Ed by Coligan *et al.*, Greene Publishing  
40 Associates and Wiley-Interscience (Chapter 7.28, Measurement of Cellular Adhesion under static conditions 7.28.1-7.28.22), Takai *et al.*, *Proc Natl Acad Sci USA* 84:6864-6868, 1987;  
25 Bierer *et al.*, J. Exp. Med. 168:1145-1156, 1988; Rosenstein *et al.*, J. Exp. Med. 169:149-160 1989; Stoltenborg *et al.*, *J Immunol Methods* 175:59-68, 1994; Stitt *et al.*, *Cell* 80:661-670,  
45 1995.

#### Anti-Inflammatory Activity

50 30 Proteins of the present invention may also exhibit anti-inflammatory activity. The anti-inflammatory activity may be achieved by providing a stimulus to cells involved in the inflammatory response, by inhibiting or promoting cell—cell interactions (such as, for example,  
55

cell adhesion), by inhibiting or promoting chemotaxis of cells involved in the inflammatory process, inhibiting or promoting cell extravasation, or by stimulating or suppressing production of other factors which more directly inhibit or promote an inflammatory response. Proteins exhibiting such activities can be used to treat inflammatory conditions including chronic or acute conditions), including without limitation inflammation associated with infection (such as septic shock, sepsis or systemic inflammatory response syndrome (SIRS)), ischemia-reperfusion injury, endotoxin lethality, arthritis, complement-mediated hyperacute rejection, nephritis, cytokine or chemokine-induced lung injury, inflammatory bowel disease, Crohn's disease or resulting from over production of cytokines such as TNF or IL-1. Proteins of the invention may also be useful to treat anaphylaxis and hypersensitivity to an antigenic substance or material.

#### **Tumor Inhibition Activity**

In addition to the activities described above for immunological treatment or prevention of tumors, a protein of the invention may exhibit other anti-tumor activities. A protein may inhibit tumor growth directly or indirectly (such as, for example, via ADCC). A protein may exhibit its tumor inhibitory activity by acting on tumor tissue or tumor precursor tissue, by inhibiting formation of tissues necessary to support tumor growth (such as, for example, by inhibiting angiogenesis), by causing production of other factors, agents or cell types which inhibit tumor growth, or by suppressing, eliminating or inhibiting factors, agents or cell types which promote tumor growth.

#### **Other Activities**

A protein of the invention may also exhibit one or more of the following additional activities or effects: inhibiting the growth, infection or function of, or killing, infectious agents, including, without limitation, bacteria, viruses, fungi and other parasites; effecting (suppressing or enhancing) bodily characteristics, including, without limitation, height, weight, hair color, eye color, skin, fat to lean ratio or other tissue pigmentation, or organ or body part size or shape (such as, for example, breast augmentation or diminution, change in bone form or shape); effecting biorhythms or circadian cycles or rhythms; effecting the fertility of male or female subjects; effecting the metabolism, catabolism, anabolism, processing, utilization, storage or elimination of dietary fat, lipid, protein, carbohydrate, vitamins, minerals, cofactors or other nutritional factors or component(s); effecting behavioral characteristics, including, without limitation, appetite, libido, stress, cognition (including cognitive disorders), depression

(including depressive disorders) and violent behaviors; providing analgesic effects or other pain reducing effects; promoting differentiation and growth of embryonic stem cells in lineages other than hematopoietic lineages; hormonal or endocrine activity; in the case of enzymes, correcting deficiencies of the enzyme and treating deficiency-related diseases; treatment of hyperproliferative disorders (such as, for example, psoriasis); immunoglobulin-like activity (such as, for example, the ability to bind antigens or complement); and the ability to act as an antigen in a vaccine composition to raise an immune response against such protein or another material or entity which is cross-reactive with such protein.

The present invention is not to be limited in scope by the specific embodiments described herein. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description and accompanying figures. Such modifications are intended to fall within the scope of the appended claims.

This invention is further illustrated by the following examples, which should not be construed as limiting. The contents of all references, patents and published patent applications cited throughout this application are hereby incorporated by reference.

## EXAMPLES

### 1. Expression of clone 2155647 in mammalian and insect cells

#### 1.1. Cloning of 2155647 cDNA for mammalian and insect cell expression.

Based on the predicted reading frame, PCR primers were designed to amplify the coding region for h2155647. The forward primer was 5'-CGAGATCTCCACCATGAAAGCTCTCTGTCTCCTCCTCCTCCCTGCTCTGGGGCTGTTGGTGTCTAG (SEQ ID NO:23), and the reverse primer was 5'-ATCTCGAGGGGCTGCACACGACAGCAGCGCGCTCCGGTCCAGTCCAT (SEQ ID NO:24). PCR was initiated by heating 25 µl Mix 1 (75 pmoles primers, 4 µg adult bone marrow cDNA, 5 µmoles dNTPs) and 25 µl Mix 2 [1 unit Fidelity Expand polymerase (Boehringer Mannheim), 5 µl 10X Fidelity Expand Buffer] separately at 96°C for 20 seconds. Mixes 1 and 2 were then pooled, and the following PCR cycling parameters were used: 96°C, 3 min (1 cycle); 96°C, 30 sec, 55°C, 1 min, 68°C, 2 min (10 cycles); 96°C, 30 sec, 60°C, 1 min, 68°C, 2 min (20 cycles); 72°C, 7 min (1 cycle). After PCR, a single DNA fragment of approximately 0.4 kb was obtained. The DNA fragment was digested with BglII and XhoI

5 restriction enzymes, and cloned into the pcDNA3.1 V5His vector (Invitrogen, Carlsbad, CA) or  
into the pBIgHis vector (CuraGen Corporation). The 2155647 insert was verified by DNA  
sequence analysis. The resulting expression vectors are called pcDNA3.1V5His2155647 for  
10 mammalian kidney 293 cell expression and pBIgHis2155647 for insect cell expression.

### 5 1.2. Expression of h2155647 in human embryonic kidney 293 cells.

The pcDNA3.1V5His2155647 vector was transfected into 293 cells using the  
15 LipofectaminePlus reagent following the manufacturer's instructions (Gibco/BRL). The cell  
pellet and supernatant were harvested 72 hours after transfection and examined for h2155647  
expression by Western blotting (reducing conditions) with an anti-V5 antibody. The h2155647  
10 protein was expressed as a 20-kDa protein secreted by 293 cells.

### 1.3. Construction of pBIgHis baculo expression vector.

To construct the pBIgHis expression vector, we designed oligonucleotide primers to  
25 amplify the Fc fragment of the human immunoglobulin heavy chain. The forward primer was 5'-  
CCGCTCGAGTGAGCCCAAATCT TGTGACAAA (SEQ ID NO:21) and the reverse primer  
15 was 5'-GCTCTAGACTTTTACCCGG GGACAGGGAG (SEQ ID NO:22). PCR was initiated  
by heating 25 ul Mix 1 (75 pmoles primers, 4 ug adult testis cDNA, 5 umoles dNTPs) and 25 ul  
30 Mix 2 [1 unit Fidelity Expand polymerase (Boehringer Mannheim), 5 µl 10X Fidelity Expand  
Buffer] separately at 96°C for 20 seconds. Mixes 1 and 2 were then pooled, and the following  
PCR cycling parameters were used: 96°C, 3 min (1 cycle); 96°C, 30 sec, 55°C, 1 min, 68°C, 2  
35 20 min (10 cycles); 96°C, 30 sec, 60°C, 1 min, 68°C, 2 min (20 cycles); 72°C, 7 min (1 cycle). After  
PCR, a single DNA fragment of approximately 0.75 kb was obtained. The DNA fragment was  
digested with XhoI and XbaI restriction enzymes and cloned into the pCDNA3.1V5His(B)  
expression vector (Invitrogen, Carlsbad, CA). This vector is named as pCDNA3.1 Ig and  
40 contains Fc fragment fused to V5 epitope and 6xHis tag. To introduce a recombinant TEV  
25 protease cleavage site adjacent to the N-terminus of the Fc fragment, the inventors designed two  
oligonucleotides (SEQ ID NO: 13: 5'-AATTCTGCAGCGAAAACCTGTATTTTCAGGGT and  
45 SEQ ID NO:14: 5'-TCGAACCCTGAAAATACAGGTTTTCGCTGCAG) and purified the  
annealed oligos on a 20% polyacrylamide gel. The double stranded oligo DNA was then ligated  
into pCNA3.1 Ig digested with EcoRI and XhoI. The resulting plasmid was digested with PstI  
50 and PmeI to release a DNA fragment of approximately 0.9 kb, which was ligated into

pBlueBac4.5 digested with PstI and SmaI (Invitrogen, Carlsbad, CA). The plasmid construct obtained is named as pBIgHis. The Fc fragment was verified by sequence analysis.

#### 1.4. Construction and isolation of recombinant cells expressing h2155647.

pBIgHis2155647 plasmid DNA was co-transfected with linearized baculovirus DNA (Bac-N-Blue) into SF9 insect cells using liposome-mediated transfer as described by the manufacturer (Invitrogen). Briefly, transfection mixtures containing 4 ug of pBIgHis2155647, 0.5 ug of Bac-N-Blue™ and InsectinPlus™ liposomes were added to 60 mm culture dishes seeded with  $2 \times 10^6$  SF9 cells, and incubated with rocking at 27°C for 4 hours. Fresh culture medium was added and cultures were further incubated for 4 days. The culture medium was then harvested and recombinant viruses were isolated using standard plaque purification procedures. Recombinant viruses expressing b-galactosidase as a marker were readily distinguished from non-recombinant viruses by visually inspecting agarose overlays for blue plaques. Viral stocks were generated by propagation on SF9 cells and screened for expression of h2155647 protein by SDS-PAGE and Western blot analyses (reducing conditions, anti-V5 antibody). The h2155647 protein is secreted as a 45-kDa protein, corresponding to the fusion of 2155647 with the Ig F<sub>c</sub> sequence.

Clone 2155647 cDNA was also subcloned into the pcDNA3 mammalian expression factor and assayed for transforming activity following transfection into murine fibroblasts (NIH 3T3). No foci were generated by the clone 2155647 cDNA, indicating that it is non-transforming in this system.

Using the same construct, clone 2155657 was transiently transfected into human 293 kidney epithelial cells. The supernatant from these cells was found to contain 2155647 protein and was assayed for the ability to activate immediate early response genes (EGR-1, ATF-3, FOS, MKP-1, c-JUN, JUNB) by a TaqMan assay. No immediate early response gene activation was found in cells treated with 2155647.

## 2. Northern Analysis OF CLONE 3224646

### 2.1. Probe Production.

A 3224646 gene fragment (nucleotides 40 - 606 ) cloned into pCR2.1 (Invitrogen) was used as a template in a PCR reaction. The primers (SEQ ID NO:15 [M13FSP6]: 5'-GGATCCATTTAGGTGACACTATAGAAGCCCAAGTCACGACGTTGTAAAACGACGGC-



3' and SEQ ID NO:16 [M13RT3]: 5'- CGGCCGAATTACCCTCACTAAAGGGACGGATAA  
CAATTTACACAGGAAACAGC-3') used in the amplification flank the 3224646 insert and  
bind to the M13 forward and reverse sequencing primer sites. M13FSP6 (SEQ ID NO:15) and  
M13RT3 (SEQ ID NO:16) contain promoters for SP6 and T3 RNA polymerases, respectively.  
The PCR mix contained 1 ng plasmid DNA, 0.2 uM M13FSP6, 0.2 uM M13RT3, 200 mM  
dNTPs, 0.5 µl Advantage cDNA polymerase mix (50X; Clontech) in 1X PCR buffer (Advantage  
cDNA Polymerase Kit, Clontech). The PCR cycling parameters were as follows: 94°C, 2 min  
(1 cycle); 94°C, 5 sec, 72°C, 5 min (5 cycles); 94°C, 5 sec, 70°C, 3 min (5 cycles); 94°C, 5 sec,  
68°C, 3 min (15 cycles). Following amplification, the PCR product containing the gene fragment  
of interest was electrophoresed through a 1% low melt agarose gel and purified using the Qiaex  
II gel extraction kit (Qiagen).

An antisense RNA probe was generated from the PCR product using the Stip-EZ RNA  
probe synthesis kit (Ambion, Inc.) according to manufacturer's instructions. One hundred ng of  
PCR product was labeled with 25 µCi <sup>33</sup>P-UTP (3 mM; Amersham) in a synthesis reaction using  
SP6 RNA polymerase. Following RNA transcription, 1 µl DNase I was added and the reaction  
was allowed to proceed for 15 minutes at 37°C. The unincorporated nucleotides were removed  
with ProbeQuant G-50 micro columns (Pharmacia Biotech) according to manufacturer's  
instructions. The probe was quantitated with a Bioscan QC-4000 according to manufacturer's  
instructions (Bioscan).

## 2.2. Hybridization.

The RNA probe was hybridized to four commercially available Northern Blots  
(Clontech) at 65°C in a Robbins Scientific Model 400 hybridization incubator. Briefly, the blots  
were inserted into 15 x 300 mm glass tubes and prehybridized at 65°C in 10 ml Zip-Hyb  
(Ambion, Inc.) for 30 min. The RNA probe (1.0 x 10<sup>6</sup> dpm/ml) was added to 1.0 ml 65°C Zip-  
Hyb and placed in the glass tube with the prehybridized Northern blots. Hybridization of the  
probe was allowed to proceed for 2 hours. Following hybridization, the buffer was removed and  
the blots were washed twice for 15 min in the glass tubes at 65°C. The first wash was with  
prewarmed (65°C) 2X SSC, 0.1% SDS, while the second wash was with prewarmed 0.1X SSC,  
0.1% SDS. The blots were removed from the glass tubes, wrapped in Saran Wrap and exposed to  
phosphor screens overnight (Molecular Dynamics). The phosphor screens were scanned the  
following day on a Molecular Dynamics Storm 840 at 50 micron resolution.

### 3. Mapping of Human 3224646

#### 3.1. Oligonucleotide Design and Synthesis

A primer pair (SEQ ID NO:17: 5' GATTCTCTTCTTGCTTTTGACTC 3', SEQ ID NO:18: 5' ACTCAGCTGTTTATGGTGG 3') was designed (Primer 3 primer selection software package) to amplify a segment of the 3224646 gene. Oligonucleotides were synthesized by Integrated DNA Technologies, (Coralville, IA).

#### 3.2. PCR, Electrophoresis and Imaging Conditions

PCR was performed using the GeneBridge 4 human radiation hybrid panel (Research Genetics Inc., Huntsville, AL) as template. In addition to the 93 hybrids in the mapping panel, hamster and human genomic DNA were used as controls. DNA from the RH cell lines (50 ng) was amplified in 10 µl reactions containing 4.5 pmole primers, 40 µM dNTPs, 10% Rediload (Research Genetics, Inc., Huntsville, AL) and 1/3 X concentration of Advantage cDNA polymerase mix (Clontech, Inc, Palo Alto, CA). PCR was performed using a Tetrad thermocycler in an oil-free system (MJ Research) with the following "touchdown" PCR profile: 3 min, 94°C (1 cycle), 94°C, 30 sec, 67°C, 30 sec, 68°C, 30 sec (2 cycles); 94°C, 30 sec, 65°C, 30 sec, 68°C, 30 sec (2 cycles); 94°C, 30 sec, 67°C, 30 sec (31 cycles).

Samples were electrophoresed on a 3% agarose gel (1X TBE) containing 0.5 µg/ml ethidium bromide and imaged using the AlphImager 950 still video system (Alpha Innotech, San Leandro, CA). The collective set of scores (0 = no amplification; 1 = amplification; 2 = uncertain) for a single marker is called an RH vector. The 3224646 marker was assayed in duplicate to reduce errors, and a consensus was generated from the duplicate vectors.

Chromosomal placement of the human 3224646 gene was accomplished using information from the Whitehead Institute/Massachusetts Institute of Technology Center for Genome Research radiation hybrid mapping website.

#### 3.3. Results

The human 3224646 gene maps onto Human chromosome 3 at a LOD score of >22. The exact placement is at 3q21, 1.6 centiRay (cR) below D3S1576 and 4.6 cR above WI-3522. One cR is the distance between markers at which there is a 1% probability of breakage.

#### 4. MAMMAGLOBIN (MammX) EXPRESSION IN KIDNEY 293 CELLS

##### 4.1. Cloning of MammX cDNA for expression in kidney 293 cells.

Based on the predicted reading frame, we designed PCR primers to amplify the coding region of hMammX. The forward primer was SEQ ID NO:19 (5'-GGATCCACCATGAAGCTG CTGATGGTCCTCATGCTG-3'), and the reverse primer was SEQ ID NO:20 (5'-CTCGAGAT TACTCTTCATATTACACCAAATGCT-3'). PCR was initiated by heating 25 µl Mix 1 (75 pmoles primers, 4 µg adult bone marrow cDNA, 5 µmoles dNTPs) and 25 µl Mix 2 [1 unit Fidelity Expand polymerase (Boehringer Mannheim), 5 µl 10X Fidelity Expand Buffer (Boehringer Mannheim)] separately at 96°C for 20 seconds. Mixes 1 and 2 were then pooled and the following PCR cycling parameters were used: 96°C, 3 min (1 cycle); 96°C, 30 sec, 55°C, 1 min, 68°C, 2 min (10 cycles); 96°C, 30 sec, 60°C, 1 min, 68°C, 2 min (20 cycles); 72°C, 7 min (1 cycle). After PCR, a single DNA fragment of approximately 0.3 kb was obtained. The DNA fragment was cloned into the pcDNA3.1 V5His TOPO vector (Invitrogen, Carlsbad, CA). The MammX insert was verified by DNA sequence analysis. The resulting expression vector, pcDNA3.1 V5HisMammX was used for transient protein expression in mammalian kidney 293 cells.

##### 4.2. Expression of hMammX in human embryonic kidney 293 cells.

The pcDNA3.1 V5HisMammX vector was transfected into 293 cells using the LipofectaminePlus reagent following the manufacturer's instructions (Gibco/BRL). The cell pellet and supernatant were harvested 72 hours after transfection and examined for hMammX expression by Western blotting (reducing conditions) with an anti-V5 antibody. A 10-kDa hMammX protein was detected in the cell pellet. No secreted form of MammX was detected.

#### EQUIVALENTS

From the foregoing detailed description of the specific embodiments of the invention, it should be apparent that particular novel compositions and methods involving the coding nucleic acids, the polypeptides, detection and treatment methods have been described. Although these particular embodiments have been disclosed herein in detail, this has been done by way of example for purposes of illustration only, and is not intended to be limiting with respect to the scope of the appended claims which follow. In particular, it is contemplated by the inventors that various substitutions, alterations, and modifications may be made as a matter of routine for a

5 person of ordinary skill in the art to the invention without departing from the spirit and scope of the invention as defined by the claims.

Sequences and Corresponding SEQ ID Numbers

10 The sequences and corresponding SEQ ID NOs discussed herein include the following:

SEQ ID NO:1	human 2155647 cDNA
SEQ ID NO:2	human 2155647 amino acid sequence
15 SEQ ID NO:3	human 2355875 cDNA
SEQ ID NO:4	human 2355875 amino acid sequence
SEQ ID NO:5	human 3223867 cDNA
20 SEQ ID NO:6	human 3223867 amino acid sequence
SEQ ID NO:7	human 3224646 cDNA
SEQ ID NO:8	human 3224646 amino acid sequence
SEQ ID NO:9	human 3482699 cDNA
25 SEQ ID NO:10	human 3482699 amino acid sequence
SEQ ID NO:11	human Mamm-X cDNA
SEQ ID NO:12	human Mamm-X amino acid sequence
30 SEQ ID NO:13	primer to 2155647
SEQ ID NO:14	primer to 2155647
SEQ ID NO:15	primer to 3224646
SEQ ID NO:16	primer to 3224646
35 SEQ ID NO:17	primer to 3224646
SEQ ID NO:18	primer to 3224646
SEQ ID NO:19	primer to Mamm-X
40 SEQ ID NO:20	primer to Mamm-X
SEQ ID NO:21	primer to 2155647
SEQ ID NO:22	primer to 2155647
45 SEQ ID NO:23	primer to 2155647
SEQ ID NO:24	primer to 2155647
SEQ ID NO:25	human 2155647 cDNA update
SEQ ID NO:26	human 3224646 reverse strand
50 SEQ ID NO:27	human 2355875 cDNA update

5

## CLAIMS

## What is claimed is:

10

1. An isolated nucleic acid molecule comprising a nucleotide sequence at least 85% homologous to a nucleotide sequence selected from the group consisting of SEQ ID NOs : 3, 5, 7, 9, 25 and 27, or a complement thereof.

15

2. The nucleic acid molecule of claim 1, wherein the nucleic acid molecule is at least 90% homologous to the nucleotide sequence, or a complement thereof.

20

3. The nucleic acid molecule of claim 1, wherein the nucleic acid molecule is at least 95% homologous to the nucleotide sequence, or a complement thereof.

25

4. The nucleic acid molecule of claim 1, wherein the nucleic acid molecule is at least 98% homologous to the nucleotide sequence, or a complement thereof.

30

5. The nucleic acid molecule of claim 1, wherein the nucleic acid molecule encodes a polypeptide that binds to syntaxin, SNAP, SNAP-25, synaptobrevin, synaptogamin or the N-type calcium channel.

35

6. The nucleic acid molecule of claim 1, wherein the nucleic acid encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:4.

40

7. The nucleic acid molecule of claim 1, wherein the nucleic acid molecule comprises any one of SEQ ID NO:3 and SEQ ID NO:27, or a complement thereof.

45

8. The nucleic acid molecule of claim 1, wherein the nucleic acid molecule encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:6.

50

55

5

9. The nucleic acid molecule of claim 1, wherein the nucleic acid molecule comprises SEQ ID NO:5, or a complement thereof.

10

10. The nucleic acid molecule of claim 1, wherein the nucleic acid molecule encodes a polypeptide reactive with an anti-claudin antibody.

15

11. The nucleic acid molecule of claim 1, wherein the nucleic acid molecule encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:8.

20

12. The nucleic acid molecule of claim 1, wherein the nucleic acid molecule comprises SEQ ID NO:7, or a complement thereof as shown in SEQ ID NO:26.

25

13. The nucleic acid molecule of claim 1, wherein the nucleic acid molecule encodes a polypeptide having T cell proliferation activity.

30

14. The nucleic acid molecule of claim 1, wherein the nucleic acid molecule encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:10.

35

15. The nucleic acid molecule of claim 1, wherein the nucleic acid molecule comprises the sequence of SEQ ID NO:9.

40

16. A vector comprising the nucleic acid molecule of claim 1.

45

17. A cell comprising the vector of claim 16.

50

55

5 18. An isolated polypeptide selected from the group consisting of:

- 10 a) a polypeptide at least 80% homologous to the amino acid sequence of SEQ ID NO:4;
- b) a polypeptide at least 80% homologous to the amino acid sequence of SEQ ID NO:6;
- 15 c) a polypeptide at least 60% homologous to the amino acid sequence of SEQ ID NO:8;
- d) a polypeptide at least 80% homologous to the amino acid sequence of SEQ ID NO:10;
- 20 e) a fragment of a polypeptide comprising any of the amino acid sequences of SEQ ID NOs: 4, 6, 8, or 10, wherein the fragment comprises at least 6 amino acids of SEQ ID NOs: 4, 6, 8, or 12; and
- 25 f) a naturally occurring allelic variant consisting of the amino acid sequence of SEQ ID NOs:4, 6, 8, or 10, wherein the polypeptide is encoded by a nucleic acid molecule that hybridizes under stringent conditions to a nucleic acid molecule consisting of SEQ ID NOs: 3, 5, 7, 9, or 27.
- 30

35 19. The polypeptide of claim 18, wherein the polypeptide, or fragment thereof, has an activity selected from the group consisting of:

- a) a syncline-like activity, wherein the activity is modulated by the binding and release of calcium ions ;
- 40 b) a claudin-like activity; and
- c) a cytokine-like activity.

45 20. The polypeptide of claim 18, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, or SEQ ID NO:10.

50

55

5           21.    The polypeptide of claim 19, wherein the polypeptide consists of the amino acid  
sequence of SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, or SEQ ID NO:10

10           22.    An antibody which selectively binds to a polypeptide of claim 18.

15           23.    An antibody which selectively binds to a polypeptide comprising the amino acid  
sequence of SEQ ID NO:2 or SEQ ID NO:12.

20           24.    A method for producing the polypeptide of claim 18, the method comprising  
culturing the host cell of claim 17 under conditions in which the nucleic acid molecule is  
expressed.

25           25.    A method for detecting the presence of a polypeptide in a sample from a  
mammal, the method comprising:

- 30           a) contacting a sample suspected of containing the polypeptide with an antibody of  
claim 22 or 34 that binds to the polypeptide under conditions which allow for  
formation of complexes comprising the antibody and polypeptide; and
- 35           b) detecting the formation of reaction complexes comprising the antibody and the  
polypeptide in the sample, wherein detection of the formation of reaction complexes  
indicates the presence of the polypeptide in the sample.

40           26.    The method of claim 25, wherein the mammal is a human.

45

50

55



5           27. A method for detecting or diagnosing the presence of a disease associated with  
altered levels of a polypeptide having an amino acid sequence at least 80% identical to a  
polypeptide with an amino acid sequence selected from the group consisting of SEQ ID NOs: 2,  
10 4, 6, 8, 10, and 12 in a sample, the method comprising:

- a) measuring the level of the polypeptide in a biological sample from the mammalian  
subject according to claim 25; and
- 15 b) comparing the level detected in step a) to a level of the polypeptide present in normal  
subjects, or in the same subject at a different time, in which an increase or decrease in  
the level of the polypeptide as compared to normal levels indicates a disease  
20 condition.

28. A method of detecting the presence of a nucleic acid molecule having a sequence  
25 at least 80% identical to a nucleic acid comprising a sequence selected from the group consisting  
of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 25, or 27, or a complement thereof, in a sample from a  
mammal, the method comprising:

- 30 a) contacting the sample with a nucleic acid probe or primer which selectively  
hybridizes to the nucleic acid molecule; and
- b) determining whether the nucleic acid probe or primer binds to a nucleic acid  
35 molecule in the sample,

wherein binding of the nucleic acid probe or primer indicates the nucleic acid molecule is  
present in the sample.

40 29. The method of claim 28, wherein the mammal is a human.

5           30. A method for detecting or diagnosing the presence of a disease associated with  
altered levels of a nucleic acid at least 80% identical to a nucleic acid comprising a sequence  
selected from the group consisting of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 25, or 27, or a complement  
10 thereof, in a sample from a mammal, the method comprising:

- a) measuring the level of the nucleic acid in a biological sample from the mammalian  
subject according to claim 28; and
- 15 b) comparing the level detected in step a) to a level of the nucleic acid present in normal  
subjects, or in the same subject at a different time, in which an increase or decrease in  
the level of the nucleic acid as compared to normal levels indicates a disease  
20 condition.

25           31. A method of treating a pathological state in a mammal, the method comprising  
administering to the subject a polypeptide to the subject in an amount to alleviate the  
pathological condition, wherein the polypeptide a polypeptide having an amino acid sequence at  
least 80% identical to a polypeptide with an amino acid sequence selected from the group  
30 consisting of SEQ ID NOs: 2, 4, 6, 8, 10, and 12, or a biologically active fragment thereof.

35           32. The method of claim 31, wherein the mammal is a human.

40           33. A method of treating a pathological state in a mammal, the method comprising  
administering to the subject the antibody of claim 22 or 23 in an amount to alleviate the  
pathological condition.

45           34. The method of claim 33, wherein the mammal is a human.

50

55

## FIGURE 1

## A. Clone 2353875f

Translated Protein: Nucleotides 25 to 426

```
1  ACGCGTGCAGGTGGCACTGCCACCATGTCCCCGCTGCGCCCGCTG
    MetSerProLeuArgProLeu
46  CTGCTGGCCCTGGCCCTTGCCTCCGTGCCTTGCGCCAGGGCGCC
    LeuLeuAlaLeuAlaLeuAlaSerValProCysAlaGlnGlyAla
91  TGCCCCGCCTCCGCCGACCTCAAGCACTCGGACGGGACGCGCACT
    CysProAlaSerAlaAspLeuLysHisSerAspGlyThrArgThr
136 TGCGCCAAGCTCTATGACAAGACGACCCCTACTATGAGAACTGC
    CysAlaLysLeuTyrAspLysSerAspProTyrTyrGluAsnCys
181 TGCGGGGGCGCCGAGCTGTGCTGGAGTCGGCGCAGACCTGCCC
    CysGlyGlyAlaGluLeuSerLeuGluSerGlyAlaAspLeuPro
226 TACCTGCCCTCCAACCTGGGCCAACACCGCCTCCTCACTTGTGGTG
    TyrLeuProSerAsnTrpAlaAsnThrAlaSerSerLeuValVal
271 GCCCCGCGCTGCGAGCTCACCGTGTGGTCCCGGCAAGGCAAGGCG
    AlaProArgCysGluLeuThrValTrpSerArgGlnGlyLysAla
316 GGCAAGACGCACAAGTTCTCTGCCGACCTACCCGCGCCTGGAG
    GlyLysThrHisLysPheSerAlaGlyThrTyrProArgLeuGlu
361 GAGTACCGCCGGGGCATCTTAGGAGACTGGTCCAACGCTATCTCC
    GluTyrArgArgGlyIleLeuGlyAspTrpSerAsnAlaIleSer
406 GCGCTCTACTGCAGGTGCAGCTGATGCATTGCTGGTCTCTCATCT
    AlaLeuTyrCysArgCysSer
451 GCAGCTTCCACAGAGTGCCAAGCCCCTCACTCACCCATCCCTGGG
496 CTCTGCTCCGGGCCCCAAGACCCAGGAGGAGGCGTTCTGCCTG
541 CCCCCTCCACCTCCCCTGCAATACAGCCTTTGTGCAGTTGTAAA
586 AAAAAAAAAA
```

## FIGURE 1 (cont.)

## B. Clone 2355875 update

Translated Protein: Nucleotides 209 to 610

```
1  TTCAACCGCACAAAGGCTGTATTGCAGGGGAGGTGGGAGGGGGCA
46  GGCAGAACGCTCCTCCTCGGGTCTTGGGGCCCCGGAGCAGAGC
91  CCAGGGATGGGCTGAGTGAGGGGCTTGGCACTCTGTGGAAGCTGC
136 AGATGAGAGACCAGCAATGCATCAGCTGCACCTGCAGTAGAGCGC

181 GGAGATAGCGTTGGACCACTCTCCTAAGATGTCCCCGCTGCGCCC
    MetSerProLeuArgPr
226 GCTGCTGCTGGCCCTGGCCCTTGCCCTCCGTGCTTGCGCCACGGG
    oLeuLeuLeuAlaLeuAlaLeuAlaSerValProCysAlaGlnG1
271 CGCCTGCCCCGCTCCGCGACCTCAAGCACTCGGACGGGACGCG
    yAlaCysProAlaSerAlaAspLeuLysHisSerAspGlyThrAr
316 CACTTGCGCCAAGCTCTATGACAAGAGCGACCCCTACTATGAGAA
    gThrCysAlaLysLeuTyrAspLysSerAspProTyrTyrGluAs
361 CTGCTGCGGGGGCGCGAGCTGTCGCTGGAGTCGGGCGCAGACCT
    nCysCysGlyGlyAlaGluLeuSerLeuGluSerGlyAlaAspLe
406 GCCCTACCTGCCCTCCAACCTGGGCCAACACCGCCTCCTCACTTGT
    uProTyrLeuProSerAsnTrpAlaAsnThrAlaSerSerLeuVa
451 GGTGGCCCCGCGCTGCGAGCTCACCGTGTGGTCCCGGCAAGGCAA
    lValAlaProArgCysGluLeuThrValTrpSerArgGlnGlyLy
496 GGCGGGCAAGACGCACAAGTTCTCTGCGGCACCTACCCGCGCCT
    sAlaGlyLysThrHisLysPheSerAlaGlyThrTyrProArgLe
541 GGAGGAGTACCGCCGGGGCATCTTAGGAGACTGGTCCAACGCTAT
    uGluGluTyrArgArgGlyIleLeuGlyAspTrpSerAsnAlaIl
586 CTCGCGCTCTACTGCAGGTGCAGCTGATGCATTGCTGGTCTCTC
    eSerAlaLeuTyrCysArgCysSer

631 ATCTGCAGCTTCCACAGAGTGCCAAGCCCTCACTCAGCCCATCC
676 CTGGGCTCTGCTCCGGGGCCCCAAGACCCAGGAGGAGGAGCGTTC
721 TGCCTGCCCCCTCCACCTCCCTGCAATACAGCCTTTGTGCAGT
766 TAAA
```

## FIGURE 2

## Clone 3223867f

Translated Protein: Nucleotides 129 to 533

```
1  AGAAGCTAGAATTGGACAGGTGGGCTCTCTGATTTAAAGTAAGTA
46 CATGAGAAAGTTAAGGCCACAATTCATGGATAGTGAAATCTGTAT

91  CCACAATTCATTTTCATCAAGTCAGAAAGTTATCAAACATGGAAT
    MetGluP

136 TCTGCACTTTTGTATGGCATCAAGCTTCAAAGCAACACAGTAA
    heCysThrPheValMetAlaSerSerPheGlnSerAsnThrValI

181 TAGTCATACACTTCAACAACCACCAACTGTGTCTCAGATGTCCAC
    leValIleHisPheAsnAsnHisGlnHisCysValArgCysProL

226 TCTTCAAGTATGAAACTTGTGCAGTAGCATGGCTTCTACCTGGTG
    euPheLysTyrGluThrCysAlaValAlaTrpLeuLeuProGlyG

271 GCAAGAACTTAGTAATCAACATTACTGATACCCCTGTCACTACTG
    lyLysAsnLeuValIleAsnIleThrAspThrProValThrThrA

316 ATATCTGGAGGGCCTATTTCTTCAGAATTATTCTCCAGAGAAAAC
    spIleTrpArgAlaTyrPhePheArgIleIleLeuGlnArgLysH

361 ACTTTCAACTCACACTGAGGTGCAAGTGATGTGTCTCCTCACGTAA
    isPheGlnThrHisThrGluValGlnValMetCysProHisValT

406 CAGAGCAAATAAACTCAACTGAAATAGAGTATTCATTTAGTA
    hrGluGlnThrLysAsnSerThrGluIleGluTyrSerPheSerI

451 TTTATGGTCAGGAGGATGGCGTAAAGATCACTCCATCTTGTGGAT
    leTyrGlyGlnGluAspGlyValLysIleThrProSerCysGlys

496 CCCATCCTTGCTATGCCACGTGGATCGAATGTCATGTTTAAAAAG
    erHisProCysTyrAlaThrTrpIleGluCysHisVal

541 TGGTCAAGTCTACTCTTTAGTTCTTCAAAGCAAGGACACAGCAG
586 GTCATTGGACACGTCTGCCACAGGCCACATCAGTTCTCCCTCTTT
631 CAAGCTCCAAGTCTGAGTCATTAGGCCAGTGTTCTGCAACACAA
676 ACAGGCATCTGTGGAAGAGCTAGTATGGTGTGGTATCAGTCACA
721 TTCAGGGTTGGAGAAATCTGTGCACTGGAAGCTTGAGTATTCAGG
766 GAGGAAAGGAGAGAAAAGGACATAGAGTAGACTGAAGACAGGTTA
811 TTACTGTAAAACAACTAAGGAAAGTATCAGCCAGGCGGGGTACC
856 TATAATCCCAGCACTTTGCAA
```

## FIGURE 3

## A. Clone 3224646 coding strand

Translated Protein: Nucleotides 301 to 1083

```
1  GCCGGTCTGGCCCGGATCAGGGAGTCCTTCTGCTCCCTGGCACGG
46  CTCTGCGCTGAACCCACCCGGCCTGCGGAGAGCAGACAAGTGCCT
91  CTTGGGCCCCGCTTCTCTAACAAATGTAAAAATAATGCCCTTGAAC
136 CAGGAGCGAAACTGAGCTATCTAAGGAAAACACTGTGAGCAAATA
181 CTGAGAGCCTAGGGAACCATCTGATTAGAAGAGCTCCCCTCAGG
226 AGCGCGTTAGCTTCACACCTTCGGCAGCAGGAGGCGGCAGCTTC

271  TCGCAGGCGGCAGGGCGGGCGGCCAGGATCATGTCCACCACCACA
      MetSerThrThrThr
316  TGCCAAGTGGTGGCGTTCTCTCTGCTCCATCCTGGGGCTGGCCGGC
      CysGlnValValAlaPheLeuLeuSerIleLeuGlyLeuAlaGly
361  TGCATCGCGGCCACCGGGATGGACATGTGGAGCACCCAGGACCTG
      CysIleAlaAlaThrGlyMetAspMetTrpSerThrGlnAspLeu
406  TACGACAACCCCGTCACCTCCGTGTTCCAGTACGAAGGGCTCTGG
      TyrAspAsnProValThrSerValPheGlnTyrGluGlyLeuTrp
451  AGGAGCTGCGTGAGGCAGAGTTCAGGCTTCACCGAATGCAGGCCC
      ArgSerCysValArgGlnSerSerGlyPheThrGluCysArgPro
496  TATTTCACCATCCTGGGACTTCAGCCATGCTGCAGGCAGTGCGA
      TyrPheThrIleLeuGlyLeuProAlaMetLeuGlnAlaValArg
541  GCCCTGATGATCGTAGGCATCGTCCTGGGTGCCATTGGCCTCCTG
      AlaLeuMetIleValGlyIleValLeuGlyAlaIleGlyLeuLeu
586  GTATCCATCTTTGCCCTGAAATGCATCCGCATTGGCAGCATGGAG
      ValSerIlePheAlaLeuLysCysIleArgIleGlySerMetGlu
631  GACTCTGCCAAAGCCAACATGACACTGACCTCCGGGATCATGTTC
      AspSerAlaLysAlaAsnMetThrLeuThrSerGlyIleMetPhe
676  ATTGTCTCAGGTCTTTGTGCAATTGCTGGAGTGTCTGTGTTTGCC
      IleValSerGlyLeuCysAlaIleAlaGlyValSerValPheAla
721  AACATGCTGGTGACTAACTTCTGGATGTCCACAGCTAACATGTAC
      AsnMetLeuValThrAsnPheTrpMetSerThrAlaAsnMetTyr
```

FIGURE 3 (cont.)

766 ACCGGCATGGGTGGGATGGTGCAGACTGTTTCAGACCAGGTACACA  
ThrGlyMetGlyGlyMetValGlnThrValGlnThrArgTyrThr

811 TTTGGTGC GGCTCTGTTCGTGGGCTGGGTCTGGAGGCCTCACA  
PheGlyAlaAlaLeuPheValGlyTrpValAlaGlyGlyLeuThr

856 CTAATTGGGGGTGTGATGATGTGCATCGCCTGCCGGGGCCTGGCA  
LeuIleGlyGlyValMetMetCysIleAlaCysArgGlyLeuAla

901 CCAGAAGAAACCACTACAAAGCCGTTTCTTATCATGCCTCAGGC  
ProGluGluThrAsnTyrLysAlaValSerTyrHisAlaSerGly

946 CACAGTGTTCCTACAAGCCTGGAGGCTTCAAGGCCAGCACTGGC  
HisSerValAlaTyrLysProGlyGlyPheLysAlaSerThrGly

991 TTTGGGTCCAACACCAAAAAACAAGAAGATATACGATGGAGGTGCC  
PheGlySerAsnThrLysAsnLysLysIleTyrAspGlyGlyAla

1036 CGCACAGAGGACGAGGTACAATCTTATCCTTCCAAGCACGACTAT  
ArgThrGluAspGluValGlnSerTyrProSerLysHisAspTyr

1081 GTGTAATGCTCTAAGACCTCTCAGCACGGGCGGAAGAACTCCCG  
Val

1126 GAGAGCTCACCCAAAAACAAGGAGATCCCATCTAGATTCTTCT  
1171 TGCTTTTGACTCACAGCTGGAAGTTAGAAAAGCCTCGATTTCATC  
1216 TTTGGAGAGGCCAAATGGTCTTAGCCTCAGTCTCTGTCTCTAAAT  
1261 ATTCCACCATAAAACAGCTGAGTTATTTATGAATTAGAGGCTATA  
1306 GCTCACATTTTCAATCCTCTATTTCTTTTAAATATAACTTTC  
1351 TACTCTGATGAGAGAATGTGGTTTTAATCTCTCTCACATTTTG  
1396 ATGATTTAGACAGACTCCCCCTCTCCTCCTAGTCAATAAACCCA  
1441 TTGATGATCTATTTCCAGCTTATCCCAAGAAAACCTTTGAAAG  
1486 GAAAGAGTAGACCCAAAAATGTTATTTCTGCTGTTTGAATTTTG

FIGURE 3 (cont.)

## B. Clone 3224646 complementary strand

caaaattcaaacagcagaaaaataacatTTTTGGGTCTACTCTTCTTTTCAAAAGTTTCT  
TTGGGGATAAGCTGGGAAATAGATCATCAATGGGTTTATTGACTAGGAGGAAGAGGGGGA  
GTCTGTCTAAATCATCAAAATGTGAGAGAGAGATTAAACCACATTCTCTCATCAGAGTA  
GAAAGTTATATTTAAAAAAGAAATAGAGGATTGAAATGTGAGCTATAGCCTCTAATTC  
ATAAATAACTCAGCTGTTTTATGGTGGAAATTTAGAGACAGAGACTGAGGCTAAGACCA  
TTTGGCCTCTCCAAAGATGAAATCGAGGCTTTCTAACTCCAGCTGTGAGTCAAAAGCA  
AGAAGAAATCTAGATGGGATCTCCTTGTTTTTGGGTGAGCTCTCCGGGAGTTCTTCCG  
CCCGTGCTGAGAGGTCTTAGAGCATTACACATAGTCGTGCTTGGAGGATAAGATTGTAC  
CTCGTCTCTGTGCGGGCACCTCCATCGTATATCTTCTTGTTTTTGGTGTGGACCCAAA  
GCCAGTGCTGGCCTTGAAGCCTCCAGGCTTGTAGGCAACACTGTGGCCTGAGGCATGATA  
AGAAACGGCTTTGTAGTTGGTTTTCTTGGTGCCAGGCCCGGCAGGCGATGCACATCAT  
CACACCCCAATTAGTGTGAGGCTCCAGCGACCCAGCCACGAACAGAGCCGACCCAAA  
TGTGTACCTGGTCTGAACAGTCTGCACCATCCACCCATGCCGGTGATACATTAGCTGT  
GGACATCCAGAAGTTAGTCACCAGCATGTTGGCAACACAGACACTCCAGCAATTGCACA  
AAGACCTGAGACAATGAACATGATCCCGGAGGTCAAGTGTCTGTTGGCTTTGGCAGAGTC  
CTCCATGCTGCCAATGCGGATGCATTTCAAGGCAAGATGGATACCAGGAGGCCAATGGC  
ACCCAGGACGATGCTACGATCATCAGGGCTCGCACTGCCTGCAGCATGGCTGGAAGTCC  
CAGGATGGTGAAATAGGGCCTGCATTCGGTGAAGCCTGAACCTCTGCCTCACGCACTCTCT  
CCAGAGCCCTTCGTACTGGAACACGGAGGTGACGGGGTTGTGCTACAGGTCCTGGGTGCT  
CCACATGTCCATCCCGGTGGCCGCGATGCAGCCGGCCAGCCCCAGGATGGACAGGAGGAA  
CGCCACCACTTGGCATGTGGTGGTGGACATGATCCTGGCCGCCGCCCTGCCGCCCTGCGA  
GAAGCTGCCGCCCTCTGTGCTGCCGAAGGTGTGAAGCTAACGCGCTCTTGAGGGGAGCTCT  
TCTAATCAGATGGTTTCCCTAGGCTCTCAGTATTTGCTCACAGTGTCTTCTCTAGATAGC  
TCAGTTTCGCTCCTGGTTCAAGGGCATTATTTTACATTTGTTAGAGAAGCGGGCCCAAG  
AGGCACCTGTCTCTCTCCGCAAGCCGGGTGGGTTCAGCGCAGAGCCGTGCCAGGGAGCA  
GAAGGACTCCCTGATCCGGGCCAGACCGGC



## FIGURE 4

## Clone 3482699

Translated Protein: Nucleotides 341 to 538

```
1 CACAGAGCCTGGGCTGCAGGCACCTCCCTGCCAGCTCTCCCGCTC
46 CTGGCACCGCCGCGCCGACCTGCCTTCTGAGCCCGGTGAAC TGCGC
91 CGCGCCCCCGCTGTCCCCCGCGCTCCCGGCTACTGCGGGCGGC
136 GCTGCTGCTCCTGCTCCTGGTAGCCTCCGGCCGGCGAGCGGCAGG
181 AGTATGGGTGGCCCATGAAC TGCCCTTGCCAGTGCTTGCAGACCCT
226 GCAGGGAATTCACCCCAAGAATATCCGAAGTGTGAACGTGAAGTC
271 CCCTGGACCCCACTGCACCCAAACCGAAGTCATATAAGTCCCTCC

316 CCGTGACTTTTTCTTTTCTCAGACCATGAGAATTAAATCTGTAGT
MetArgIleLysSerValVa

361 CATTTTTCTAATTAGTGGCTGGATCCAAAAGAATAATAAAATATA
IlePheLeuIleSerGlyTrpIleGlnLysAsnAsnLysIleTy

406 TCTAATCTCCCGAAGAAAGCCCAAAGGTTACATCCAGGACTTGG
rLeuIleSerProLysLysAlaGlnArgLeuHisProGlyLeuGl

451 TCCTAGGTTAAGCCCTAAGGTGCTGGGGAGAGTGGAATGCTATCT
yProArgLeuSerProLysValLeuGlyArgValGluCysTyrLe

496 TCCTAATTATTTACATATCAAAGAGATGAAGCCACAGAACCTA
uProAsnTyrLeuHisIleLysArgAspGluAlaHisArgThr

541 AAGACATCAGTAGGACACATAAATTGAAGACCAGAGGGCTCTTAG
586 GTTCCAGGGGAAAGGTAT
```

## FIGURE 5

## A. Clone 2155647f

Translated Protein: Nucleotides 148 to 402

```
1 AAAGAAAGAGCTGCGGTGCAGGAATTCGTGTGCCGGATTGGTTA
46 GCTGAGCCCACCGAGAGGCGCCTGCAGAATGAAAGCTCTCTGTCT
    MetLysAlaLeuCysLe
91 CCTCCTCCTCCCTGTCTCTGGGGCTGTTGGTGTCTAGCAAGACCCT
    uLeuLeuLeuProValLeuGlyLeuLeuValSerSerLysThrLe
136 GTGCTCCATGGAAGAAGCCATCAATGAGAGGATCCAGGAGGTCGC
    uCysSerMetGluGluAlaIleAsnGluArgIleGlnGluValAl
181 CGGCTCCCTAATATTTAGGGCAATAAGCAGCATTGGCCTGGAGTG
    aGlySerLeuIlePheArgAlaIleSerSerIleGlyLeuGluCy
226 CCAGAGCGTCACTCCAGGGGGACCTGGCTACTTGCCCCCGAGG
    sGlnSerValThrSerArgGlyAspLeuAlaThrCysProArgGl
271 CTTGCGCGTCACCGGCTGCACTTGTGGCTCCGCCTGTGGCTCGTG
    yPheAlaValThrGlyCysThrCysGlySerAlaCysGlySerTr
316 GGATGTGCGCGCCGAGACCACATGTCAGTCCAGTGCGCGGCAT
    pAspValArgAlaGluThrThrCysHisCysGlnCysAlaGlyMe
361 GGA CTGGACCGGAGCGCGCTGCTGTCGTGTGCAGCCCTGAGGTGG
    tAspTrpThrGlyAlaArgCysCysArgValGlnPro
406 CGCGCAGCCCCACAGTGGACGCGGGCGGAAGGCGGCTCCAGGTCC
451 GGAGGGGTTGCGGGGAGCTGGAATAAACCTGGAGATGATGATG
496 ATGATGATGA
```

## FIGURE 5 (cont.)

## B. Clone 2155647f update

```
1 AAAGAAAGAGCTGCGGTGCAGGAATTCGTGTGCCGGATTGGTTA
46 GCTGAGCCCACCGAGAGGCGCCTGCAGAATGAAAGCTCTCTGTCT
    MetLysAlaLeuCysLe
91 CCTCCTCCTCCCTGTCTGGGGCTGTTGGTGTCTAGCAAGACCCT
    uLeuLeuLeuProValLeuGlyLeuLeuValSerSerLysThrLe
136 GTGCTCCATGGAAGAAGCCATCAATGAGAGGATCCAGGAGGTCCG
    uCysSerMetGluGluAlaIleAsnGluArgIleGlnGluValAl
181 CGGCTCCCTAATATTTAGGGCAATAAGCAGCATTGGCCTGGAGTG
    aGlySerLeuIlePheArgAlaIleSerSerIleGlyLeuGluCy
226 CCAGAGCGTCACCTCCAGGGGGACCTGGCTACTTGCCCCGAGG
    sGlnSerValThrSerArgGlyAspLeuAlaThrCysProArgGl
271 CTTGCGCGTCACCGGCTGCACTTGTGGCTCCGCCTGTGGCTCGTG
    yPheAlaValThrGlyCysThrCysGlySerAlaCysGlySerTr
316 GGATGTGCGCGCCGAGACCACATGTCACTGCCAGTGCGCGGGCAT
    pAspValArgAlaGluThrThrCysHisCysGlnCysAlaGlyMe
361 GGA CTGGACCGAGCGCGCTGCTGTCGTGTGCAGCCCTGAGGTCG
    tAspTrpThrGlyAlaArgCysCysArgValGlnPro
406 CGCGCAGCCCCACAGTGGACGCGGGCGGAAGGCGGCTCCAGGTCC
451 GGAGGGGTTGCGGGGAGCTGGAAATAAACCTGGAGATGATGATG
496 ATGATGATGATGG
```

## FIGURE 6

## MammX Clone

Translated Protein: Nucleotides 65 to 349

```
1 CCTCCACAGCAACTTCCTTGATCCCTGCCACGACGACTGAACAC
46 AGACAGCAGCCGCTCGCCATGAAGCTGCTGATGGTCCTCATGCT
   MetLysLeuLeuMetValLeuMetLe
91 GGCGGCCCTCCTCCTGCACTGCTATGCAGATTCTGGCTGCAAACT
   uAlaAlaLeuLeuLeuHisCysTyrAlaAspSerGlyCysLysLe
136 CCTGGAGGACATGGTTGAAAAGACCATCAATCCGACATATCTAT
   uLeuGluAspMetValGluLysThrIleAsnSerAspIleSerIl
181 ACCTGAATACAAAGAGCTTCTTCAAGAGTTCATAGACAGTGATGC
   eProGluTyrLysGluLeuLeuGlnGluPheIleAspSerAspAl
226 CGCTGCAGAGGCTATGGGGAAATTCAAGCAGTGTTCCTCAACCA
   aAlaAlaGluAlaMetGlyLysPheLysGlnCysPheLeuAsnGl
271 GTCACATAGAACTCTGAAAACTTTGGACTGATGATGCATACAGT
   nSerHisArgThrLeuLysAsnPheGlyLeuMetMetHisThrVa
316 GTACGACAGCATTTGGTGTAAATATGAAGAGTAATTAACCTTACCC
   lTyrAspSerIleTrpCysAsnMetLysSerAsn
361 AAGGCGTTTGGCTCAGAGGGCTACAGACTATGGCCAGAACTCATC
406 TGTGATTGCTAGAAACCACTTTTCTTTCTGTGTGTCTTTTTA
451 TGTGGAACTGCTAGACAACTGTTGAAACCTCAAATTCATTCCA
496 TTTCAATAACTAACTGCAAATC
```